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Cancer in general
Cancer is the second leading cause of death in the Netherlands affecting 69.000 people 
annually (KWF 1999). It refers to any malignant growth of cells in the body. Tumour 
cells grow tempestuously and have acquired the ability to invade surrounding 
tissues. This implies, in general, that they can escape and enter the bloodstream or 
lymphatic vessels, and form secondary tumours at other sites of the body. Cancer 
can be divided in two separate groups: haematological and solid malignancies. 
Chromosomal aberrations in cancer
Every normal human somatic cell has a diploid karyotype consisting of 46 
chromosomes, from which 22 pairs of autosomes (1-22) and 2 sex chromosomes (X 
and Y). In 1890 David von Hansemann already observed abnormal mitoses in cancer 
cells. Boveri (1914) elaborated on this finding by suggesting that abnormalities of 
chromosome constitution are fundamental to cancer. These alterations may involve 
the number, or more frequently, the structure of the chromosomes. Numerical changes 
comprise losses and gains of chromosomes and an altered ploidy. Tumours with 
characteristic ploidy changes are colorectal cancers, melanoma (skin/uvea), bladder 
and breast tumours. Structural changes may arise through breakage and reunion of 
different chromosomes resulting in deletions, insertions, inversions, translocations 
and rings. The first recurrent chromosomal alteration was the Philadelphia 
chromosome in chronic myelogenous leukaemia discovered by Hungerford in 
1960. This rearrangement resulted in formation of a fusion gene that encoded for a 
fusion protein with oncogenic activity. Furthermore, gene amplifications are seen as 
homogenously stained regions or double minute chromosomes (Heim 1995; Lengauer, 
et al. 1998). The amplicons contain 0.5-1.0 megabases of DNA and at molecular level 
multiple copies of gene(s) can be seen. An example is the amplification of N-myc that 
occurs in approximately 30% of advanced neuroblastoma (Seeger, et al. 1985).
Initiation and progression related chromosomal aberrations
Tumorigenesis has long been thought to be a multi step process with genetic 
alterations. Based on the amount of chromosomal aberrations two karyotypic 
patterns can be distinguished: simple and complex patterns. The simple pattern 
is characterised by rearrangements of chromosomal segments in specific cancers. 
Amongst these are the haematological malignancies, lymphomas, some sarcomas 
and other rare tumours (Le Beau and Rowley 1986). The simple karyotype 
represents in general primary chromosomal changes. These primary changes can 
be specific for a certain tumour-type, occur frequently and indicate a causal role 
in tumour initiation. Generally, these rearrangements lead to the activation of an 
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oncogene (s.a. c-MYC translocation in Burkitt’s lymphoma) or fusion with another 
gene (s.a. fusion of BCR and c-ABL on the Philadelphia chromosome in chronic 
myelogenous leukaemia). The number of aberrations increases in more advanced 
tumours (Albertson, et al. 2003), and aggressive tumours have relative high copy 
number alterations per case (Ried, et al. 1999). Thus, the complex karyotype exhibits 
many chromosomal aberrations and supports a role for acquisition of additional 
chromosomal changes (secondary changes), which are less tumour-type specific, 
during tumour progression (Albertson, et al. 2003; Lengauer, et al. 1998; Sandberg 
1991). Since there are many more aberrations in solid tumours than the non-
random ones, it is assumed that many aberrations are mere noise representing the 
chromosomal instability of the tumour. Chromosomal instability, involving gains 
and losses of whole chromosomes, is likely to occur in most human malignancies 
(Albertson, et al. 2003; Lengauer, et al. 1998). In breast cancer, for example, the 
frequency of aberrations is low in hyperplasia and higher in carcinoma in situ. The 
same holds for colorectal carcinomas (Albertson, et al. 2003). Furthermore, due to the 
chromosomal instability a tumour can lose for example one maternal chromosome 
and duplicate the paternal counterpart, which results in two copies, but an abnormal 
‘allelotype’ (Lengauer, et al. 1998), indicating an underestimation of such changes.
“…In every normal cell there is a specific arrangement for inhibiting, which allows 
the process of division to begin only when the inhibition has been overcome 
by a special stimulus…On the other hand, the assumption of the existence of 
chromosomes which promote division, might satisfy this postulate…”  
 Boveri 1914
Genes involved in cancer
Changes in gene copy number due to recurrent chromosomal aberrations may 
probably contribute to tumour development or progression (Albertson, et al. 2003). 
The genes that play a part in tumour development encode proteins, which regulate 
cellular growth and differentiation under normal circumstances. These processes 
are controlled through inactivation and activation of genes with growth inhibiting 
(tumour suppressor genes) and growth promoting (proto-oncogenes) function. 
Predisposition to cancer was explained by Knudsons’ two-hit-hypothesis where two 
successive inactivating hits (mutations) of tumour suppressor genes are required 
for malignant transformation of cells (Knudson 1971). Examples of classical tumour 
suppressor genes are Rb and p53. Both have a regulatory role during the cell cycle, thus 
when activated cell cycle arrest and apoptosis is induced. Rb was the first discovered 
tumour suppressor gene. In familial cases of retinoblastoma one allele had a germ-
General introduction
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Figure 1.
Schematic illustration of the eye on 
the left. Histological sections of uveal 
melanoma on the right; melanoma lo-
cated in the iris (A), ciliary body (B) and 
choroid (C).
line mutation and the second allele was inactivated by a somatic mutation (Cavenee, 
et al. 1983). In contrast to inactivation of tumour suppressor genes, proto-oncogenes 
need to be activated. Oncogenes may cause malignant transformation when they 
are overexpressed due to amplification or constitutively activated by mutation(s). 
An example of an oncogene is RAS. Under normal circumstances the RAS-family of 
genes mediates cellular responses to growth signals. Activating mutations of RAS 
are found in 25% of all cancers, for example colon and lung cancers (Bos 1989).
Uveal Melanoma
During embryogenesis neural crest cells migrate to the uveal tract, where they develop 
into melanocytes. Melanomas of the uvea are derived from these melanocytes. Uveal 
melanoma is the most common cause of primary eye cancer in the Western world 
with an annual incidence of approximately 7 per million per year. Approximately 
80% of the primary intraocular tumours above the age of 20 years are diagnosed as 
uveal melanoma, with a mean age of 60 years (Singh and Topham 2003). Nearly 50% 
of all patients will die from distant metastasis that are mainly located in the liver 
(Zimmerman and McLean 1984), with a peak incidence of death due to melanoma 2 
years after enucleation (Zimmerman, et al. 1978). Uveal melanomas may arise in the 
iris (5%), ciliary body (23%) or choroid (72%) (Figure 1). Choroidal melanomas are the 
most common and usually display a discoid, dome-shaped or mushroom-shaped 
growth pattern. 
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Prognostic factors
Prognostic factors for uveal melanoma can be subdivided into three categories: 
clinical histopathological and genetical. Clinical predictive factors have been 
extensively described. Location of the tumour, tumour thickness and tumour 
diameter (Augsburger and Gamel 1990; Augsburger, et al. 1989; Coleman, et al. 1993; 
Seddon, et al. 1983; Shields, et al. 2000; Shields, et al. 1995) are clinical factors predicting 
tumour growth. In addition, age at time of treatment, male gender (Augsburger and 
Gamel 1990; Luyten, et al. 1995) and secondary glaucoma (Coleman, et al. 1993) were 
prognostic relevant. Shields et al. constructed a mnemonic ”TFSOM” “to find small 
ocular melanoma” (thickness greater than 2 mm, subretinal fluid, symptoms, orange 
pigment and margin at the disc) to assist in identifying small choroidal melanoma at 
risk for growth (Shields, et al. 2000). The most important histopathological markers 
predicting clinical behaviour are the presence of epithelioid cells (Coleman, et al. 
1993; Seddon, et al. 1983), largest tumour diameter (Mooy, et al. 1995), scleral invasion 
(Seddon, et al. 1983) and presence of vascular loops (Folberg, et al. 1993).  Other 
valuable prognostic factors are the presence of mitotic figures (Folberg, et al. 1993; 
Mooy, et al. 1995) and tumour-infiltrating lymphocytes (de Waard-Siebinga, et al. 
1996; Whelchel, et al. 1993). 
Genetic prognostic factors in uveal melanoma consist mainly of the chromosomal 
aberrations. As is the case in other solid tumours non-random chromosomal 
alterations occur in uveal melanoma. Uveal melanoma often contain minimal 
chromosomal alterations and are highly amenable to chromosome analysis 
(Prescher, et al. 1995; Sisley, et al. 1990). This has led to identification of abnormalities 
of chromosomes 1, 3, 6 and 8 (Figure 2) Loss of chromosome 3 is clearly associated 
with a decreased survival (Prescher, et al. 1996; Sisley, et al. 1997; White, et al. 1998a). 
In general, loss of chromosome 3 involves the whole chromosome, however, partial 
deletions, one on the long arm and one on the short arm, of chromosome 3 have 
been identified, suggesting a role for tumour suppressor genes which might explain 
the frequently observed loss of an entire chromosome 3 (Tschentscher, et al. 2001). 
Additionally, several studies indicated that monosomy 3 seemed to be an early event 
in uveal melanoma (Aalto, et al. 2001; Prescher, et al. 1994), causing isochromosome 
formation of especially isochromosome 6p and 8q (Prescher, et al. 1994; Prescher, 
et al. 1995). Gain of chromosome 6p has been associated with a better survival 
(White, et al. 1998a), whereas loss of chromosome 6q has been associated with a 
decreased survival (Aalto, et al. 2001). Sisley et al. demonstrated that presence of 
extra copies of chromosome 8q was correlated with a decreased survival (Sisley, et 
al. 1997). Furthermore, loss of chromosome 1p was identified in these tumours. Any 
prognostic significance has not been determined, yet Aalto et al. detected loss of 
chromosome 1p particularly in metastasising tumours (Aalto, et al. 2001). 
General introduction
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Familial uveal melanoma
The hereditary basis for uveal melanoma was first questioned by Silcock et al., who 
described in 1892 a mother and daughter, both with apparent intraocular melanoma 
(Silcock 1892). More families have been described in literature and an autosomal 
dominant inheritance with incomplete penetrance was suggested (Lynch, et al. 1968; 
Singh, et al. 1996b). The occurrence of familial uveal melanoma is rare, only 0.6% 
of all uveal melanoma cases (Singh, et al. 1996a), making it hard to identify genetic 
predisposing factors. Familial uveal melanoma have been reported to occur in several 
familial cancer syndromes: familial atypical mole and malignant melanoma (FAMM) 
syndrome, xeroderma pigmentosum (XP), Li-Fraumeni syndrome and familial 
breast and ovarian cancer. CDKN2A is the main cutaneous melanoma predisposing 
gene and mutations have been described in families with both cutaneous and uveal 
melanoma. Expression of this gene causes cells to arrest in the G1 phase of the cell 
cycle by Rb inactivation. CDKN2A gives a predisposition in the FAMM syndrome, 
but is rarely involved in familial uveal melanoma (Singh, et al. 1996b; Soufir, et al. 
2000). Persons with FAMM (Familial Atypical Mole Syndrome) were more likely to 
possess conjunctival, iris and choroidal nevi (Rodriguez-Sains 1986). In addition, 
BRCA2, another cell cycle regulator, was mutated in a number of cases with uveal 
Figure 2. 
Karyotype of tumor EOM 207 
This tumor showed the typical chromosomal changes for uveal melanoma, -3, i(6)(p) and +8. In addition, there 
is a loss of a Y chromosome, which is commonly observed in solid tumors.
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melanoma. However, germline BRCA2 mutations, which are present in only a small 
proportion of the patients (Hearle, et al. 2003), do not explain all familial cases.
Genes and uveal melanoma
Losses and gains of chromosomes will result in gain and loss of genes that may 
play an important role in cell cycle regulation, differentiation and apoptosis. As 
described in a previous paragraph tumour suppressor genes and oncogenes may 
play a role. According to the Knudsons’ two hit hypothesis, the first hit could be 
a mutation or small deletion, whereas the second hit might the loss of a part of a 
chromosome. This hypothesis is applicable to classical tumour suppressor genes, 
such as p53 and Rb. Association of cytogenetic alterations in uveal melanoma with 
survival enables researchers to identify regions of interest. Chromosome 1p36 is 
frequently deleted in solid tumours, such as uveal melanoma, skin melanoma and 
neuroblastoma. In the latter tumour type it is also a predictor for an unfavourable 
outcome of the patient (Caron, et al. 1996). P73, a candidate tumour suppressor gene, 
is located in this region. Another chromosome of interest is chromosome 3, on which 
p63 is located, 3q27-28. Both genes, p73 and p63, will be explained in more detail in 
the following paragraph. The role of oncogenes restricts to overexpression due to 
amplification of the complete gene or constitutively activation due to mutations. One 
of such genes is BRAF, which will be described, in addition to p73 and p63.
P73 / P63
The candidate tumour suppressor genes p73 gene and the p63, both encoding 
homologues of p53, are located on chromosome 1p36 and 3q27-28, respectively 
(Kaghad, et al. 1997; Yang, et al. 1998). P73 and p63 are homologous to p53, a well-
known tumour suppressor gene. They have a similar structure with an amino-
terminal transactivation domain, a central core DNA-binding domain and a 
carboxy-terminal oligomerisation domain (Kaghad, et al. 1997; Yang, et al. 1998). The 
p53-protein is a key regulator of the cell cycle as a checkpoint mediator during the 
G1/S and G2/M transition. Upon DNA damage p53 is stabilised and accumulated 
resulting in an increased activity and consequently cell cycle arrest and apoptosis 
is mediated. P53, located on chromosome 17q13.1, is mutated in 50% of all human 
cancers. In uveal melanoma, however, p53 mutations or loss of the p53 locus do not 
seem to be a cause of protein inactivation (Chana, et al. 1999), but instead the p53 
pathway may be functionally impaired (Brantley and Harbour 2000). In experimental 
set-up both, p73 and p63, showed p53 like properties, s.a. binding to p53 DNA target 
sites, transactivate p53-responsive genes and induce cell cycle arrest and apoptosis 
(Jost, et al. 1997; Kaghad, et al. 1997; Yang, et al. 1998). In contrast to p53, transcripts 
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lacking the N-terminal transactivation domain have been identified for p73 and 
p63. Both are transcribed by an alternative promoters located in intron 3 of either 
gene. Furthermore, once in a complex with e.g. p53 the ΔN-variants have dominant 
negative activity (Irwin and Kaelin 2001) (Figure 3).
Figure 3.
A: Schematic representation of TP63 and TP73 in upper panel. The lower panel illustrates the mRNA sequence.
B: Diagram illustrating the interaction between p53, p63 and p73 proteins. P53 is able to drive the cell into 
apoptosis or cell cycle arrest in reaction to specific stimuli. P63 and p73 proteins can act in two different man-
ners. Since the TA-forms are able to transactivate p53 target genes they can induce apoptosis. The ∆N-forms 
that lack the transactivating domain act as dominant-negatives and therefore induce proliferation. 
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BRAF
The RAF family consists of three genes, ARAF, BRAF and CRAF, encoding for 
cytoplasmic serine/threonine kinases (Chong, et al. 2003; Peyssonnaux and Eychene 
2001). The RAF proteins are part of the RAS-RAF pathway. This pathway plays 
an important role in melanogenesis by mediating cellular responses to growth 
signals. In response to UVB-radiation cAMP is upregulated, leading to increased 
proliferation and melanogenesis (Barbacid 1987). The RAF proteins are activated by 
the upstream component in this pathway, RAS. 
Comparable to RAS, RAF-genes are also considered as proto-oncogenes. Activating 
mutations of BRAF in human cancer have been identified by Davies et al. (Davies, 
et al. 2002).  BRAF mutations were present in 60-66% of the malignant melanoma 
and at a lower frequency in a wide range of other human cancers (Brose, et al. 2002; 
Davies, et al. 2002). The most common mutation, 1796T-A transversion in exon 15 
of the BRAF gene, was located in the serine/threonine kinase domain, resulting in 
a Valine to Glutamic Acid substitution at position 599 (Davies, et al. 2002). Thus, 
resulting in a constitutive active protein promoting proliferation (Zhang and Guan 
2000). Several less common mutations of BRAF were located in exon 11 (Brose, et al. 
2002; Davies, et al. 2002).
Therapy
Nowadays there are many more treatment options besides enucleation, which 
was the only option for most of last century (COMS 1998). The more conservative 
treatment options aim to spare the affected eye and retain vision. Treatment of 
uveal melanoma depends on various factors including age of the patients, systemic 
health of the patient, condition of the opposite eye, tumour size and location.  In 
general small and medium melanomas may be treated with transpupillary 
thermotherapy (TTT), plaque radiotherapy combined with TTT, proton beam or 
stereotactic radiotherapy. Large melanomas are usually treated with enucleation 
while in some cases proton beam radiotherapy or stereotactic radiotherapy is 
indicated. With stereotactic radiotherapy several large dose fractions are given 
to reduce the side effects of radiotherapy and gain an optimal result in tumour 
control. Reduction of side effects and improvement of the therapeutic ratio can be 
achieved with a better understanding of the radiosensitivity and capacity for DNA 
damage repair of these tumours. Smaller fraction doses and consequent smaller 
high-dose volumes are justified to optimise dose and fractionation. Fractionated 
stereotactic irradiation has a challenging potential as an eye-preserving treatment 
in uveal melanoma. Nevertheless, metastases cannot be prevented. Based on 
theoretical models, clinically manifest metastases are likely to occur 5 or 6 years 
General introduction
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after onset of the systemic dissemination (Gamel, et al. 1992; Manschot and van 
Peperzeel 1980; Manschot and van Strik 1992; McLean 1993). At the time that uveal 
melanoma is diagnosed, micrometastases may have been spread already (Eskelin, 
et al. 2000; Manschot and van Strik 1992). Therefore, metastatic disease occurring 
after treatment is not uncommon. Approximately half of the patients will die from 
the disease within 10 to 15 years of enucleation. Once a metastasis is discovered 
the survival is less than 7 months (Kath, et al. 1993). If a metastasis arises as a 
solitary lesion in the liver, increased survival may be obtained by local resection of 
the lesion (Aoyama, et al. 2000). Furthermore, there have been reports on tumour 
regression after treatment with hepatic arterial chemo-embolisation (Mavligit, et 
al. 1988), isolated hepatic perfusion with high-dose melphalan (Noter, et al. 2004) 
and a combination of chemo-immunotherapy in the BOLD study (Kivela, et al. 2003; 
Pyrhonen, et al. 2002). These therapies may prolong survival, but they will not cure 
the patients. Enucleation induced metastases may occur through manipulation of 
the eye during treatment, as was demonstrated in animal studies (Niederkorn 1984). 
Pre-enucleation radiotherapy, aimed at reducing enucleation induced metastases, 
proved to be effective in animal models (Char and Phillips 1982; Hoye and Smith 
1961; Kenneally, et al. 1988; Powers and Palmer 1968; Sanborn, et al. 1987). However, 
it is not applied at the moment since clinical studies did not show any survival 
benefit (Augsburger, et al. 1990; Bornfeld, et al. 1989; Char, et al. 1988; COMS 1998; 
Gunalp and Batioglu 1998; Kreissig, et al. 1989; Luyten, et al. 1995). Despite diagnostic 
advances the rate of metastatic disease is still not reduced, making it more important 
to find alternative treatments for metastases in particular.
Scope and outline of this thesis
Identification of prognostic factors is a major goal of current cancer research. It can 
be used to ease diagnostics and speculate on disease progress. Moreover, patients 
may be treated selectively or at an earlier stage in which the disease has not yet 
disseminated. To avoid dissemination radiotherapy may be applied. In the first part 
of this thesis the effect of radiotherapy in uveal melanoma cell lines and primary 
uveal melanoma will be discussed. Results of dose fractionating will be presented 
in Chapter 2. Chapter 3 reports for the first time a reduction in melanoma related 
mortality after pre-enucleation radiotherapy. 
Cytogenetic abnormalities that occur non-randomly in uveal melanoma, such as 
monosomy 3, amplification of 8q, 6p and deletion of chromosome 6q and 1p are 
associated with prognosis of UM patients. The association of these cytogenetic 
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alterations with survival will be dealt with in the second part of this thesis. Chapter 
4 reports mainly on the importance of concurrent loss of chromosome 1p and 3 as 
a prognostic parameter for uveal melanoma metastases. However, there are several 
different aberrations, which will be discussed in more detail in chapter 5. Besides 
the sporadic occurrence of uveal melanoma it may also appear in predisposed 
families. Chapter 6 will illustrate the cytogenetic aberrations observed in familial 
uveal melanoma. 
The association of cytogenetic alterations with survival enables us to identify 
regions of interest. Part 3 of this thesis concerns structural deletions and candidate 
genes involved in uveal melanoma progression. Demarcation of structural deletions 
of chromosome 3 may aid in delineation of candidate regions for tumour suppressor 
genes (chapter 7). In addition, the association of concurrent loss of chromosome 1p 
and chromosome 3 with decreased survival (chapter 4) suggests the presence of 
genes involved in tumour progression on these chromosomes. Candidate tumour 
suppressor genes, TP73 and TP63, were located on chromosome 1p36 and 3q27-29, 
respectively. In Chapter 8 the expression of various transcripts of these genes is 
described. Another candidate gene analysed was BRAF (Chapter 9). This gene is 
mutated in 80% of the cutaneous melanoma in which no RAS mutation was present. 
Considering the common origin of uveal and cutaneous melanoma, both arise from 
neural crest derived melanocytes and lack of RAS mutations in uveal melanoma, 
BRAF was an interesting candidate.  
A general discussion and future prospects are presented in chapter 10.
Part 1. Radiotherapy in uveal melanoma 
Chapter 2
Dose fractionation effects in primary and metastatic human
uveal melanoma cell lines
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Abstract
Purpose:  To investigate the effects of split dose irradiation on primary and metastatic 
uveal melanoma cell lines using a clonogenic survival assay. Methods: Appropriate cell 
concentrations of four primary and four metastatic human uveal melanoma cell lines were 
cultured for irradiation with single doses and with two equal fractions separated by 5 h. After 
irradiation colony formation was allowed for 7-21 days. Two cutaneous melanomas were also 
tested for comparison. All survival curves were analysed using the Linear Quadratic (LQ) 
model. Specific parameters for the intrinsic radiosensitivity (α-component, SF2 –value), for 
the capacity of repair of DNA damage (β-component), as well as the α/β ratio were calculated. 
Results: After single dose irradiation a wide range in α- and β-values was obtained for both 
primary and metastatic uveal melanomas, which resulted in a wide range of α/β ratios. In 
contrast, calculations based on split dose data with which the β-component could be estimated 
independent of the α-component, indicated that estimates for the capacity of sublethal 
DNA damage repair was very similar for all cell lines. This indicated that intrinsic factors 
dominated the radiosensitivity of these cell lines. Split dose irradiation had little influence on 
the intrinsic radiosensitivity (α-component), but cell survival increased for all cell lines.  For 
the two cutaneous melanomas comparable split dose results were obtained. Conclusions: For 
both primary and metastatic uveal melanoma cell lines data from single and fractionated doses 
do indicate large variations in radiosensitivity, which are mainly dominated by the intrinsic 
radiosensitivities. Doses of around 8 Gy in 5 fractions would be sufficient to eradicate 109 
cells (approximately 1 cm3) of the most radioresistant tumour cell lines, but this schedule 
is overkill for the radiosensitive tumour cell lines. Based on specific morphological and 
histological tumour markers more individualised dose fractionation schedules could improve 
the therapeutic ratio for uveal melanomas. IOVS 2003 Nov;44(11):4660-4. 
Dose fractionation effects in primary and metastatic human uveal melanoma cell lines
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Introduction
For small and medium sized uveal melanomas radiotherapy is the first choice 
of treatment. Large dose fractions of 10 – 12 Gy offer patients an eye and vision-
sparing alternative to enucleation. However, radiotherapy-related acute and late 
ocular complications have been reported (Char, et al. 1998; Finger 1997). Reduction 
of these side effects and improvement of the therapeutic ratio could be achieved by 
a better understanding of the radiosensitivity and capacity for DNA damage repair 
of these tumours. So far, only limited information on the cellular radiosensitivity 
of uveal melanoma cell lines is available (Logani, et al. 1995a; Logani, et al. 1995b; 
Soulieres, et al. 1995). In a recent publication large differences in the intrinsic cellular 
radiosensitivity were demonstrated for primary and metastatic human uveal 
melanoma cell lines (van den Aardweg, et al. 2002). The data also pointed to large 
differences in the capacity for repair of radiation-induced DNA damage justifying a 
more refined study with the use of split dose irradiation. 
In this paper we present single dose and split dose data for cell survival curves 
analysed with the Linear Quadratic (LQ) model (Barendsen 1982; Douglas and Fowler 
1976; Thames, et al. 1982). This provides information on the intrinsic radiosensitivity 
and repair capacity of these uveal melanoma cell lines. In the LQ model the 
α-component is regarded as a suitable parameter for the intrinsic radiosensitivity. 
An alternative way of expressing the radiosensitivity is the surviving fraction at 2 Gy 
(SF2) (Brock, et al. 1989; Davidson, et al. 1990; Steel and Peacock 1989). When a single 
dose of X-rays is divided into two fractions separated by an interval of several hours, 
an enhancement in survival occurs. The magnitude of this recovery, interpreted as 
a reflection of the repair of sublethal DNA damage induced by the first dose, can be 
expressed by the β-component in the LQ model. 
Material and methods
Cell lines and culture conditions
 Four primary and four metastatic uveal melanoma cell lines were used throughout 
this study. Two cutaneous melanoma cell lines were also tested for comparison. 
Details of the cell lines and culture conditions have been described previously 
(van den Aardweg, et al. 2002). A few adjustments were made in comparison with 
the previous study. Cells were plated with a range of increasing concentrations 
and incubated for 2 hr instead of overnight incubation, to allow cell attachment 
before commencing with radiation. Overnight incubation for cell attachment is not 
appropriate for cell lines with short doubling times, as indicated in this study. For 
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some cell lines (OCM-1, 92-1, OMM-1 and Bowes) higher cell concentrations were 
also used in this study, particularly after the higher doses, in order to increase colony 
numbers and hence to obtain more reliable data 
Irradiation and clonogenic assay
Technical details of the irradiation procedure and the colony assay have been described 
previously (van den Aardweg, et al. 2002).  Single doses of 0-10 Gy were given with 
one 6-well plate per dose point containing two consecutive cell concentrations. In 
the dose fractionation experiment the total dose was split in two equal fractions with 
a time interval of 5 h. An interval of 5 h is sufficient for maximum repair of DNA 
damage without substantial cell cycle progression (Elkind and Sutton 1960; Steel 
1993).  For the split dose study a separate set of 6-well plates was used again with one 
plate per dose point and containing two consecutive cell concentrations. Both single 
and fractionated irradiations were carried out in conjunction on the same day. After 
irradiation cells were incubated for colony formation. Slow growing cell lines (92-1) 
were incubated for 21 days instead of the standard 7 days (OCM-1, MelSK28, Bowes) 
or 14 days  (Mel 202, OMM 2-2, OMM 2-3, OMM 2-6, Mel 270, OMM-1) to achieve 
sufficient colony formation. Once the colonies reached an appropriate size they were 
fixed and counted, as published previously (van den Aardweg, et al. 2002).
Data Analysis
Cell survival curves were obtained for each cell line by analysing the surviving 
fractions with the Linear Quadratic (LQ) model, as described in detail previously 
(van den Aardweg, et al. 2002). For both single dose and split dose irradiations cell 
survival curves were averaged from at least 3 repeat experiments per cell line and 
with two different cell concentrations per dose point (Table 1). The α-coefficients 
and the surviving fractions at 2 Gy (SF2) were calculated as estimates of the intrinsic 
radiosensitivity. Along similar lines β-coefficients were calculated, which represent 
the capacity for repair of sublethal DNA damage. Both the α- and β-components are 
cell (and tissue) specific and were used to derive the α/β  ratio, the dose at which the 
contribution of the linear and the quadratic component are equal. Low α/β  ratios 
(<5 Gy) provides a ‘curvy’ cell survival curve for radiosensitive cells with a relatively 
low α-value, while higher α/β ratios give less ‘curvier’ cell survival curves indicative 
for cells with a relatively high α-value. In addition, cells displaying low α/β  ratios 
are being spared by dose fractionation, while opposite effects are seen for cells with 
high α/β  ratios.
For very steep cell survival curves representing radiosensitive cells, the 
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correspondingly low α- and SF2 -values dominate these curves, which makes it 
difficult to establish reliable values for the β-coefficients. In such cases large values 
for the β-component can be overlooked (Peacock, et al. 1988; Steel and Peacock 
1989). A low plating efficiency would hamper the analysis even further, due to the 
small dose range for which cell survival could be measured (Peacock, et al. 1988). 
To overcome this problem the use of the split-dose method provides a much more 
reliable estimate for the β-component. Based on the LQ-model it is predicted that 
the survival recovery ratio, the ratio of split dose and single dose cell survival, 
increases progressively with dose per fraction (Thames, et al. 1982). There is a linear 
relationship between the recovered ratio and the dose per fraction d. 
Recovered ratio (RR)=exp(2βd2) which converts into ln(RR)=2βd2. In this formula d are 
equal doses per fraction in a split dose experiment; a split of d + d (i.e. 1 + 1 Gy, 2 + 2 Gy, etc). 
The slope of this linear relationship provides an estimate of the β-component, 
termed βRR, which is derived independently of the α-component. It was argued that 
at least 4 different dose levels were required for a proper estimate of the slope of 
this linear relationship (Peacock, et al. 1992). In this study all split-dose experiments 
were carried out standard at 6 different dose levels. The βRR values presented in 
Table 1 are averages of at least 3 independent experiments per cell line with two 
different cell concentrations per experiment.
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Cell type Plating Eff. (%)
(Mean ± SEM)
Cell doubling time (h)
Mean ± SEM
α(Gy –1) β (Gy –2) α/β (Gy)
(Mean ± SEM)
SF2 βRR (Gy 
–2) α/β RR (Gy)
Uveal melanoma
OCM-1
100 – 6400 a)
29.4 ± 2.3b)
29.9 ± 3.0c)
18.1 ± 0.4 0.153
0.154
0.047   3.5 ± 0.5
  
0.61
0.66
0.039 3.9
Mel 270
800 – 25600
9.4 ± 1.0
8.8 ± 1.2
42.7 ± 1.3 0.534
0.451
0.027 20.8 ± 1.6 0.31
0.37
0.031 17.5
OMM 2-2
200 – 6400
42.2 ± 3.7
43.1 ± 2.7
28.7 ± 1.6 0.436
0.439
0.092   4.7 ± 0.5
  
0.29
0.34
0.048 9.2
OMM 2-3
400 – 12800
18.5 ± 4.1
18.5 ± 4.0
36.4 ± 2.6 0.364
0.341
0.039 10.3 ± 1.6 0.41
0.47
0.041 8.9
OMM 2-6
400 – 12800
9.2 ± 0.6
9.6 ± 0.6
35.2 ± 1.7 0.330
0.365
0.046   8.8 ± 2.0
  
0.43
0.45
0.034 9.6
Mel 202
400 – 25600
32.1 ± 2.8
31.5 ± 1.9
25.1 ± 0.7 0.274
0.250
0.035 10.3 ± 3.0 0.50
0.56
0.032 8.5
92-1
400 – 51200
11.1 ± 1.2
10.2 ± 1.8
47.3 ± 2.0 0.860
0.833
0.010 84.5 ± 28.4 0.17
0.19
0.037 23.2
OMM-1
800 – 204800
5.8 ± 0.9
5.4 ± 0.7
37.5 ± 3.0 0.521
0.557
0.042 14.1 ± 2.6 0.30
0.30
0.024 21.3
Cutaneous melanoma
MelSK28
200 – 6400
26.7 ± 1.3
26.0 ± 1.8
16.9 ± 1.2 0.155
0.115
0.053 3.3 ± 0.6 0.59
0.66
0.029 5.3
Bowes
100 – 12800
28.7 ± 6.0
26.7 ± 5.9
18.5 ± 0.3 0.353
0.332
0.114 3.7 ± 1.2 0.34
0.36
0.062 5.7
a) Range of cell numbers plated per well 
b) Single dose data
Data for two equal fractions with a time interval of 5 h
Table 1.  Parameters for uveal and cutaneous melanomas                           after single and fractionated doses of X-irradiation
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Table 1.  Parameters for uveal and cutaneous melanomas                           after single and fractionated doses of X-irradiation
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Sulforhodamine B (SRB) assay
The cell doubling times were determined with the SRB-assay, which is a colorimetric 
and non-destructive assay (Skehan, et al. 1990). Cells were grown at 37°C in 96-well 
plates with lanes of 8 wells containing cell concentrations of 100, 250, 500, 1000, 2500 
and 5000 cells/ml and 200 μl medium / conditioned medium (1:1 v/v) per well. For 
each consecutive day, excluding Sundays, up to 7 days a separate plate was used. 
In each plate a lane of 8 wells with medium only acted as control.  At harvest the 
medium was removed and cells were washed three times with distilled water. Cells 
were fixed with 10% trichloroacetic acid (TCA) solution for 1 h at 4°C using 200 μl per 
well. The plates were washed 5 times with distilled water, air dried overnight and 
kept at 4°C.  All plates were stained simultaneously for 2 h adding 50 μl per well of a 
0.4% sulforhodamine B (SRB) solution in 1% acetic acid. Plates were washed 5 times 
in 1% acetic acid to remove unbound SRB. Per well 150 μl Tris (10 mMol/l) was added 
and kept overnight at room temperature to dissolve the bound SRB. The following 
day the optical density of the dye was measured for each well at 540 nm using a 
spectrophotometer (Biorad). For each lane of 8 wells the optical density was averaged 
omitting the highest and lowest value and subtracting the averaged control value. 
For each cell concentration the logarithmic values for the mean optical densities, 
expressed in arbitrary units and plotted as a function of time, gave straight lines. In 
a Slide Write Plus program linear regression analysis was used to computer fit lines 
to the data points. Examples of optical densities as a function of time are presented 
in Figure 1. From the slopes of these lines the cell doubling time was calculated. 
Data for the lowest cell concentration were occasionally unreliable producing lines 
with very shallow slopes indicating a very slow cell growth. For the highest cell 
concentrations and the longer growth periods arbitrary units in excess of 2000 were 
ignored, because it appeared the maximum reliable value in this assay. Beyond this 
value cell growth was not logarithmic anymore and diminished due to too high cell 
densities in the wells, as seen in figure 1 for OCM-1. Growth curves for the high cell 
concentrations based on only 2 or 3 time points were ignored. Values for the slopes 
of the growth curves from the intermittent cell concentrations were averaged and 
used to calculate a cell doubling time for each experiment. The overall cell doubling 
time for each cell line was an average obtained from at least three independent 
experiments.  
Results 
Cell doubling time
The cell doubling times for the uveal and cutaneous melanomas are presented in 
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Table 1. They range from 16.9 h (MelSK28) to 47.3 h (92-1). Examples of growth curves 
for a fast (OCM-1) and slow growing cell line (Mel 270) are presented in Figure 1. 
The short doubling times for some of these cell lines justified a short attachment 
period after plating before commencing irradiation. The short doubling times for 
some of these cell lines could have influenced the outcome of dose fractionation due 
to cell growth in between fractions. For the fast growing cell lines no significant cell 
growth could be determined with the SRB assay within 6 h after plating (data not 
shown).
Plating efficiency
The plating efficiencies, as obtained from the surviving fractions after a dose of 0 Gy, 
ranged from 5.4 % (OMM-1) to 43.1 % (OMM 2-2) with no significant differences with 
cell concentration for both single and fractionated doses (p> 0.16). Hence for each 
cell line data obtained for the two consecutive cell concentrations were combined. 
Also the plating efficiencies between the single and fractionated doses differed not 
significantly (p> 0.38) (Table 1). 
Cell survival curve parameters
Cell survival curves after single and fractionated doses are presented in Figure 
2 for the uveal and cutaneous melanomas. The parameters associated with these 
survival curves are presented in Table 1.  A wide range of α-coefficients was found 
after single doses with very high and low values for OCM-1 cells (0.153 Gy -1) and 
for 92-1 cells (0.860 Gy -1), respectively. Estimates for the α-coefficients, indicative 
for the intrinsic radiosensitivity, are reflected in the SF2 values with high values for 
radioresistant cell lines and lower values for the more radiosensitive cell lines. After 
single doses the β-coefficients ranged from 0.027 Gy –2 to 0.053 Gy –2, except for OMM 
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Figure 1. Growth curves for a fast (OCM-1) and a slow growing cell line (Mel 270) as obtained with the SRB 
assay. The slope of the curves is an estimate for the cell doubling time. Increasing cell concentrations of 100 
cells/ml ( ), 250 cells/ml ( ), 500 cells/ml ( ), 1000 cells/ml ( ), 2500 cells/ml ( ), and 5000 cells/ml ( ) were 
used. Cells were cultured in standard medium in the presence of conditioned medium (1:1 v/v).
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2-2 cells and the cutaneous melanoma Bowes cells, which produced much larger 
β -values of ≈ 0.10 Gy -2  (Table 1) indicating less efficient repair of DNA damage. This 
resulted in low α/β ratios of 3.5 - 4.7 Gy (OCM-1, OMM 2-2, SK28 and Bowes) and 
higher α/β ratios (> 8.8 Gy) for the other primary and metastatic uveal melanomas. 
The exception is cell line 92-1 with a large α-value of 0.86 Gy -1, while the β-value is 
very low resulting in a high α/β ratio of 84.5 Gy.  The low SF2 value indicates that this 
cell line is very radiosensitive. 
As expected, after split dose irradiation the α-components (initial DNA damage) 
remained very similar to those obtained after single doses with only minor 
deviations of ± 10%. For cell lines Mel270 and MelSK28 larger deviations of +15.4% 
and +25.5%, respectively, were obtained for the α-component.  As expected, the SF2 
values increased after split dose irradiation for all but one cell line, OMM-1. This 
increment in SF2 values is a reflection of repair of sublethal DNA damage in between 
the two fractions. 
The alternative method for obtaining a more accurate estimate for the β-component 
independent of the α-component, as reported by Peacock et al. (Peacock, et al. 1988; 
Peacock, et al. 1992), resulted in βRR- values similar to those obtained with single 
dose survival curves for the majority of cell lines (Table 1). Only for cell lines OMM 
2-2, 92-1, and OMM-1 the βRR- values deviated substantially which resulted in much 
higher (OMM 2-2 and OMM-1), or lower α/β ratios (92-1). 
Figure 2. Cell survival curves for various primary (OCM-1, Mel 270, Mel 202, 92-1) and metastatic (OMM 2-2, 
OMM 2-3, OMM 2-6, OMM-1) human, uveal melanomas in comparison with cutaneous melanomas (MelSK28, 
Bowes) after single doses of X-rays (solid lines) and split dose irradiation involving 2 equal fractions with an 
interfraction interval of 5 h (dotted lines). Cells were cultured in standard medium in the presence of condi-
tioned medium (1:1 v/v). If standard errors are not present they fall within the symbol. Data indicate a/b ratios 
(± SEM).
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Discussion
The single dose data, presented in this paper on the radiosensitivity for primary 
and metastatic human uveal melanoma cell lines, are more refined compared with 
those published earlier (van den Aardweg, et al. 2002). These earlier results could 
have been influenced by a confounding factor as cell growth during overnight 
attachment. The short cell doubling time for some of the cell lines indicated that a 
short attachment period of 2 h before commencing irradiation was more appropriate 
than overnight attachment. Apart from reduced plating efficiencies for nearly all 
cell lines this shorter attachment period gave also much higher α-values for OCM-1 
cells and Bowes cells, while for the cell types OMM 2–2, OMM 2-3, OMM 2-6 and 
MelSK28 cells the β-coefficient increased. This resulted in low α/β ratios of ≈ 3.5 Gy 
for the fast growing cell lines. In this study also better estimates for the single dose 
cell survival curves of 92-1 cells and OMM-1 cells could be obtained due to higher 
cell concentrations at the higher dose points and a longer post-radiation incubation 
time of 21 days (92-1). This resulted in more reliable data at higher doses explaining 
the differences in parameters with previously published data for these two cell lines 
(van den Aardweg, et al. 2002). 
Cells displaying a low α/β ratio, which is indicative for a sparing effect after dose 
fractionation, require large doses per fraction for effective tumour treatment. In 
this instance little benefit in therapeutic ratio will be seen, since the late responding 
normal tissues also display low α/β ratios in the range of 1-5 Gy. For cell lines with 
higher α/β ratios (> 6 Gy) conventional doses per fraction of 2 Gy should provide 
therapeutic gain with increased probability of tumour cure and sparing of late 
responding normal tissues. 
In this study, cell lines Mel270, 92-1, and OMM-1 displayed low plating efficiencies 
and high α-values after single dose irradiation and therefore estimates for the β-value 
could be inaccurate (Peacock, et al. 1988; Steel and Peacock 1989). The βRR-values for 
all cell lines displayed a narrow range of 0.024 Gy -2 (OMM-1) to 0.047 Gy -2 (OMM 2-
2), which was much smaller than that obtained from analysis of the single dose cell 
survival curves (Table 1). It appeared that for cell lines OMM 2-2, 92-1 and OMM-1 the 
βRR-values differed substantially from those obtained after single dose irradiation, 
but were now within the range of the other cell lines. Surprisingly, also for OMM2-2 
cells a much lower βRR-value was found as compared with the original β-value after 
single dose irradiation. Only for Bowes cells the βRR-value (0.0622 Gy 
-2) was outside 
this range, but it was about half the value obtained from the single dose cell survival 
curve. This had an effect on the new α/βRR ratios with that for OMM 2-2 cells in the 
same range as for the other metastatic cell lines OMM 2-3 and OMM 2-6; all three 
cell lines derived from the same primary melanoma Mel 270 (Table 1). Also for cell 
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line 92-1 and OMM-1 the α/βRR ratios changed to approximately 22 Gy. The new α/βRR 
ratios for the cutaneous melanomas increased to around 5.5 Gy.  
For a number of human tumour cell lines a linear relationship between ln(RR) and 
fraction dose (d), as predicted by the LQ model, has been demonstrated (Holmes, et 
al. 1990; Peacock, et al. 1988; Peacock, et al. 1992; Yang, et al. 1990), which resulted in 
a βRR-value independent of the α-component. It was also argued that an estimate of 
the α-component could be obtained independent of the β-component by low dose 
irradiation (Peacock, et al. 1988; Peacock, et al. 1992). In our institute facilities for 
low dose irradiation were not available and hence an estimate for an independent 
α-component could not be achieved. 
The βRR-values are in the normal range for tumour cell lines and differ only by a 
factor of 2. This would indicate that the capacity for repair of sublethal DNA 
damage is fairly constant for all cell lines investigated. This implies that the 
variations in radiosensitivity of these melanoma cell lines are more determined 
by the α-components, i.e. the intrinsic radiosensitivity, and to a lesser extent by 
contributions of sublethal DNA damage repair.  This has implications for clinical 
relevant dose fractionation schedules since cell types OCM-1, Mel 202 and MelSK28 
with low α-values and high SF2 -values would require relative large doses of around 
8 Gy in 5 fractions for effective elimination of a tumour containing approximately 
109 cells. In contrast, for cell type 92-1 doses of around 4 Gy in 5 fractions should be 
sufficient for effective eradication with a beneficial effect of limiting adverse normal 
tissue toxicity. 
In low dose rate (LDR) brachytherapy cell survival is entirely determined by the 
α-component, i.e. the intrinsic radiosensitivity, due to repair of sublethal DNA 
damage during the long exposure times and hence the absence of the β-component. 
For the two most extreme α-values in this study elimination of 109 cells of tumour 
type OCM-1 would require around 135 Gy, while this is only around 24 Gy for 
tumour type 92-1. With a dose rate of approximately 1 Gy /h this would indicate an 
exposure time of around 5.6 days for OCM-1 cells, while cells of tumour type 92-1 
would be eliminated in 1 day. 
Caution should be taken in translating these in vitro data directly to the clinical 
practice. However, studies have shown that for many tumour cell lines in vitro data and 
especially parameters related to the initial part of the cell survival curve, such as the 
α-component and SF2-value, seem to correlate with the clinical radioresponsiveness 
of human tumours (Malaise, et al. 1986). The fact that the radiosensitivity of these 
uveal melanomas is mainly determined by the intrinsic radiosensitivity should 
encourage a study on specific morphological and histological tumour markers, 
which could be applied in the clinical situation without biopsying the tumour. Based 
on these morphological markers tumour classification would become a possibility 
leading to more individualised dose fractionation schedules.  
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Abstract
Context: Radiotherapy of an eye before enucleation, so called pre-enucleation radiotherapy 
(PER) of uveal melanoma patients, was initiated in order to reduce enucleation-induced 
systemic metastasis. So far, earlier studies with a short follow-up period did not demonstrate 
a significant effect on survival. Objective: To study the effect of PER on melanoma-related 
mortality after over nine years of follow-up. Design In a prospective study, 167 uveal 
melanoma patients were treated between 1978 and 1992 by irradiation with 8 Gy given in 
two fractions two days before enucleation. A group of 108 uveal melanoma patients, treated 
between 1971 and 1992 by enucleation only (EO) in the same hospital, served as a historical 
control group. Patients were followed until December 2002 or until death. Main Outcome 
Measure: Effect of PER on survival. Results: Melanoma-related death occurred in 32.3% 
of the PER treated group and in 40.7% of the EO group. Mean follow-up was 9.25 years. 
After 48 months of follow-up a significant difference in survival became evident in favour of 
the PER group. The estimated 15-year survival rates for patients with melanoma in the PER 
group and EO group were 63.7% and 51.0%, respectively. For patients dying due to all causes 
these percentages were 47.5% and 25.2%, respectively. In both groups, women had a better 
prognostic outcome than men. Conclusions: This study suggests that PER improves long-
term survival in uveal melanoma patients. Arch Ophthalmol. 2005 Oct;123(10):1363-7
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Introduction
Uveal melanoma is the most common primary malignancy of the eye. Although 
radiotherapy has become the treatment of choice, primary enucleation of the 
tumour-containing eye is still indicated in 30 to 50% of the cases. Nearly half of all 
patients will die from distant metastasis in time (Zimmerman and McLean 1984). 
In the past there was a controversy if early metastasis was due to the enucleation 
procedure or to undetectable micro-metastases prior to enucleation (Manschot 
and van Peperzeel 1980; Zimmerman, et al. 1978). Spreading of melanoma cells 
has been detected during the enucleation procedure in animal models as a result 
of physical manipulation of the eye (Niederkorn 1984). One method to reduce the 
potential risk of enucleation-induced metastasis is pre-enucleation radiotherapy 
(PER), which proved to be effective in animal models (Char and Phillips 1982; Hoye 
and Smith 1961; Kenneally, et al. 1988; Powers and Palmer 1968; Sanborn, et al. 1987). 
However, clinical application of PER has been abandoned, because no significant 
difference in survival could be demonstrated between PER and enucleation only 
(EO) groups (Augsburger, et al. 1990; Bornfeld, et al. 1989; Char, et al. 1988; COMS 
1998; Gunalp and Batioglu 1998; Kreissig, et al. 1989; Luyten, et al. 1995). The mean 
follow-up time in these clinical studies ranged from 5 to 8 years. Based on theoretical 
models, clinically manifest metastases are likely to occur 5 or 6 years after onset of 
the systemic dissemination (Eskelin, et al. 2000; Gamel, et al. 1992; Manschot and 
van Peperzeel 1980; Manschot and van Strik 1992; McLean 1993). For this reason, we 
extended our earlier study (Luyten, et al. 1995) with a longer follow-up to study the 
effect of PER.
Methods
Data collection
All consecutive patients with a diagnosis of choroidal or ciliary body melanoma 
without clinical evidence of metastatic disease at presentation and who were 
treated either by EO or by PER between 1971 and 1992 (Table 1) were entered in 
this study. All patients were diagnosed and treated in the Rotterdam Eye Hospital 
or the University Hospital Rotterdam. Patients were extensively informed on the 
various treatment options, such as observation, EO or PER. Between 1978 and 1982 
patients were treated by PER or EO depending on personal preference of their 
ophthalmologist in the hospital. From 1982 until 1992 all patients were treated by 
PER as a standard protocol, unless there were contraindications. From April 1992 
on, PER was discontinued because interim analysis showed no beneficial effect on 
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survival. PER was delivered 48 and 24 hours before enucleation by two fractions 
of 4 Gy electron beams (16 MeV) by means of a 5 x 5 cm anterior field on a linear 
accelerator. The present study includes the same groups of uveal melanoma patients 
treated between 1971 and 1990 on which we previously reported (Luyten, et al. 1995), 
plus all consecutive uveal melanoma patients treated till December 1992. The control 
group consisted of all patients treated by EO between 1971 and 1992 (Table 1). All 
patients were followed till death or December 2002. 
Patients had a complete physical examination before surgery, including chest X-ray, 
and liver function tests; from 1978 on liver ultrasonography was routinely added. In 
case of clinical evidence for metastatic disease prior to surgery they were excluded 
Patients were followed up twice a year in the first two postoperative years; after that 
annual check-ups were performed. The follow-up program included ophthalmoscopy 
of the remaining eye, inspection of the socket, palpation of pre-auricular and 
submandibular lymph nodes, and liver-enzyme tests. Follow-up data on patients 
failing their appointment were obtained by contacting their general practitioner, 
local ophthalmologist, or both. To verify the date and cause of death, the files from 
the general practitioner, hospital or both were recovered. Melanoma-related death 
was diagnosed in case of histopathologic confirmation of metastases or by clinical 
evidence (laboratory and radiodiagnostic) of metastatic disease. Otherwise, the 
patients were considered to have died from other causes. 
The following patient and histopathologic data were recorded: date of enucleation, 
age at date of the enucleation, gender, location of the tumour (ciliary body, choroid), 
on histology largest tumour diameter (mm) and tumour thickness (mm), cell type 
(epitheloid, non-epitheloid), extrascleral growth, follow-up time, and eventual cause 
of death. An ophthalmic pathologist reviewed all histopathologic data. From each 
tumour, at least ten consecutive slides were examined.
Data analysis
The χ2-test was used for comparison of gender, tumour location, cell type and extra-
scleral growth in the PER and control group. We used the two-sample Student t-test 
comparing largest tumour diameter and age. Univariate survival analysis was 
performed by Kaplan Meier curves accompanied by the log rank test to study the 
effect of PER. To investigate whether PER had a different effect on late follow-up 
compared with early follow-up, the log rank test was performed separately for both 
periods. A cut-off period of 48 months was chosen because for this time point the 
likelihood of our statistical model was maximal. The Cox regression model was 
used for multivariate analyses. In this model, the effect of PER was allowed to 
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differ between the periods before and after 48 months of follow-up, using two time-
dependent covariates defined as follows: the first, representing the effect of PER in the 
first 48 months, was defined as being equal to 1 at follow-up times before 48 months 
for patients with PER, and equal to 0 otherwise. The second, which represented the 
PER effect after 48 months, was defined as being 1 after 48 months for patients in the 
PER group, and 0 otherwise. We checked on the linearity assumption of each of the 
continuous covariates in the model by looking whether adding its square made the 
model significantly better. We also checked on the proportional hazards assumption 
by testing the significance of the interaction of each covariate with the logarithm of 
follow-up time. All survival analyses were performed both for melanoma-related 
death (other causes of death censored) as well as for death due to all causes.
Table 1. Clinical and histopathologic data
Enucleation only 
(N=108)
Pre-enucleation 
radiotherapy (N=167)
P-value
1971 - 1977 53 0
1978 - 1981 31 21
1982 - 1992 24 146
Average age, mean (range), yr 62.5 (16-89) 57.6 (21-92) 0.006
Gender, No. (%) 0.388
Male 64 (59.3%) 90 (53.9%)
Female 44 (40.7%) 77 (46.1%)
Posterior location, No. (%) 98 (90.7%) 144 (86.2%) 0.261
Largest tumor diameter, mean (range), mm 12.2 (4 - 20) 11.6 (2 - 22) 0.150
Prominence, mean (range), mm 7.0 (1 - 20) 6.4 (1 - 20) 0.248
Epitheloid cell type, No. (%) 61 (56.5%) 90 (53.9%) 0.673
Extrascleral growth, No. (%) 29 (26.6%) 39 (23.4%) 0.114
Mean Follow-up (Months) 111 114
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Results
Between 1971 and 1992 275 patients were treated of whom 167 patients received 
PER (Table 1). Seven cases received no PER because of acute angle closure glaucoma 
(n=1), unexpected melanoma in a phthisic eye (n=1) and a period of breakdown of the 
radiation equipment (n=5), and were included in the EO group. Mean follow-up was 
114 months in the PER group and 111 months in the EO group. In the PER group four 
patients were lost to follow-up after 115-234 months; in the EO group one patient 
after 24 months. Six patients in the PER group and 10 in the EO group received 
postoperative radiation therapy (28-32 Gy in fractions of 4 Gy) due to extrascleral 
tumour extension. Data on age, gender, tumour location, tumour size, cell type and 
extrascleral growth for the PER and the EO group are shown in table 1. The two 
groups differed significantly (P=.006) in age. There was no statistically significant 
difference between both groups in gender, tumour location, largest tumour 
diameter, cell type and extrascleral growth. In 54 of 167 (32.3%) patients treated with 
PER and in 44 of 108 (40.7%) EO patients melanoma-related death occurred. All-
cause death was specified in 90 of 167 (53.9%) patients treated with PER and 81 of 
108 (78.8%) patients treated with EO. The estimated Kaplan Meier 5-, 10- and 15-year 
survival rates in the patient group with melanoma-related death were 76.5%, 69.8% 
and 63.76% respectively in the PER group and 71.2%, 57.2% and 51.0%, in the EO 
group (Figure 1A). No difference in survival rates between the PER and EO group 
was found with the log-rank test (P=.091) for the whole period of follow-up. Also in 
the early follow-up, the period before 48 months, no significant difference (P=.709) 
between both groups could be demonstrated by the log-rank test. However, survival 
was better (P=.003) after 48 months in the PER group. The estimated 5-, 10- and 15-
year survival rates in the patient group dying of all causes were 71.3%, 57.5% and 
47.5%, respectively, in the PER group and 62.7%, 40.2% and 25.2%, respectively, in 
the EO group (Figure 1B).
Melanoma-related death was associated with older age (P<.001), male gender (P=.026), 
larger tumour size (P<.001), and epitheloid cell type (P=.006) in the univariate 
analysis. No association was found for the year of treatment (P=.164). To adjust for 
the potential confounding prognostic variables, such as year of enucleation, age at 
enucleation, gender, tumour location, tumour size and cell type, on the effect of PER 
a multivariate Cox-regression was used (Table 2) for melanoma-related death. In the 
first period of 48 months there was no significant effect of PER (P=.479) on survival, 
whereas after 48 months there was a significant association (P=.006).
Reduced melanoma-related mortality in uveal melanoma by pre-enucleation radiotherapy
41
The estimated adjusted hazard ratio (PER versus EO) for melanoma-related death 
after 48 months was 0.39 (P=.006). Similar Cox regression was also used for death 
due to all causes (results not shown). The estimated adjusted hazard ratio (PER 
versus EO) for all cause death before 48 months was 1.21 (P=.476) and after 48 months 
0.50 (P=.003). In the EO group metastases seemed to occur more often in men than 
in women (P=.073), whereas in the PER group the percentages were not significantly 
different (P=.994). A significant difference was demonstrated in the effect of PER on 
survival between men and women (P=.026) when the interaction between gender 
and PER was added in the multivariate analysis.
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Figure 1.
Estimated Kaplan-Meier survival curves of patients managed by pre-enucleation radiotherapy versus enucle-
ation alone. A. indicates melanoma-related deaths and B. deaths from all causes.
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Discussion
In this study, we observed a beneficial effect on long-term survival of PER by two 
fractions of 4 Gy compared to EO. The effect became apparent after 48 months of 
follow-up. This dose should be sufficient to eradicate most (±90%) of the tumour 
cells and induce a reduction in proliferation activity of melanoma cells as has been 
demonstrated in in vitro and experimental studies (Kenneally, et al. 1988; Mooy, et al. 
1990; van den Aardweg, et al. 2002).
Pre-enucleation radiotherapy did not decrease the short-term melanoma-related 
death (Augsburger and Gamel 1990; Bornfeld, et al. 1989; Gunalp and Batioglu 1998). 
Likewise, no beneficial effect of PER on survival was found in an uncontrolled 
prospective study of 80 patients with primary choroidal and ciliary body melanoma 
(Bornfeld, et al. 1989) or in an uncontrolled retrospective study on 26 patients with 
choroidal melanoma (Kreissig, et al. 1989). Moreover, preoperative radiation with 
five fractions of 4 Gy had a worse prognosis in a series of 41 non-randomly selected 
patients (Char, et al. 1988). Augsburger et al. (Augsburger, et al. 1990) found a non-
significant cumulative 5-year survival probability of 63.9% for 29 patients in the PER 
group versus 57.9% for 29 patients in the EO group. The COMS trial (COMS 1998) 
reported an estimated 5-year survival rate of 62% in the PER group and 57% in the 
EO group. In our earlier report we found a cumulative 7.5-year survival probability 
Table 2. Influence of treatment and possible confounders on melanoma-related death
ß¹ standard 
error
p-value hazard ratio² 
(95% CI)
PER vs. EO
before 48  months .22 .31 .479 1.25 (0.67-2.31)
after 48 months -.94 .34 .006 0.39 (0.20-0.76)
Age (one year increase) .04 .01 <.001 1.03 (1.02-1.06)
Gender (women vs. men) -.48 .21 .026 0.62 (0.41-0.95)
Tumour location (anterior vs. posterior) .63 .25 .014 1.88 (1.14-3.10)
Largest tumour diameter (one mm increase) .12 .03 <.001 1.13 (1.07-1.19)
Cell type (epithelioid vs. spindle) .62 .23 .006 1.86 (1.19-2.90)
Year of treatment .03 .02 .164 1.03 (0.99-1.07)
¹The ß-coefficient is the natural logarithm of the hazard ratio.
²A hazard ratio, for instance .62 for gender, means that at each time during follow-up women have a 
chance of dying within one month equal to .62 times the chance of dying within one month for men.
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of 75.9% in the PER group and 72.1% in the EO group (Luyten, et al. 1995), which was 
not significantly different. However, in the present extended study we observed a 
reduction in risk in the PER group after a period of 48 months (P=.006). This suggests 
that a longer follow-up is needed to confirm differences.
Death in the first 48 months is therefore probably mainly due to micrometastatic 
spreading of tumour cells before initiation of the treatment (Eskelin, et al. 2000; 
Manschot and van Strik 1992). Peroperative spreading is most likely responsible 
for a significant part of the melanoma-related deaths after 48 months and could be 
prevented by irradiation prior to enucleation.
The positive effect of PER is more evident in the 15-year all-cause survival rates 
(PER group versus the EO group 47.5% and 25.2%, respectively) in our study while 
these melanoma-related survival rates were 63.7% in the PER group and 51.0% in 
the EO group. All-cause survival is considered to be important since a significant 
proportion of melanoma patients die of non-melanoma causes after treatment 
(COMS 1998; Kroll, et al. 1998). However, Kroll et al. (Kroll, et al. 1998) published 
a report on all-cause versus cause-specific analyses of mortality after radiation of 
uveal melanoma. They reported that in analysing prognostic factors information 
might be lost if analyses are based only on all-cause survival, since the disease does 
not appear to increase the risk of death from other causes. Survival after treatment 
is dependent on tumour parameters as well as the expected survival of the patients 
independent of the melanoma. 
In our Cox proportional hazard analysis, melanoma-related death was associated 
with age, tumour size and cell type as previously described by others (Augsburger 
and Gamel 1990; Coleman, et al. 1993; Folberg, et al. 1993; Jensen 1982; McLean, et al. 
1982). Although no significant difference was observed in several previous studies 
between men and women (Augsburger and Gamel 1990; Coleman, et al. 1993; Egan, 
et al. 1993; Gamel, et al. 1992; Jensen 1982; McLean, et al. 1982), we found that women 
had a better prognostic outcome than men. This difference in prognosis remained 
after adjusting for irradiation, age, tumour size, tumour location, cell type, and 
year of treatment. This confirms Folbergs’ finding of a more favourable outcome for 
women (Folberg, et al. 1993) and more recently it was put forward that women with a 
history of childbearing had an even better survival compared to nulliparae and men 
(Egan, et al. 1999). Also in studies with cutaneous melanoma women have a better 
prognosis than men (Stidham, et al. 1994; Thorn, et al. 1987). 
Compared to other studies our study has a large sample size and a long follow-up 
with little drop out. Patients of the EO and PER groups were not treated during the 
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same period, which could be considered as a shortcoming of our study. However, the 
effect of year of treatment, studied in a multivariate analysis, showed no significant 
association with melanoma-related death (P=.164). A significant difference in age was 
observed between the PER group and EO group. The average ages in EO and PER 
groups were 62.5 and 57.6 years, respectively. The older age in the EO group could 
have a negative influence on survival in this group. This might be a reason for the 
difference in the Kaplan-Meier survival estimate in favour for the PER group. After 
adjusting for this prognostic covariate in the multivariate analysis, the difference 
was still present. We cannot tell if this difference in age between the EO and PER 
groups was due to earlier tumour detection or shorter observation time of smaller 
tumours before the advice for enucleation was given. 
In conclusion, we found a long-term beneficial effect on survival after two fractions 
of 4 Gy PER. Life expectancy in women was more favorable than in men. Even 
though, our study has a long-term follow-up after PER, it would be interesting to see 
if longer follow-up in similar studies would lead to the same conclusion.
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Abstract
Purpose: Uveal melanoma is a highly malignant disease with a mortality of 50% at 10-15 
years. Previous studies have shown that chromosomal changes are associated with a decreased 
survival of the patient. However, these studies analysed small numbers of tumours that did 
not allow robust statistical analysis. Here we assess the independent value of numerical 
changes of chromosomes 1, 3, 6 and 8 on the disease free survival (DFS) in a large series 
of uveal melanoma patients. Patients and methods: 120 tumours from uveal melanoma 
patients were analysed for numerical changes of chromosomes 1, 3, 6 and 8 with cytogenetic 
analysis, fluorescent in situ hybridisation and/or comparative genomic hybridisation. Data 
were correlated with disease outcome in univariate and multivariate analyses using Kaplan-
Meier and Cox regression analyses. Results:  At a mean follow-up time of 45 months, 42 
patients had died or were suffering from metastatic disease. In the univariate analysis, loss 
of chromosome 3, gain of 8q, largest tumour diameter or the presence of epithelioid cells was 
associated with a decreased disease free survival. In the multivariate analysis, the effect of 
monosomy 3 on survival was largely modified by changes in chromosome 1p36. We found 
that, regarding all chromosomal changes, only concurrent loss of chromosome 1p and 3 was 
an independent prognostic parameter for DFS (p<0.001). Conclusions: In uveal melanoma, 
concurrent loss of chromosomes 1p and 3 is an independent predictor of decreased disease free 
survival. IOVS 2005 Jul;46(7):2253-7
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Introduction
Uveal melanoma is the most common form of primary eye cancer in adults with a 
mortality rate of fifty percent after ten to fifteen years (Egan, et al. 1988). Metastases 
occur predominantly in the liver. Early identification of patients at high risk of 
metastases may allow detection of metastases at a stage in which adjuvant therapy 
can be justified. Several prognostic factors based on clinical and histological features 
are known, for instance gender, age at time of diagnosis, largest tumour diameter 
(LTD), involvement of ciliary body and presence of epithelioid cells (Mooy and De 
Jong 1996). Nevertheless, none of these prognostic factors is specific enough for 
identification of patients at risk of metastatic disease. Cytogenetic abnormalities 
are correlated with the clinical outcome of patients with leukaemia and lymphoma 
(Le Beau and Rowley 1986). Uveal melanomas are highly amenable for cytogenetic 
analysis and show mostly simple karyotypes in contrast to most other solid tumours. 
Non random chromosomal abnormalities, such as variation in chromosomes 1p, 3, 
6 and 8 were detected in these tumours (Prescher, et al. 1995; Sisley, et al. 1990). Loss 
of chromosome 3 and gain of chromosome 8q have been associated with a high 
mortality rate, whereas abnormalities of chromosome 6 were found to correlate 
with a good prognosis (White, et al. 1998a). However, these data were obtained from 
relatively small studies. Furthermore, the independent value of these chromosomal 
changes and the effect of chromosome 1p loss on survival remain to be determined. 
The purpose of this present study was to investigate the association between 
chromosomal changes and clinical and histological variables. Furthermore, we 
aimed to examine the independent effect and interactions of numerical changes 
of chromosomes 1, 3, 6 and 8 on disease free survival (DFS) of uveal melanoma 
patients. 
Patients and methods
Patients and tumour samples
From March 1992 to April 2003, we collected tumour material of 152 consecutive 
patients who underwent enucleation for ciliary body or choroidal melanoma. 
Informed consent was obtained prior to enucleation and the study was performed 
according to the tenets of the Declaration of Helsinki. Fresh tumour material was 
obtained within 1 hour after enucleation according to a standardised protocol; 
incision is made through the tumour leaving the optic nerve intact. The quantity 
of obtained tissue (5-8 mm3) depended on tumour size. A sample was taken from 
the side opposed to the optic nerve and divided into two; one part was processed 
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for cytogenetic analysis and/or fluorescent in situ hybridisation (FISH), whereas 
the other part was stored in liquid nitrogen. Until January 1995 only cytogenetic 
analysis was performed which was successful in 15 out of 46 cases. From that time on 
tumours (n=106) were analysed with FISH and, if metaphases could be obtained, with 
cytogenetic analysis. In the latter ones comparative genomic hybridisation (CGH) 
analysis (n=30) was performed on tumour material that could not be completely 
analysed by these two techniques. Conventional histopathologic examination was 
performed on all tumours and confirmed the origin of the tumour. Cytogenetic 
studies were also carried out on stimulated peripheral blood samples of each 
patient to exclude the presence of congenital chromosome abnormalities. Follow-up 
data from time of diagnosis till the end of the study in April 2004 were obtained 
by reviewing each patient’s charts and contacting their general physician. Three 
patients were at that time lost to follow-up. From two of these patients, however, 
a late date of follow-up was obtained and they were therefore also included in the 
study. From the 120 patients included in the survival analysis, there were 67 men 
and 53 women. The age at time of diagnosis ranged from 21 to 87 years (mean 61). 
The mean duration of follow-up, from diagnosis to presence of metastases or end of 
study, was 45 months (range 6-142 months). 
Histological findings 
The mean and median tumour diameter and thickness were 12.7 and 13.0 mm (SD 
3.3; range 4.5-19), and 7.8 and 8.0 mm (SD 3.7; range 1.5-22), respectively. Twenty 
tumours showed involvement of the ciliary body and 100 were located in the choroid. 
Cell type was classified as mixed/epithelioid in 69 tumours and spindle cell type in 
51 tumours.
Cytogenetic, FISH and CGH analysis
Cytogenetic analysis
Chromosome preparations were made according to standard procedures and stained 
with acridine orange or atebrine to obtain R or Q banding. Cytogenetic abnormalities 
were described in accordance with the ISCN (1995)(Mitelman 1995). 
FISH analysis
Dual colour FISH on uncultured tumour material using centromeric and locus 
specific cosmid, P1 or YAC probes for chromosome 1, 3, 6 and 8 was performed as 
described previously (Naus, et al. 2002). Seven probes were used: p1-79 (mapped to 
chromosome band 1p36), Pa 3.5 (centromere 3), YAC 827D3 (3q24), cos85 (6p21) and 
cos52 (6q23) (Prof. Y Nakamura, Tokyo, Japan), D8Z2 (centromere 8) and ETO (8q22). 
The probes were validated on normal peripheral blood cell metaphase spreads and 
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ten metaphases were analysed for each probe. Cut-off limits were less than three 
percent. The concentration for centromeric probes was 5 ng per slide; for cosmids, P1 
and YAC probes 50 to 75 ng per slide were used. After hybridisation and washing, 
slides were counterstained with 4’, 6-diamidino-2-phenylindole and mounted in 
anti-fade solution (Dabco-Vectashield 1:1). Signals were counted in 300 interphase 
nuclei according to the criteria of Hopman et al. (Hopman, et al. 1988). Scoring for 
deletion (>15% of the nuclei with one signal) or amplification (>10% of the nuclei 
with 3 or more signals) were adapted from the available literature (van Dekken, et 
al. 1990). 
CGH analysis
DNA from formalin-fixed paraffin-embedded tumour material was isolated from 40 
10μm sections. The pigmented tumour was scraped off from the glass slides using 
a fine scalpel. Excised material was deparaffinised in xylene and ethanol and air-
dried. Isolation of DNA was performed using the DNA tissue kit (Qiagen, Hilden, 
Germany). Concentration was determined using a fluorometer (Biorad, Veenendaal, 
The Netherlands), whereas molecular weight was estimated on ethidium-bromide 
stained agarose gels. Tumour DNA and reference DNA (0.5mg) was labelled using 
the Bio-prime DNA labelling kit (Invitrogen, Breda, The Netherlands) with Spectrum 
Green (Vysis, Hoofddorp, The Netherlands) or Alexa 594 (Molecular Probes, Leiden, 
The Netherlands) respectively. Equal probe mixture of tumour and reference DNA 
was denatured and hybridised in the presence of human cot-1 DNA to normal male 
metaphase chromosomes for three days at 37ºC. Samples were counterstained with 
DAPI in anti-fade solution. Images were acquired with a Zeiss axioplan microscope 
equipped with Isis software from Metasystems (Metasystems, Altlussheim, 
Germany). For each case ten metaphases were analysed. Loss of DNA sequences 
was defined as chromosomal regions where the mean green: red ratio was below 
0.8, while gain was defined as chromosomal regions where the ratio was above 
1.2. Threshold levels were determined on basis of analysis of known chromosomal 
aberrations.
Data classification
We subdivided the variation in chromosomes 1p, 3, 6p, 6q and 8q using cytogenetic 
and FISH analysis into 3 categories: loss of one copy, normal copy numbers (two 
copies) and gain of one or more copies. Monosomy 3 was defined when, using FISH, 
there was only one signal seen for both the centromere 3 and 3q24 probe. Gains of 
6p and 8q were scored when more than 2 signals were found for both the 6p21 and 
8q22 probe, and loss of 1p and 6q when the probes for 1p36 and 6q23 showed only 
one signal.
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When different subclones were identified, only the FISH findings of the largest 
clone were classified. Cytogenetic and CGH results were classified for those regions 
studied with FISH analysis. All major chromosomal changes detected by cytogenetic 
analysis could also be detected by FISH analysis. 
Statistical analysis
The primary end point for DFS was the time to development of metastatic disease 
from time of enucleation, whereby death due to other causes was treated as censored. 
The influence of single prognostic factors on DFS was assessed using the log rank 
test (for categorical variables) or Cox proportional hazard analysis (for continuous 
variables) and Kaplan-Meier curves were made to illustrate the differences in 
survival. Comparisons of the distributions of clinical and chromosomal variables 
were performed with Fisher’s exact test (for categorical variables) and the Mann-
Whitney test (for continuous variables). To identify the independent value of the 
prognostic factors on disease-free survival we used a multivariate Cox proportional 
hazard analysis and the likelihood ratio test. Possible prognostic factors were age at 
time of diagnosis, cell type (spindle cell vs. mixed / epithelioid cell), largest tumour 
diameter, mutual loss of chromosome 1p36 and 3, and gain of 8q. All tests were 
two-sided. An effect was considered significant if the p-value was 0.05 or less. The 
statistical analyses were performed with the SPSS-11 software.
Results
 
Of the 152 uveal melanoma, 32 cases we could not be analysed for chromosome 1p, 
3, 6 and 8 abnormalities. A total of 120 uveal melanoma cases were analysed for 
chromosomal changes using cytogenetic, FISH and/or CGH analyses. Cytogenetic 
analysis was successful in 69 out of 120 tumours. For 55 tumours cytogenetic and FISH 
data were available, while for 47 tumours only FISH was performed. Additionally, 
in 30 tumours CGH analysis was performed. Not all probes could be tested on all 
tumours because of lack of material. The mean number of probes successfully used 
for FISH was 5.5. Combining cytogenetic, FISH and CGH data genomic abnormalities 
were found in 88 percent of the 120 tumours. Results for all chromosome regions (1p, 
3, 6p, 6q and 8q) were obtained for 108 tumours (varying from 108-118 successful 
analyses per region, Table 1). Thirty-eight patients had died from metastatic disease 
and four were suffering from metastases at time of evaluation.
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Univariate analysis of the single prognostic factors showed significantly lower DFS 
for patients with loss of chromosome 3, gain of 8q and with a mixed/epithelioid cell 
type in the tumour compared to patients without these chromosomal changes or 
with a spindle cell type (Table 1). The largest tumour diameter was also significant 
in the univariate analysis. Other potential prognostic factors such as gender, age 
at time of diagnosis, tumour thickness and tumour location (i.e. involvement of 
ciliary body) did not reach significance. Also chromosomal changes such as loss of 
chromosome band 1p36, gain of chromosome 6p and loss of chromosome 6q were 
not significantly associated with disease free survival. 
To examine the possibility that other chromosomal variations may affect the 
prognosis of the monosomy 3 patients, we constructed Kaplan-Meier curves of 
Table 1. Univariate analysis of prognostic markers on disease free survival 
in uveal melanoma
variable mean p-value*
Age at time of diagnosis (yrs) 61 0.079†
Largest tumor diameter (mm) 12.7 0.011†
Tumor thickness (mm) 7.8 0.293†
variable no. of patients (%) p-value*
Mixed/epithelioid cell type 69 (58) 0.003
Involvement ciliary body 20 (17) 0.521
Male gender 67 (56) 0.978
loss of 1p36 41/118 (35) 0.081
loss of chromosome 3 55/109 (50) <0.001
gain of chromosome 6p 34/111 (27) 0.497
loss of chromosome 6q 33/108 (31) 0.319
gain of chromosome 8q 69/110 (63) <0.001
* Log-rank test 
† Cox-regression analysis
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chromosome 3 changes stratified for the other chromosomal changes and performed 
log rank tests (results not shown). We found that the effect of monosomy 3 on DFS 
was substantially modified by changes in copy number of chromosome 1p36. In 
tumours with normal copy numbers of chromosome 1p36, a small difference in 
DFS was observed between those patients with and without loss of chromosome 
3 (p=0.064) whereas this difference was highly significant in patients with tumours 
with also loss of chromosome 1p36 (p<0.001). The interaction term between tumours 
with loss of chromosome 1p36 and 3 and the remaining patients (i.e. patients with 
tumours with normal copies of chromosome 1p36 and 3 or with either 1p36 or 3 loss) 
was highly suggestive (HR= 3.61), but did not reach significance (p=0.155). In addition, 
we compared the DFS of patients with a concurrent loss of chromosome 1p36 and 
chromosome 3 with the remaining patients using the log rank test. The difference in 
survival was found to be highly significant (p<0.001) (Figure 1). Remarkably, gain of 
chromosome 1p36 occurred in 5 patients, but this number was too small to perform 
statistical analysis.
Considering the strong interaction between chromosome 1p and 3 losses, we 
validated whether this concurrent loss is an independent parameter for DFS. 
Significant correlations between age at time of diagnosis, tumour diameter, cell type, 
chromosome 6p and 8q gains using Mann-Whitney and Fisher’s exact tests (Table 2) 
were observed. Monosomy 3 was associated with age at time of diagnosis (p=0.050), 
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Figure 1. Kaplan-Meier survival curve of loss of chromosome 1p36 and/or chromosome 3 
Dashed line: tumours with concurrent loss of 1p36 and 3; solid line: tumours with loss of only chromosome 1, 
region p36; only monosomy 3; or neither 1p36 nor 3 (P < 0.001). 
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cell type (p=0.013) and mean tumour diameter (p=0.002). Gain of chromosome 6p was 
correlated with cell type (p=0.008) and gain of chromosome 8q with mean tumour 
diameter (p<0.001). These chromosomal changes and confounding variables were 
analysed in a multivariate model. After correcting for these variables, we found that 
patients with tumours with concurrent loss of chromosomes 1p36 and 3 have an 
almost 7.8 times higher chance of developing metastases compared to those without 
these losses or with either 1p36 or 3 loss (p=0.039) (Table 3). Gain of chromosome 
8q (HR=2.43, p=0.054) and mixed/epithelioid cell type (HR=2.24, p=0.077) almost 
reached significance and the other variables (gain of chromosome 6p, largest 
tumour diameter and age at time of diagnosis) were not significant. Furthermore, 
the interaction term between monosomy 3 and gain of chromosome 8q was not 
significant (HR=0.53; p=0.469). When analysed in a multivariate model with the 
confounding variables, such as age at time of diagnosis, gain of chromosome 6p, cell 
type and mean tumour diameter, we found a hazard ratio of 0.67 with a p-value of 
0.676 (data not shown).
Discussion
Previous studies already demonstrated the non-random occurrence of cytogenetic 
abnormalities of chromosome 1, 3, 6 and 8 in uveal melanoma. Monosomy 3 and 
gain of 8q have been shown to be associated with poor survival after treatment for 
uveal melanoma (Prescher, et al. 1996; Sisley, et al. 1997; White, et al. 1998a). Using 
univariate analysis we confirmed these findings. In addition, we demonstrated in 
the present study, which is the largest series described so far therefore allowing 
multivariate statistical analysis, that tumours with a concurrent loss of chromosomes 
3 and 1p36 are at high risk of metastasising (HR=7.81, Table 3). The molecular genetic 
changes that underlie these chromosomal changes have not yet been determined. 
Chromosome 1p loss occurs frequently in many solid tumours like skin melanoma 
and neuroblastoma. In the latter tumour type, loss of chromosome 1p is known to 
be a predictor of unfavourable outcome of the patient (Caron, et al. 1996; Knuutila, 
et al. 1999). In uveal melanoma loss of chromosome 1p has been described, but any 
prognostic significance had not been determined up to now.  Contrary to Sisley et 
al. (Sisley, et al. 2000) in our study loss of material of 1p36 was not associated with 
large ciliary body melanomas, but was rather detected in metastasising tumours in 
agreement with Aalto et al. (Aalto, et al. 2001). Eighty-nine percent of the metastasised 
tumours with chromosome 1p36 loss had concurrent monosomy 3. Concurrent loss 
affecting survival suggests an interaction of proteins encoded by genes located on 
these chromosomes, which may promote tumorigenesis, metastatic disease and 
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Chromosome 1p36 loss*  Chromosome 3 loss* Chromosome 6p gain* Chromosome 8q gain*
          
Clinical data - + p-value - + p-value - + p-value - + p-value
    
Gender        male 
                     female
42 20
0.193† 
32 29
0.311† 
45 19
0.481† 
24 39
0.498† 
29 21 22 26 32 15 17 30
     
Mean age (yrs)  61 61 0.345‡ 57 64 0.050‡ 61 59 0.298‡ 59 61 0.223‡
      
Cell type  spindle
                  mixed/epithelioid
32 17
0.432† 
24 17
0.013† 
27 21
0.008† 
23 24
0.024† 
39 24 25 38 50 13 18 45
    
Mean tumor thickness (mm)  7.8 8.0 0.355‡ 7.7 8.5 0.133‡ 7.8 8.6 0.135‡ 7.5 8.4 0.127‡
    
Mean tumor diameter (mm)  12.5 13.0 0.186‡ 12.1 13.9 0.002‡ 12.6 13.6 0.059‡ 11.3 13.9 <0.001‡
    
Involvement of ciliary body  no
                                                   yes
61 31 0.133† 48 43 0.106† 62 30 0.239† 34 57 0.592† 
10 10 6 12 15 4 7 12
Table 2. Correlation between chromosomal abnormalities and clinical data
Table 3. Prognostic markers for metastasis in 120 uveal melanoma patients *
variable hazard ratio p-value†
Loss of chromosome 1p36 with loss of 3 7.81 0.039
Gain of chromosome 8q 2.43 0.054
Mixed/epithelioid cell type 2.24 0.077
Gain of chromosome 6p 1.33 0.558
Largest tumor diameter 1.03 0.588
Age at time of diagnosis 1.00 0.900
* Multivariate analysis using Cox proportional hazard analysis
† Likelihood ratio test
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Chromosome 1p36 loss*  Chromosome 3 loss* Chromosome 6p gain* Chromosome 8q gain*
          
Clinical data - + p-value - + p-value - + p-value - + p-value
    
Gender        male 
                     female
42 20
0.193† 
32 29
0.311† 
45 19
0.481† 
24 39
0.498† 
29 21 22 26 32 15 17 30
     
Mean age (yrs)  61 61 0.345‡ 57 64 0.050‡ 61 59 0.298‡ 59 61 0.223‡
      
Cell type  spindle
                  mixed/epithelioid
32 17
0.432† 
24 17
0.013† 
27 21
0.008† 
23 24
0.024† 
39 24 25 38 50 13 18 45
    
Mean tumor thickness (mm)  7.8 8.0 0.355‡ 7.7 8.5 0.133‡ 7.8 8.6 0.135‡ 7.5 8.4 0.127‡
    
Mean tumor diameter (mm)  12.5 13.0 0.186‡ 12.1 13.9 0.002‡ 12.6 13.6 0.059‡ 11.3 13.9 <0.001‡
    
Involvement of ciliary body  no
                                                   yes
61 31 0.133† 48 43 0.106† 62 30 0.239† 34 57 0.592† 
10 10 6 12 15 4 7 12
* Chromosome locus at which the abnormality is 
absent (-) or present (+)
† The p-value is for the comparison among 
different subgroups within a chromosome 
aberration group and was calculated by Fisher’s 
exact test
‡ The p-value is for the comparison of means 
among different subgroups within a chromosome 
aberration group and was calculated by Mann-
Whitney test
Significant p-values are indicated in bold
consequently reduce survival. However, we cannot exclude that these sites encode 
for proteins that might independently promote tumorigenesis and metastasis.
Gain of chromosome 8q was a significant predictor of survival in the univariate 
analysis. In the multivariate analysis it did not reach statistical significance as an 
independent prognostic marker. Previous studies already suggested that acquisition 
of isochromosome 8q is a secondary event and that gain of additional copies is related 
to tumour size (Gordon, et al. 1994; Prescher, et al. 1994; Sisley, et al. 1997). Moreover, 
monosomy 3 seemed to predispose to isochromosome formation (Prescher, et al. 
1995). This may explain the correlation of gain of chromosome 8q with survival as 
observed in other studies (Sisley, et al. 1997; White, et al. 1998a). We demonstrated 
a strong correlation between the largest tumour diameter and the presence of 
chromosome 8q abnormalities, suggesting that acquisition of additional copies of 8q 
may result in a growth advantage of the tumour. 
Similarly, the abnormalities of chromosome 6 were not independently associated 
with survival, in contrast to previous claims (White, et al. 1998a). We found a strong 
correlation between the gain of chromosome 6p and spindle cell type. Sisley and 
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White and coworkers associated chromosomal changes, such as loss of chromosome 
3, gain of chromosome 8q and abnormalities of chromosome 6 with prognosis (Sisley, 
et al. 2000; White, et al. 1998a). However, as far as we know their findings were not 
corrected for tumour diameter or cell type as in the present study. This could have 
influenced their findings, leading to contradictory observations. Another known 
prognostic marker for a poor outcome of uveal melanoma patients is the presence of 
epithelioid cells. We found a strong correlation between chromosomal aberrations 
(chromosomes 3, 6 and 8) and cell type (Table 2). Even though epithelioid or mixed 
cell type was significantly associated with decreased DFS in the univariate analysis, 
it was not in the multivariate analysis. 
Although loss of an entire chromosome is a common change in uveal melanoma, 
partial deletions of chromosome 3 have been reported leading to the hypothesis 
that two regions, one on the p-arm and one on the q-arm, might be involved in 
metastasis (Tschentscher, et al. 2001). Seven patients in our study had a partial 
deletion of chromosome 3 (either one copy of the centromeric region or 3q-region) 
from whom 2 patients had died due to metastatic disease. In five tumours two signals 
for the centromere and only one signal for the 3q probe were observed, whereas 
two tumours had one copy of the centromere and two of the 3q-probe. Since these 
changes were observed with FISH analysis and karyograms of these tumours were 
not available, we were not able to identify any breakpoints. These and more subtle 
structural aberrations can be resolved with techniques with higher resolution, such 
as genomic arrays or LOH. However, changes such as base substitutions, very small 
deletions or insertions will still be missed. 
Our study on chromosomal abnormalities in uveal melanoma is, to our knowledge, 
the largest series reported in the literature. Our study may be biased because we 
examined only tumours from patients treated by enucleation, as no tumour material 
is available from patients treated with radiotherapy protocols. There is a need to 
stratify patients prospectively into low and high-risk groups for metastases.  Our 
findings suggest that chromosomal abnormalities may be useful in identifying 
patients at high risk of metastases. Previous studies by Sisley et al. have shown a 
correspondence between major clonal alterations in FNAB’s and the main tumour 
using cytogenetic techniques (Sisley, et al. 1998). Furthermore, they showed that 
with short-term cultures of FNAB’s conventional cytogenetic analysis was possible 
in 60% of the cases. In addition, Naus et al. indicated that application of FISH on 
FNAB’s is a reliable method for assaying genetic prognostic parameters (Naus, et al. 
2002). Only in 0.8% a small variation that have could lead to a misclassification was 
found. 
There are at least two potential challenges involved in the application of our data 
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to patients on a prospective basis. First, our study involves patient samples from 
relatively large tumours that were treated by enucleation. It remains to be seen that 
our data can be applied to smaller tumours that will be treated by radiation therapy. 
Second, despite correspondence between chromosomal abnormalities detected from 
FNAB samples and tissue retrieved at enucleation, there are no studies to date that 
confirm the uniform distribution of cytogenetic abnormalities in uveal melanoma, 
and it is at least theoretically possible that an FNAB might capture tissue that does 
not contain the cytogenetic markers of interest. Nevertheless, data from our study, 
the largest cohort of patients studied to date for cytogenetic abnormalities in primary 
uveal melanoma, suggests the feasibility of studying patients with uveal melanoma 
in prospective trials using samples retrieved by FNAB. 
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Abstract
Purpose: Uveal melanoma is one of the most frequent primary intraocular malignancies in 
the western world. Cytogenetically these tumours are characterised by typical chromosomal 
losses and gains, such as loss of chromosome 1p, 3, 6q and gain of chromosome 6p, and 8q. 
Whereas most studies focus on known aberrations we characterised cytogenetic changes and 
correlated them with clinical and histopathological parameters. Patients and methods: 
Karyotypes of 74 primary uveal melanomas were analysed with respect to the presence or 
absence of chromosomal gains and losses. In the analysis classical clinical and histopathological 
parameters were analysed together with the chromosomal aberrations. Results: At a median 
follow up of 43 months 34 patients had died or were suffering form metastatic disease. Clonal 
chromosomal abnormalities were present in 59 tumours. The most frequent chromosomal 
abnormalities involved chromosome 8 (53%), loss of chromosome 3, p-arm (41%) and 
q-arm (42%), partial loss of chromosome 1p (24%) and abnormalities of chromosome 6, which 
results in gain of material of 6p (18%) and/or loss of 6q (28%). Less frequent aberrations 
were abnormalities of chromosome 16, in particular loss of chromosome 16q (16%). In the 
univariate analysis loss of chromosome 3, largest tumour diameter, gain of 8q and mixed/
epithelioid cell type in the tumour compared to tumours without these chromosomal changes 
or with a spindle cell type was associated with a decreased disease free survival. Conclusions: 
Monosomy 3 and largest tumour diameter are the most significant in determining survival 
for uveal melanoma patients. Abnormalities of chromosome 16q are relatively common in 
uveal melanoma, but are not associated with survival or other cytogenetic or histopathological 
parameters. Submitted for publication
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Introduction
Uveal melanoma (UM) is the most common primary intra-ocular tumour in the 
western world, affecting approximately 7 per million people each year. Tumorigenesis 
and progression of cancer is in general preceded by the occurrence of genetic changes 
in normal cells (Heim 1995). In this respect UMs are quite homogenous with a few 
tumour specific cytogenetic aberrations. Some of these aberrations are correlated 
with the metastatic potential of the tumour resulting in metastatic disease followed 
by death. Recurrent aberrations in UM concern loss of chromosome 1p, monosomy 
of chromosome 3, loss of chromosome 6q and 8p, gain of chromosome 6p and 8q.
Loss of chromosome 1p was observed in metastases (Aalto, et al. 2001) and concurrent 
loss of chromosome 1p and 3 is associated with decreased survival (Hausler, et al. 
2005; Kilic, et al. 2005). Furthermore, monosomy 3 is considered to be an early event 
in UM and several studies have shown that it is a strong predictor for survival 
(Prescher, et al. 1996; Sisley, et al. 1997; White, et al. 1998a). Loss of chromosome 
3 is frequently associated with amplification of chromosome 8q, often seen as an 
isochromosome 8q (Prescher, et al. 1994; Prescher, et al. 1995).
Recently, Hoglund et al. elucidated a common genetic pathway for both uveal as 
cutaneous melanoma (Hoglund, et al. 2004). Monosomy 3 occurs probably as an 
early event and loss of chromosome 1p, 8p and gain of 8q as secondary events. 
Regions of chromosomal loss are thought to harbour tumour suppressor genes and 
regions of gain oncogenes. Previous cytogenetic analyses focus in general on the 
known aberrations. In this study we performed cytogenetic analysis on short-term 
cell cultures of fresh tissue from 74 primary UMs to characterize all chromosomal 
changes and correlate these changes with clinical and histopathological parameters. 
Significant prognostic parameters for UM at high-risk for metastases were 
identified.
Material and methods
Patients and tumour samples
From March 1992 to April 2003, we collected tumour material of patients who 
underwent enucleation for ciliary body or choroidal melanoma. Informed consent 
was obtained prior to enucleation and the study was performed according to the 
tenets of the Declaration of Helsinki. Fresh tumour material was obtained within 
1 hour after enucleation and processed as described before (Kilic, et al. 2005). 
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Conventional histopathologic examination was performed on all tumours and 
confirmed the origin of the tumour. Cytogenetic studies were also carried out on 
stimulated peripheral blood samples of each patient to exclude the presence of 
congenital chromosome abnormalities. Follow-up data from time of diagnosis till 
the end of the study in December 2005 were obtained by reviewing patient’s charts 
and contacting their general physician. 
Cytogenetic analysis
Chromosome preparations were made according to standard procedures and stained 
with acridine orange or atebrine to obtain R or Q banding. Cytogenetic abnormalities 
were described in accordance with the ISCN (1995)(Mitelman 1995). 
Data classification
Based on the cytogenetic analysis tumours were classified for gain and or loss for all 
chromosomal regions, p-arm or q-arm. When different subclones were identified, 
only the cytogenetic findings of the largest clone were classified. Chromosomal 
regions with loss in more than 10% of all tumours and gain in more than 15% of all 
tumours were included for analysis. Tumours were identified as small (<12mm) and 
large (> 12mm).
Statistical analysis
The primary end point for disease free survival (DFS) was the time to development 
of metastatic disease, whereby death due to other causes was treated as censored. 
The influence of single prognostic factors on DFS was assessed using the log rank 
test (for categorical variables) or Cox proportional hazard analysis (for continuous 
variables) and Kaplan-Meier curves were made to illustrate the differences in 
survival. To examine the possibility that other clinical, histopathological or 
chromosomal variations may affect the prognosis we performed Cox proportional 
hazard analysis for each confounding variable. An effect was considered significant 
if the p-value was 0.05 or less. The odds-ratios with corresponding p-values were 
calculated to identify association between the different parameters. The statistical 
analyses were performed with the SPSS-11 software.
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Results
Patients
Chromosome analysis was successfully performed in 74 cases. The clinical and 
histopathological features of the 74 primary UMs are listed in the supplementary 
information. The median age of the patients at time of enucleation was 60 years 
(range 21-87 years), 29 women and 45 men. One patient was lost to follow-up after 
27 months. At the end of follow-up time 31 patients had died of melanoma-related 
disease, 3 patients were diagnosed with metastases, 9 patients had died due to other 
causes and 31 patients were still alive without metastases. The median follow-up 
time was 42.8 months (range 6.4 - 164.4 months).
Histolopathology 
All tumours were confirmed histopathologically as UM. Based on their cell type 
16 tumours were classified as epithelioid cell type, 24 as mixed cell type and 34 
tumours as spindle cell type. The mean tumour diameter and thickness were 13.2 
mm (range 6-19) and 8.4 mm (range 2-22), respectively. Four tumours were located in 
the ciliary body and 70 were located in the choroid. 
 
Cytogenetic
Seventy-four UMs were analysed for cytogenetic changes (see supplementary 
information) and classified for gain and loss for all chromosomal regions (Table 1). 
Clonal chromosomal abnormalities were present in 59 tumours. The most frequent 
chromosomal abnormality involved chromosome 8, trisomy of chromosome 
8 or gain of material of from 8q, most often in the form of an i(8q) (53%). Other 
abnormalities involved loss of chromosome 3, p-arm (41%) and q-arm (42%). Partial 
loss of chromosome 1p (24%) and abnormalities of chromosome 6, resulting in gain 
of material of 6p (18%) and/or loss of 6q (28%). Other less frequent aberrations were 
abnormalities of chromosome 16, in particular loss of chromosome 16q (16%) (Figure 
1). Other chromosomal aberrations, such as loss of 6p, 9p, 15p, 15q, 21p, 22p and gain 
of 2p, 2q, 7q, 9p, 11q were present but did not reach the 10%.
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Loss and gain >10% of all tumors n=74
1p loss 18 (24%)
3p loss 30 (41%)
3q loss 31 (42%)
6p gain 13 (18%)
6q loss 21 (28%)
8p gain 13 (18%)
8p loss 18 (24%)
8q gain 39 (53%)
16q loss 12 (16%)
Loss and gain <10% of all tumors
2p gain 4 (5%)
2q gain 4 (5%)
6p loss 7 (9%)
7q gain 4 (5%)
9p gain 4 (5%)
9p loss 7 (9%)
11q gain 7 (9%)
15p loss 7 (9%)
15q loss 7 (9%)
21p loss 7 (9%)
22p loss 7 (9%)
Figure 1.
Karyotype of tumour EOM 63
This tumour showed chro-
mosomal changes for UM: -3, 
i(6)(p), i(8)q (multiple copies) 
and del(16)(q21). 
Table 1. Recurrent changes in karyotype of primary uveal melanoma
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Statistical analysis
Univariate analysis was performed for all clinical, histopathological and cytogenetic 
parameters (Table 2, Figure 2). Univariate analysis of the single prognostic factors 
showed significant lower disease free survival (DFS) for patients with loss of 
chromosome 3, largest tumour diameter, gain of 8q and with a mixed/epithelioid 
cell type in the tumour compared to tumours without these chromosomal changes 
or with a spindle cell type. Other potential prognostic factors such as gender, age 
at time of diagnosis and tumour location (i.e. involvement of ciliary body) did not 
reach significance. Also chromosomal changes such as loss of chromosome 1p, gain 
of chromosome 6p and loss of chromosome 6q were not significantly associated with 
disease free survival. To examine the possibility that other clinical, histopathological 
or chromosomal variations may affect the prognosis we performed Cox proportional 
hazard analysis for each confounding variable (Table 2). Parameters presented in the 
columns are the investigated prognostic parameters; in the rows the same parameters 
resemble the confounders with a possible modifying effect. Significance of loss 
of chromosome 3p/3q did not alter after correcting for the possible confounders. 
A similar pattern was observed for largest tumour diameter and cell type. Odds 
ratios were calculated to identify association between the different parameters 
(Table 3). Associations were shown for loss of chromosome 3 with gain of 8q, loss 
of chromosome 8p, vascular patterns and largest tumour diameter (>12mm), and a 
weak association with mixed/epithelioid cell type. Presence of vascular patterns and 
largest tumour diameter (>12mm) showed also association with gain of chromosome 
8q. Associations were also present for loss of chromosome 1p with loss of 16q and 
loss of chromosome 3p, and weak association with cell type, vascular patterns 
largest tumour diameter, chromosome 3q loss and 8q gain. Loss of chromosome 6q 
was weakly associated with gain of chromosome 8q. Loss of chromosome 16q was 
weakly associated with gain of chromosome 8p.
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Discussion
By means of karyotyping we have analysed chromosomal aberrations in UM. 
Previous reports have revealed that abnormalities of chromosome 1, 3, 6 and 8 occur 
non-random in UM. Some of these tumour specific aberrations have been associated 
with the metastatic potential of the tumour. In this study loss of chromosome 1p, 
chromosome 3, aberrations of chromosome 6, 8 and 16 are most often encountered. 
Furthermore, we have demonstrated that tumours with abnormalities of chromosome 
3, gain of chromosome 8q, epithelioid/mixed cell type and a larger tumour diameter 
are strongly associated with a poor prognosis. 
In UM numerous parameters have been used to predict survival, with the 
conventional parameters being tumour size, tumour location, cell type and vascular 
patterns (Foss, et al. 1997). None of these factors are entirely solid, and there has been 
considerable variation in interpretation among observers. 
 In contrast to some earlier reports (Sisley, et al. 2000) we did not find chromosome 11 
and 21 to occur very often (Table 1) and therefore these aberrations were not included 
in the analysis. In addition, we identified loss of chromosome 16q. Chromosome 
16 loss, in particular 16q, also mentioned in earlier reports (Hoglund, et al. 2004; 
Sisley, et al. 2000; Kilic et al. unpublished results) occurred in more than 10% of the 
UMs. Even though it was not significantly associated with disease free survival it 
still might be involved in tumour progression. A remarkable association was shown 
for loss of chromosome 16q with loss of chromosome 1p. Delineation of a region 
on chromosome 16q may depict a region of interest with possible candidate genes. 
Other tumours, s.a. breast cancer and neuro-ectodermal tumours have also shown 
deletion on 16q (Dallas, et al. 2005). Since UM cells are derived from neuro-ectodermal 
tissue this might be of potential interest. In many reports outcome was correlated 
with tumour location (Sisley, et al. 1992; White, et al. 1998a). Since we had limited 
sample size in the group tumours located in the ciliary body we were not able to 
make reliable assumptions on association of outcome with tumour location. Largest 
tumour diameter in our study was histopathologically measured. This parameter 
may be used non-invasively in a clinical setting (measurement on ultrasound) and 
may be the most reliable non-invasive prognostic parameter. However, there is a 
variation between clinical and histopathological measurements. The tumour size 
measured on ultrasound is in general larger than the histopathological measurement. 
In contrast, the detection of specific chromosomal aberrations by routine FISH, 
CGH and karyotyping provides a more objective measurement of potential tumour 
behaviour. Identification of monosomy 3 in a tumour sample is widely accepted 
as the most reliable prognostic parameter (Prescher, et al. 1996; Sisley, et al. 1997; 
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White, et al. 1998a). Monosomy of chromosome 3 is considered as an early event, 
occurring before alterations of chromosome 8, 1 and 6. In table 3 the odds ratios were 
shown for different chromosomal parameters. If we put the odds ratios in following 
order, chromosome 8q gain, and consequently 8p loss, follows monosomy 3, and 
loss of chromosome 1p and 16q occur thereafter. This is consistent with the findings 
observed by Hoglund et al. (Hoglund, et al. 2004). Furthermore, tumour diameter is 
associated with most of the chromosomal aberrations, implying that larger tumours 
have more aberrations. Our study involves patient samples from relatively large 
tumours that were treated by enucleation. Considering monosomy 3 as an early 
event it would be observed in even the smallest amount of tissue (e.g. FNAB) despite 
the heterogeneity of UM (Naus, et al. 2002). Though, there are no studies to date that 
confirm the uniform distribution of cytogenetic abnormalities in UM, and it is at 
least theoretically possible that a FNAB might capture tissue that does not contain 
the cytogenetic markers of interest. 
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Abstract
Introduction: Familial melanoma accounts for 0.6% of all uveal melanoma patients. A locus 
for genetic predisposition is still unknown and so far the chromosomal aberrations arising in 
these tumours have not been characterised. To elucidate the genetic similarity between familial 
uveal melanoma and sporadically occurring primary uveal melanoma, tumour material of 
individuals with a family history of uveal melanoma and sporadic occurring melanoma were 
screened for DNA copy number alterations by comparative genomic hybridisation (CGH). 
Patients and methods: DNA copy number changes were studied on six familial uveal 
melanoma and 15 sporadic primary uveal melanomas. Tumour DNA extracted from paraffin-
embedded uveal melanoma labelled with Spectrum Green and normal DNA labelled with 
Alexa 594 were hybridised to normal metaphase chromosomes. Results and conclusion: The 
changes in both groups were similar. Comparison between both showed that the most common 
DNA copy number alterations were monosomy 3 (83.3% and 80%), gain of 8q (66.7% and 
73.3%), loss of 8p (50% and 40%), 1p (66.7% and 40%), and 16q (66.7% and 33.3%). In 
conclusion, familial and sporadic uveal melanomas display similar aberrations, indicating 
tumorigenesis involves a common genetic pathway. Submitted for publication
Chromosome imbalances in familial uveal melanoma detected by comparative genomic hybridisation
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Introduction
Uveal Melanoma (UM) is the most common primary intraocular malignancy in 
adults in the western world, accounting for 70% of all malignant ocular tumours. 
Environmental and genetic factors involved in the pathogenesis are rather unknown. 
It is a rare disease with an annual incidence of 6-7 per million. The occurrence of 
familial melanoma (FUM) is even more rare, only 0.6% of all UM cases (Singh, et 
al. 1996a). A total of 73 families have been described in literature and an autosomal 
dominant inheritance with incomplete penetrance was suggested (Lynch, et al. 1968; 
Singh, et al. 1996b). Nevertheless, genetic predisposing factors have not yet been 
clarified. In a small proportion of all UM patients germline BRCA2 mutations are 
present, but not all familial cases can be explained by these mutations (Hearle, et al. 
2003). Uveal melanomas occur in several familial cancer syndromes: familial atypical 
mole and malignant melanoma (FAMM) syndrome, xeroderma pigmentosum (XP), 
Li-Fraumeni syndrome and familial breast and ovarian cancer. CDKN2A, which 
gives a predisposition in the FAMM syndrome, is rarely involved in familial UM 
(Singh, et al. 1996b; Soufir, et al. 2000). 
Chromosomal changes occur in sporadic UM, with monosomy 3, loss of 1p and 
6q, and gains of 6p and 8q being the most common changes. In familial UM 
chromosomal changes have not been identified. By using comparative genomic 
hybridisation, a molecular cytogenetic technique that allows the comprehensive 
analysis of genomes, gains and losses of chromosomal material can be detected. An 
additional advantage of this technique is that it is applicable to paraffin embedded 
archived tumour specimens. To elucidate the genetic similarity between familial 
UM and sporadically occurring primary UM, tumour material of individuals with 
a family history of UM and sporadic occurring UM were screened for chromosomal 
abnormalities.
Material and Methods
Patient and tumour samples
Tumour material was collected from six patients with a positive family history 
of UM. Informed consent was obtained prior to enucleation and the study was 
performed according to the tenets of the Declaration of Helsinki. Samples FU 4 
and FU 5 were obtained from patients who were related. The other samples (n=4) 
were single cases with a one other relative with an uveal melanoma. FU3 and FU6 
had a first-degree relative, whereas FU1 and FU2 could be coupled through family 
studies to another relative with an uveal melanoma. A family history of any cancer 
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was obtained from all patients. Fifteen UMs from patients without a positive family 
history were randomly selected as a control group. The clinical diagnosis was 
confirmed by histology. 
Comparative Genomic Hybridisation (CGH)
DNA from formalin-fixed paraffin-embedded tumour material was isolated from 
40 10μm sections. The tumour was scraped off from the glass slides using a fine 
scalpel. Excised material was deparaffinised in xylene and ethanol and air-dried. 
Isolation of DNA was performed using the DNA tissue kit (Qiagen, Hilden, 
Germany). Concentration was determined using a fluorometer (Biorad, Veenendaal, 
The Netherlands), whereas molecular weight was estimated on ethidium-bromide 
stained agarose gels. Tumour DNA and reference DNA was labelled using the 
Bio-prime DNA labelling kit (Invitrogen, Breda, The Netherlands) with Spectrum 
Green (Vysis, Hoofddorp, The Netherlands) or Alexa 594 (Molecular Probes, Leiden, 
The Netherlands) respectively. The probe mixture of tumour and reference DNA 
was denatured and hybridised to normal male metaphase chromosomes for three 
days at 37˚C. Samples were counterstained with DAPI in anti-fade solution. Images 
were acquired with a Zeiss axioplan microscope equipped with Isis software from 
Metasystems (Metasystems, Altlussheim, Germany). For each case at least ten 
metaphases were analysed. Loss of DNA sequences was defined as chromosomal 
regions where the mean green: red ratio was below 0.8, while gain was defined 
as chromosomal regions where the ratio was above 1.2. Threshold levels were 
determined on basis of analysis of known chromosomal aberrations.
Results
In all cases CGH was performed and results were obtained (Figure 1). All tumours 
showed changes in DNA copy number, with a mean of 7 aberrations per tumour in 
the familial melanoma (range 3-11) and 4.5 aberrations per tumour in the sporadic 
melanoma (range 2-7) (Table 1). Due to the limited number of tumours statistical 
analysis could not be performed. The most common changes in both groups were 
monosomy 3, 83.3% of the familial melanoma and 80% of the sporadic melanoma, 
and gain of 8q in 66.7% and 73.3%, respectively. Other losses concerned 8p (50% 
and 40%), 1p (66.7% and 40%), 6q (66.7% and 26.7%), and 16q (66.7% and 33.3%) and, 
whereas gain of 6p was not seen in familial UM, but solely in sporadic melanoma 
(20%).
Chromosome imbalances in familial uveal melanoma detected by comparative genomic hybridisation
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Samples FU 4 and FU 5 displayed similar aberrations. In both tumours, loss of 
chromosome 3, 6q and 16q and gain of 8q was present, whereas loss of 8p and gain 
of chromosome 21 occurred only in sample FU 5. In addition, in sample FU 4 loss of 
chromosome 1p and gain of chromosome 16p, 19 and 21 was observed.
Figure 1A. 
Example of a CGH hybridisation of FU 5.
Figure 1B.
Summary of the most frequent DNA copy number changes detected by CGH in six familial uveal melanoma, 
upper panel, and 15 sporadic uveal melanomas, lower panel. Vertical lines on the right side of the chromosome 
represent gains and vertical lines on the left side of the chromosome indicate losses. Bold lines indicate high-
level amplifications.
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Table 1. CliniCal CharaCteristiCs and dna Copy number Changes in 21 uveal melanoma
No. Age/sex Cell type Localisation Gains Losses
Follow-
up 
(months)
Death
(melanoma 
related)
FU 1 74/F mixed choroid 1p32.3-36.3, 1q32.1-32.3, 6q, 10p, 16, 21
85 no
FU 2 62/M mixed choroid 8q  3, 8p 16 yes
FU 3 69/F spindle choroid 8q, 19, 20, 22 1, 3, 8p, 16 40 yes
FU 4 51/F epithelioid choroid 8q, 16p, 19, 22 1p21-31.1, 3, 6q, 16q 56 no
FU 5 65/M epithelioid choroid 8q, 21 3, 6q, 8p, 16q 31 yes
FU 6 73/M mixed choroid 16, 17, 19, 20, 22
1p21-31.3, 1q25-32.1, 3, 
4q, 5, 6q
50 -
S 1 73/F mixed choroid 8q, 19p 3, 8p 37 no
S 2 72/F mixed choroid 21 3 28 no
S 3 62/M epithelioid choroid 8q, 19p 3, 6q, 8p, 16q 10 yes
S 4 61/M spindle choroid 6p22, 8q13 1p32, 6q, 19, 20, 21 64 yes
S 5 65/M spindle choroid 8, 16p, 19, 22 3, 10 46 no
S 6 52/F mixed choroid 1p, 3 36 yes
S 7 53/F spindle choroid 1q, 11q, 22 1p, 3, 11p 45 no
S 8 59/M spindle choroid 6p12, 8q, 22 8p 35 yes
S 9 42/M spindle choroid 6p12, 8q23, 11q13.1-13.5 11q23.1
41 no
S 10 70/F mixed choroid 1p21, 3, 6q13 16 yes
S 11 52/F spindle choroid 8 1p21, 3, 16q 30 no
S 12 64/F mixed choroid 8q, 21 3, 6q, 8p, 16q 19 yes
S 13 64/F spindle choroid 8q 1p21, 3, 16q, 19 49 yes
S 14 80/F unknown choroid 7q, 8q 3, 8p, 16q 17 yes
S 15 47/F epithelioid choroid 8q, 19 3, 8p 32 yes
Chromosome imbalances in familial uveal melanoma detected by comparative genomic hybridisation
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Discussion
In this study we have investigated six patients that had a highly suspected UM 
predisposition. The events that are important in malignant transformation and 
melanoma progression remain unclear. We observed that several chromosomal 
imbalances were consistently present in familial UM. The most common losses, 
monosomy 3 and loss of 1p and 6q, and the most frequent gain, 8q, were seen in both 
familial and sporadic melanoma. In general, the samples of the familial UM showed 
relatively more aberrations than the sporadic tumour samples, though this could not 
be statistically supported. Compared to results described in the literature (Aalto, et 
al. 2001; Ghazvini, et al. 1996; Hughes, et al. 2005; Kilic, et al. 2005; Tschentscher, et al. 
2000) the occurrence of monosomy 3 seems to be similar in the familial UM group as 
well as in the sporadic group (Table 2). Since the sporadic group in this study is small 
there might be a selection bias. In addition, with CGH analysis clonal imbalances 
are not identified and loss is more easily detected than gain (Lichter, et al. 2000). 
The results of the studies mentioned before are mainly based on analyses, among 
whilst is FISH analyses, where the largest clone is selected as a representative of the 
primary tumour (Aalto, et al. 2001; Kilic, et al. 2005). 
Previous studies have shown that loss of one copy of chromosome 3 occurs exclusively 
in UM, whereas loss of one part of chromosome 3, short arm, may occur in other 
tumour types. The short arm of chromosome 3 harbours candidate genes, such as 
VHL, MLH1, and XPC, whereas candidate genes on the long arm are not identified 
yet. Nevertheless, two regions, one on the short arm and one on the long arm, show 
LOH in some studies (Horsman and White 1993; Prescher, et al. 1994; Sisley, et al. 
1998; Tschentscher, et al. 2001). These regions might be important in the initiation 
of loss of one copy of chromosome 3, which is thought to be an early event and may 
lead to increased genomic instability, resulting in isochromosome formation (Aalto, 
et al. 2001; Prescher, et al. 1994). Corresponding with CGH analyses of other studies 
we assessed isochromosome-like findings of chromosome 6p and 8q (Aalto, et al. 
2001; Gordon, et al. 1994; Speicher, et al. 1994). Gain of chromosome 8q, which is 
considered to be a late event in sporadic UM (Horsman and White 1993; Prescher, 
et al. 1995; Sisley, et al. 1992), was present in the familial tumours, whereas gain of 
chromosome 6p was not observed at all. 
Deletion of chromosome 1p does not occur solely in UM, but is also present in other 
solid tumours. It has been associated with tumour progression and was detected 
in metastasising UM (Aalto, et al. 2001; Kilic, et al. 2005). Remarkably, we observed 
deletion of the short arm of chromosome 1 (Figure 1A) in the sporadic tumours and 
a loss of the complete chromosome 1 in the familial tumours, which is interesting 
for further analysis. In our series we could not make reliable assumptions on the 
8
Chapter 6
metastatic potential of the tumours, since we had a limited number of tumours. In 
this small series we found however an increased number of losses of chromosome 
1p in FUM (66.6%) compared to our sporadic UM control group (40%). Also in other 
larger series with sporadic primary UM loss of chromosomal region 1p seemed to 
occur lest often (Hughes, et al. 2005; Kilic, et al. 2005; Tschentscher, et al. 2000) (Table 
2). This might indicate that chromosome 1p may harbour genes specifically involved 
in familial UM. Even so chromosome region 1p is difficult to analyse with CGH due 
to the limited resolution of CGH (5-10 Mb) in combination with many repeats at the 
telomeric region (Yu, et al. 2003), and therefore additional FISH analyses for this 
region might be useful. 
Although the number of familial cases is low, again we found a higher incidence of 
loss of 6q compared to the sporadic UM control group and literature (p=.045) (Table 
2.). As for the absence of a gain of chromosome 6p in familial UM this might be due 
to the small series of available patients and tumours and the relative low incidence 
of this change in primary UM. 
Table 2. Results of cgh analysis (%)
variable
fu um1 sporadic um1 Kilic et al. 
20051
Aalto et al.* 20011
Ghazvini et 
al. 19961
Hughes et al. 
20053
Tschentscher et 
al. 20002
PM
NM
PMM MM
Monosomy 3 83.3 80 50 21 73 67 85 56 45
Gain chromosome 8q 66.7 73.3 63 14 53 100 57 78 65
Loss chromosome 8p 50 40 21** 14 27 0 28 39 15
Loss of chromosome 1p 66.7 40 35 0 33 33 14 33 nd
Loss chromosome 6q 66.7 26.7 31 7 40 83 28 39 40
Loss chromosome 16q 66.7 33.3 nd 7 0 nd 0 nd
Gain chromosome 6p 0 20 27 29 20 17 42 67 55
* PM NM :  non-metastasizing primary melanoma, PMM: metastasizing primary melanoma, MM: metastases
** personal communication
1Paraffin embedded tumour specimens
2Fresh frozen tumour specimens
3Not specified
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In our present series we perceived aberrations of chromosome 16, especially 
loss of 16q, next to the non-random aberrations. Two samples, FU 4 and FU 5, of 
patients who were related to each other displayed similar aberrations. In both 
samples we observed beside the non-random aberrations a loss of chromosome 16q. 
Additionally, in sample FU 5 a gain of 16p was observed. Moreover, also sporadic 
melanoma, displayed loss of 16q, which may indicate that it could play a larger role 
in UM progression than was assumed up to now. Even though our sample size 
was too small to correlate prognostic data with specific copy number alterations 
further study needs to clarify the significance of this loss in UM development and 
progression.
In conclusion, familial UM and sporadic UM seem to display similar aberrations, 
indicating a common genetic pathway in tumor initiation. Although there is not 
statistical evidence, chromosomal aberrations seem to occur more often in familial 
cases and specifically loss of 1p and 6q are seen more frequently. Performing larger 
studies on familial UM may give more insight into UM development.
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Abstract
Purpose: Loss of chromosome 3 is frequently observed in uveal melanoma and is associated 
with poor prognosis. In about half of the uveal melanomas one copy of chromosome 3 is 
lost. Using comparative genomic hybridisation (CGH) we have detected a chromosome 
3q13-3q21 deletion in a uveal melanoma cell line, Mel270, which is derived from a primary 
tumour. The aim of the present study is to demarcate this region, which could presumably 
harbour a tumour suppressor gene (TSG). Methods: Genomic DNA was extracted from 
nine uveal melanoma cell lines, established from primary and metastatic tumours, amongst 
which Mel270. Subsequently, loss of heterozygosity (LOH) analysis was performed. In case 
of Mel270, LOH studies were complemented with fluorescent in situ hybridisation (FISH). 
Results: LOH and FISH studies revealed a chromosome 3q deletion ranging from 3q21.2-
3q24 in two cell lines, Mel270 and OMM2.3, derived from the primary tumour and one of 
its metastases, respectively. In addition, a region of allelic loss, mapping to 3p24, was found 
in these cell lines. In contrast, FISH probes mapping to 3p24 revealed the presence of two 
copies. In OMM2.2, established from a different metastasis that originated from the same 
primary tumour from which OMM2.3 was also derived, LOH was detected at most of the loci 
that were analysed. This finding is consistent with isodisomy of chromosome 3 in OMM2.2. 
Conclusions: We have fine-mapped structural deletions located at chromosome 3q and a 
hemizygous region at chromosome 3p in uveal melanoma cell lines. These results contribute 
to a further demarcation of a candidate region for tumour suppressor genes. Submitted for 
publication
Fine mapping of chromosome 3 structural deletions in uveal melanoma cell lines
83
Introduction
Uveal melanoma, the most common malignant intra-ocular tumour in adults, affects 
6 per 1,000,000 adults of the Western population yearly (Egan, et al. 1988). Uveal 
melanomas originate from neural crest derived melanocytes of the uvea and can 
be located posterior in the choroid and anterior in the ciliary body or in the iris. In 
the past the only treatment available was enucleation of the eye, while nowadays 
eye-conservative treatments like brachytherapy and external beam irradiation have 
become the first choice of treatment. Only 2% of the cases have clinically detectable 
metastasis at presentation and despite improved primary tumour treatment 
protocols, 50% of the patients die from distant metastasis that most often disseminate 
to the liver (90% of all cases with metastasis) (Diener-West, et al. 1992).
Cytogenetic and molecular genetic studies revealed that the larger part of the 
uveal melanomas from sporadic cases have a nearly diploid character with simple 
non-random chromosomal aberrations. Loss of chromosomes 1 and 3, structural 
abnormalities of chromosome 6, and gain of chromosome 8q are most frequently 
observed (Aalto, et al. 2001; Horsman and White 1993; Parrella, et al. 1999; Prescher, 
et al. 1996; Sisley, et al. 1997; White, et al. 1998a). Chromosome 3 loss is a prognostic 
marker for decreased survival of the patient (Prescher, et al. 1996; Sisley, et al. 2000; 
Sisley, et al. 1997; White, et al. 1998a) and several studies indicated gain of chromosome 
8 as an independent prognostic marker of poor survival (Sisley, et al. 1997; White, et 
al. 1998a). Furthermore, loss of chromosome 1p was observed in primary tumours 
that had metastasised and in metastases (Aalto, et al. 2001; Kilic, et al. 2005).
Involvement of chromosome 3 is considered a primary event (Horsman and White 
1993; Prescher, et al. 1994). In uveal melanomas that are characterised by different 
sub-populations, loss of chromosome 3 is a constant event, whereas a variable 
number of copies of the long arm of chromosome 8 can be observed. In many uveal 
melanomas an entire chromosome 3 is lost (Aalto, et al. 2001; Scholes, et al. 2001; 
White, et al. 1998b) and in some cases with two apparently normal chromosomes 3, 
acquired isodisomy has been observed (White, et al. 1998b). It is generally believed 
that loss of a tumour suppressor gene (TSG) located at chromosome 3 plays a role in 
uveal melanoma development. Only a few melanomas with structural abnormalities 
of chromosome 3 or translocations involving chromosome 3 have been reported up to 
now, which complicates mapping of putative TSGs. However, a study by Tschentscher 
et al. (Tschentscher, et al. 2001), who investigated uveal melanomas with structural 
abnormalities of chromosome 3, revealed two regions of allelic loss on chromosome 
3, i.e. 3p25 and 3q24-3q26. Moreover, they concluded that tumours that metastasised 
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showed loss of both regions. Parrella et al. (2003) defined a minimal region of allelic 
loss, ranging from 3p25.1-3p25.2 in a set of uveal melanomas (Parrella, et al. 2003).
The present study aimed at further delineation of a chromosome 3q deletion, 
previously detected with conventional comparative genomic hybridisation (CGH) 
in Mel270, a uveal melanoma cell line established from a primary tumour that 
metastasised (Naus, et al. 2001). LOH analysis and FISH analysis were performed 
on a series of primary and metastasis-derived uveal melanoma cell lines, including 
Mel270 and its liver metastasised cell lines, allowing identification of chromosomal 
aberrations on a single cell level. In addition, we have analysed the p-arm of 
chromosome 3 for the presence of allelic loss. Our results are discussed in the context 
of other published structural chromosome 3 deletions found in uveal melanomas.
Material and methods
Cell lines
For the present study nine different uveal melanoma cell lines were used. Four cell 
lines, OCM1 (Kan-Mitchell, et al. 1989), Mel202, Mel270 (Verbik, et al. 1997) and EOM3 
(Luyten, et al. 1996), were established from primary uveal melanomas. OMM2.2, 
OMM2.3 and OMM2.6 are metastatic cell lines that originated from three different 
liver metastases of the same patient from whose primary tumour Mel270 was 
established (Luyten, et al. 1996). The other metastatic cell lines OMM1 and OMM3 
were derived from metastases of two different patients(Luyten, et al. 1996). All cell 
lines were grown in HEPES and glutamate containing RPMI 1640 culture medium, 
supplemented with 10% fetal calf serum, 1% penicillin and 1% streptomycin. Cells 
were passaged, depending on growth rate.
Comparative Genomic Hybridisation (CGH)
Comparative genomic hybridisation on metaphases was performed according to 
Naus et al. (Naus, et al. 2001).
Loss of Heterozygosity (LOH)
Polymorphic microsatellites for LOH studies were selected using the UCSC Genome 
Bioinformatics website (http://www.genome.cse.ucsc.edu) and synthesised by Life 
Technologies (Breda, The Netherlands). An overview of the markers that we used is 
given in Table 1 (chromosome 3q) and Table 2 (chromosome 3p). Primer sequences 
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and locations are available upon request. Genomic DNA was isolated from the cell 
lines using standard techniques. Amplification reactions were performed in a 50 
μl mixture, containing 50 pmoles of each oligonucleotide, 10 mM of each dNTP, 
0.25 units Supertaq polymerase (HT Biotechnology Ltd., Cambridge, England), 
Supertaq buffer and about 100 ng genomic DNA. Reactions were denatured at 95ºC 
and subjected to 30 cycles of denaturation at 95ºC for 1 minute, annealing for 1.5 
minutes at 55ºC (except for markers D3S1580 and D3S3703: annealing temperatures 
57ºC and 58ºC, respectively) and elongation at 72ºC for 2 minutes, followed by 10 
minutes final extension at 72ºC. Obtained polymerase chain reaction (PCR) products 
were purified using Qiaquick PCR purification system (Qiagen, Westburg, Leusden, 
The Netherlands). Subsequently, 1 μl purified PCR product was radioactively end-
labelled, using 5 U polynucleotide kinase (Roche Molecular Biochemicals, Almere, 
The Netherlands) and 2 μCi [γ-32P] ATP (Amersham Pharmacia Biotech UK Ltd., 
Little Chalfont, United Kingdom). Denaturing stop mix (95% deionised formamide, 
20 mM EDTA, 0.02% xylene cyanol FF, 0.02% bromophenol blue) was added in an 
equal volume. After heating for 5 minutes, the samples were quickly chilled and 3 μl 
samples were loaded on a 6% denaturing polyacrylamide gel, which was run at 60 W. 
After electrophoresis the gel was dried on Whattman paper and a Fuji super RX film 
was exposed. Autoradiograms were visually analysed. Since cell lines were used, 
marker patterns specific for the uveal melanoma cell lines could not be compared 
with that of a corresponding control. Therefore, results obtained for Mel270 were 
compared to those achieved for the corresponding metastases. Furthermore, DNA 
samples extracted from other uveal melanoma cell lines and human placenta DNA 
from a healthy individual were taken along. 
Fluorescent in Situ Hybridisation (FISH)
Dual colour interphase FISH was performed on cultured Mel270 cells as described 
previously by Naus et al. (Naus, et al. 2002). The probes that we used are locus-
specific bacterial artificial chromosome (BAC) clones, selected from the Roswell Park 
Cancer Institute database (http://genomics.roswellpark.org/human/overview.html) 
and obtained from CHORI-BACPAC Resources (Oakland, CA, United States). An 
overview of the BAC probes that we used is given in Tables 1 and 2. Some of them 
correspond to the markers that we selected for LOH analysis. Five ng of centromeric 
probe Pα3.5 was used per slide, 100 ng of telomeric probe B47A2 (kind gift of L. 
Kearney and J. Flint) (Ning Y 1996) and 75 ng probe in case of BAC clones. Probes were 
tested first on normal peripheral blood cell metaphase spreads and 10 metaphases 
were analysed for each probe. For deletion mapping, signals in 300 interphase 
nuclei were counted according to the criteria of Hopman et al. (Hopman, et al. 1988). 
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The cut-off values used for monosomy (only one signal in more than 15% of the 
nuclei) or polysomy (more than 10% of the nuclei with 3 or more signals) were 
adapted from available literature (van Dekken, et al. 1990). In case subclones were 
identified, only findings concerning the largest clone were used for analysis.
Table 1. Results of chromosome 3q analysis of Mel270, using fish and loh
BAC Position*
Copy 
number
Marker Position*
Number 
of alleles
217P4 3q21.1 2 D3S1267 3q21.1 2
95H16 3q21.2 2 D3S1269 3q21.2 2
205A6 3q21.2 1 D3S1589 3q21.2 1
59J16 3q21.3 ? D3S3606 3q21.3 1
- D3S1587 3q21.3 1
- D3S1292 3q22.1 1
- D3S1273 3q22.1 1
220J13 3q22.2 ? D3S1615 3q22.2 1
219P10 3q22.3 1 D3S3528 3q22.3 1
162J10 3q22.3 1 D3S1576 3q22.3 1
166D18 3q23 1 D3S3554 3q23 1
- D3S1309 3q23 (2)
- D3S3694 3q23 1
- D3S3546 3q23 1
160A13 3q23 1
165M11 3q24 ? D3S1569 3q24 2
72E23 3q24 1 D3S1557 3q24 1
- D3S1593 3q24 1
88H10 3q24 1 D3S1608 3q24 (2)
- D3S3627 3q24 1
- D3S196 3q24 (2)
- D3S2440 3q24 1
- D3S3618 3q24 (2)
- D3S1306 3q24 1
- D3S3626 3q24 2
229G6 3q24 2 -
145F16 3q25.1 ? D3S1299 3q25.1 1
64F6 3q25.1 2 D3S1279 3q25.1 2
65L11 3q25.1 2 -
80I14 3q25.2 2 D3S1280 3q25.2 2
- D3S3702 3q26.1 2
- D3S2421 3q26.31 1
- D3S1580 3q28 (2)
- D3S1294 3q28 2
147L6 3q28 2 -
- D3S1601 3q28 2
- D3S1272 3q29 1
Corresponding FISH clones and markers are presented at the same line. ?: presence 
of a subclone, (2): presence of a weak second allele.
* position according to the Humane Genome Browser (May 2004)
(http://genome.cse.ucsc.edu/).
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Table 2. Results of chromosome 3p analysis of Mel270, using fish and loh
BAC Position*
Copy 
number
Marker Position*
Number 
of alleles
D3S3050 3p26.2 2
28P14 3p26.1 2 D3S1304 3p26.1 (2)
- D3S3728 3p26.1 2
- D3S3591 3p26.1 1
- D3S1537 3p25.3 2
- D3S4545 3p25.3 2
-
128A5 3p25.3 2 D3S3691 3p25.3 2
- D3S1597 3p25.3 2
- D3S3693 3p25.2 1
- D3S3608 3p25.1 2
255O19 3p25.1 2 D3S1286 3p25.1 2
- D3S1293 3p24.3 1
208G16 3p24.3 2 -
41F5 3p24.3-24.2 2 -
- D3S1266 3p24.1 1
11L6 3p24.1 2 -
D3S3727 3p24.1 1
D3S1211 3p24.1 1
D3S2432 3p24.1 2
D3S3518 3p23 2
D3S1619 3p23 2
209O16 3p22.2 2 -
189H19
3p21.32-
3p21.31
2 -
D3S2406 3p13 2
Corresponding FISH clones and markers are presented at the same line. (2): 
presence of a weak second allele.
* Position according to the Humane Genome Browser (May 2004)
(http://genome.cse.ucsc.edu/).
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Results
Loss of Heterozygosity (LOH)
We have previously shown a deletion of chromosome 3q13-3q21 in Mel270, using 
conventional CGH (Figure 1) (Naus, et al. 2001). For a further demarcation of this 
region of loss, LOH studies were performed. For the LOH analyses microsatellite 
markers were selected in and around the deletion region 3q13-3q21 in Mel270. Using 
this set of markers, loss of heterozygosity was identified for Mel270 but only with 
markers, mapping to chromosome 3q22.1. Therefore, we extended our marker set 
with markers mapping between chromosome band 3q22 and the 3q telomere. Cell 
lines from corresponding metastases, i.e. OMM2.2, OMM2.3, and OMM2.6 and 
several other uveal melanoma cell lines were analysed along with Mel270. Mel270 
and OMM2.3 showed LOH with consecutive markers, mapping to loci at 3q21.2-3q23 
(Figure 2 and 3). In OMM2.6 our results were indicative of loss at loci from 3q13.31 to 
the 3q telomere, whereas OMM2.2 and Mel202 showed loss at most loci tested along 
the q-arm (Figure 2). In uveal melanomas that metastasised, another region of LOH, 
mapping to chromosome 3p25, has been observed (Parrella, et al. 2003; Tschentscher, 
et al. 2001). To establish whether chromosome 3p deletions could also be detected in 
Mel270 and related cell lines OMM2.2, OMM2.3 and OMM2.6, nineteen different 
markers, mapping between chromosome band 3p26.2 and 3p13, were analysed 
(Figure 2). In Mel270, OMM2.3 and OMM2.6 loss of heterozygosity was detected 
with successive markers D3S1293, D3S1266, D3S3727 and D3S1211, representing loci 
at 3p24.1-3p24.3 (Figure 2). Results obtained for OMM2.2 and Mel202 were again 
indicative of isodisomy. In the other cell lines no obvious regions of LOH were 
detected. 
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Figure 1. CGH analysis of Mel270 
The green and red line represent, res-
pectively, the upper and lower thresholds 
of the normal range. The red line on the 
left of the ideogram represents the copy 
number decrease. Average expression 
profile of 9 metaphases.
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D3S3050 3p26.2 nd
D3S1304 3p26.1
D3S3728 3p26.1
D3S3591 3p26.1
D3S1537 3p25.3
D3S4545 3p25.3
D3S3691 3p25.3
D3S1597 3p25.3
D3S3693 3p25.2 ni ni ni ni ni ni
D3S3608 3p25.1
D3S1286 3p25.1 nd
D3S1293 3p24.3
D3S1266 3p24.1 nd
D3S3727 3p24.1 ni
D3S1211 3p24.1 nd
D3S2432 3p24.1
D3S3518 3p23
D3S1619 3p23 nd nd
D3S2406 3p13 n.d.
D3S3045 3q13.12 n.d.
D3S3675 3q13.2 nd nd nd nd
D3S1558 3q13.31 nd nd nd nd
D3S3649 3q13.32 nd nd nd nd nd
D3S1303 3q13.32 nd nd nd nd nd
D3S3703 3q13.32 nd nd nd nd nd
D3S3515 3q13.32
D3S3620 3q13.33 nd nd nd nd nd
D3S3576 3q21.1 nd
D3S1267 3q21.1 n.d.
D3S1269 3q21.2 ni
D3S1589 3q21.2 ni ni ni ni ni ni ni
D3S3606 3q21.3 ni ni ni ni nd nd nd nd nd nd
D3S1587 3q21.3
D3S1292 3q22.1 n.d.
D3S1273 3q22.1
D3S1615 3q22.2
D3S3528 3q22.3 ni ni ni ni ni nd nd ni
D3S1576 3q22.3
D3S3554 3q23 n.d.
D3S1309 3q23
D3S3694 3q23 nd
D3S3546 3q23
D3S1569 3q24 nd
D3S1557 3q24
D3S1593 3q24 n.d.
D3S1608 3q24
D3S3627 3q24
D3S196 3q24
D3S2440 3q24 n.d.
D3S3618 3q24
D3S1306 3q24
D3S3626 3q24 n.d. n.d.
D3S1299 3q25.1
D3S1279 3q25.1 nd
D3S1280 3q25.2
D3S3702 3q26.1
D3S2421 3q26.31 nd nd
D3S1580 3q28
D3S1294 3q28
D3S1601 3q28
D3S1272 3q29 nd
Figure 2. Results of 
microsatellite analy-
ses of chromosome 
3p and 3q in 9 UM 
cell lines
Light gray box: no 
copy number change 
was observed; black 
box: loss of hetero-
zygosity; gray box: 
presence of a weak 
second allele; n.d.: 
not determined.
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Fluorescent In Situ Hybridisation (FISH)
Complementary to the LOH studies, interphase FISH was performed on Mel270 
cells, using eighteen BAC clones mapping to 3q21.1-3q28. Fourteen of these clones 
corresponded to the markers used (see Table 1). Results obtained from LOH analysis 
and FISH studies were not completely in accordance with each other. While FISH 
clone RP11-88H10 showed loss of one copy, the corresponding microsatellite marker 
D3S1608 showed the presence of a weak second allele (Table I and Figure 4A). With 
FISH clone RP11-165M11 unclear results were obtained and the corresponding 
marker D3S1569 showed presence of 2 alleles. Markers D3S1309, D3S196 and D3S3618 
also revealed a weak second allele while flanking FISH probes and markers were 
indicative of loss. Marker D3S3626 showed no allelic loss and could demarcate the 
telomeric border of the deletion. Results obtained with markers D3S1299, D3S2421 
and D3S1272, located at the telomeric site of the deletion border, showed the presence 
of one allele and marker D3S1580 the presence of a weak second allele.
The p-arm of chromosome 3 was studied with a panel of eight FISH clones, mapping 
from 3p21.32-3p26.1. Although microsatellite analysis was indicative of allelic loss 
at four consecutive loci ranging from 3p24.1-3p24.3, interphase FISH revealed 
the presence of two copies of chromosome 3p at all the loci studied (Table 2 and 
Figure 4B). Signals obtained with probe RP11-11L6 were not specific enough, using 
interphase FISH. Therefore, metaphases were analysed; in 33 out of 36 metaphases 
two copies were detected.
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Discussion
Cytogenetic studies revealed that Mel270 exhibits the most important chromosomal 
aberrations, i.e. loss of chromosome 3 and gain of chromosome 8, which are 
consistently observed in uveal melanoma (Naus, et al. 2001). Therefore, we believe 
that Mel270 can safely be used as a model system, guaranteeing an unlimited 
supply of material, which is very helpful in the search of putative TSGs. Loss of 
heterozygosity analysis on cell lines is complicated by the fact that corresponding 
A
RP11-95H16
RP11-208G16 RP11-255O19 RP11-41F5
RP11-88H10 RP11-229G6
B
Figure 4. FISH analysis of Mel270
A: representative results of dual color FISH on Mel270 cells, hybridised with a combination of a chromosome 
3q probe (red) and a centromere 3 probe (Pa3.5) (#3) (green), except for probe RP11-95H16 (green) that was 
combined with a 3pter probe (B47A2) (red). Panel A: 3pter probe and RP11-95H16; #3 and RP11-88H10; and 
#3 and RP11-229G6.
B: representative results of dual color FISH on Mel270 cells, hybridised with a combination of a chromosome 
3p probe (red) and a centromere 3 probe (Pa3.5) (#3) (green). Panel B: #3 and RP11-208G16, #3 and RP11-
255O19, and #3 and RP11-41F5.
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wild type cells are not available. In case only one allele is observed it is not possible 
to discriminate between loss of one allele and lack of heterozygosity of the used 
microsatellite. However, we were able to compare a cell line derived from a primary 
tumour (Mel270) and three metastatic cell lines (OMM2.2, OMM2.3 and OMM2.6) 
obtained from three different liver metastases from this same primary tumour. 
Furthermore, in case of Mel270, FISH was performed, complementary to LOH 
analysis. 
Combining the data obtained with microsatellite analysis and FISH revealed allelic 
loss at chromosome 3q21.2-3q24 in Mel270 (Table 1). Cell line OMM2.3 showed LOH 
at the same loci. Results obtained with microsatellite analysis and FISH were not 
always in concordance. Markers D3S1569 and D3S3626 showed presence of two 
alleles, while FISH revealed only one copy of chromosome 3 in the same region. 
Marker D3S3626 could, however, be located at the breakpoint. Markers D3S1309, 
D3S1608, D3S196 and D3S3618 showed the presence of a weak second allele, which 
could be explained by the presence of a subclone. However, FISH data obtained 
with probe RP11-88H10, corresponding to D3S1608 clearly showed loss of one allele, 
while results, obtained with RP11-165M11, corresponding to D3S1569, pointed to 
the presence of a subclone. Also at the telomeric site of the deletion border some 
inconsistencies were observed. Markers D3S1299, D3S2421 and D3S1272 showed 
the presence of one allele and marker D3S1580 showed only a weak second allele. 
Inconsistencies like this can also be explained by lack of heterozygosity for these 
markers. Furthermore, it is also known from literature that LOH analysis is not 
always a reliable technique (Tomlinson, et al. 2002). While CGH analysis previously 
revealed a deletion at 3q13-3q21 (Naus, et al. 2001), our fine-mapping studies pointed 
to a deletion ranging from 3q21.2-3q24. This discrepancy can be explained by the 
fact that the resolution of conventional CGH on metaphases is limited (Pinkel, et 
al. 1998). Along the p-arm allelic loss was detected in Mel270 and corresponding 
cell lines OMM2.3 and OMM2.6 with four consecutive markers, mapping to 3p24.1-
3p24.3. Since FISH analysis revealed two copies in this region, this could point to a 
hemizygous region. However, false positive results, due to lack of heterozygosity, 
cannot be excluded.
While CGH analysis and karyotyping (results not shown) were not indicative of 
any chromosome 3 loss in OMM2.2 and OMM2.6, our LOH analysis pointed to 
isodisomy of chromosome 3 in OMM2.2, whereas allelic loss of a large part of the 
long arm of chromosome 3 was observed in OMM2.6.
The other uveal melanoma cell lines, taken along in the present study, were 
cytogenetically characterised in previous studies (Luyten, et al. 1996; Naus, et al. 
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2001). OCM1, established from a primary tumour, is a tetraploid cell line with many 
structural chromosomal aberrations, including net loss of chromosome 3q. Our 
analysis indicated LOH for the 3q21 and 3q22 region but whether this was real LOH 
or just lack of heterozygosity for these markers could not be established. Despite the 
observed net loss of 3q, cytogenetically two alleles were retained from 3q23 till 3qter. 
OMM1, derived from a metastasis, is nearly triploid with net gain of chromosome 
3. Our microsatellite analysis visualized the presence of at least two different 
copies of chromosome 3 in both cell lines. EOM3, derived from a primary tumour, 
is a pseudodiploid cell line with numerical changes i.e. loss of the Y chromosome, 
trisomy 5, monosomy 6, and trisomy 18 (Luyten, et al. 1996). Both OMM1 and EOM3 
demonstrated a possible LOH of the 3p24.1-3p25.2 region. Metastatic cell line OMM3 
shows a normal karyotype (Luyten, et al. 1996) and our LOH studies confirmed the 
presence of two different copies of chromosome 3. In case of Mel202, established 
from a primary UM (Verbik, et al. 1997), loss of chromosome 3 was not detected with 
either karyotyping, Spectral Karyotyping or CGH analysis (Naus, et al. 2001). Our 
LOH studies, however, revealed the presence of only one allele at different loci along 
chromosome 3, which is indicative of isodisomy. 
Although in a large part of the uveal melanomas monosomy of chromosome 3 is 
found (Scholes, et al. 2001), several studies revealed structural abnormalities of 
chromosome 3p and or 3q in uveal melanomas. A partial duplication, involving 
the long arm of chromosome 3 with a breakpoint at 3q25 has been described by 
Prescher et al. (1995) (Prescher, et al. 1995). Scholes et al. (2001) (Scholes, et al. 2001), 
who performed LOH studies, reported a 3q deletion, ranging from a region between 
marker D3S1589 (3q21.2) and D3S1605 (3q25.32) to the telomere. A LOH study by 
Tschentscher et al. (2001) (Tschentscher, et al. 2001), performed on uveal melanoma 
with structural abnormalities, allowed definition of a smallest region of overlap 
(SRO) at chromosome 3q24-3q26. At the telomeric site the SRO is flanked by marker 
D3S1763, mapping to 3q26.1, and marker D3S2425 located at 3q26.31, showing loss 
and retention, respectively. At the centromeric site the SRO is flanked by marker 
D3S196 (3q24) showing LOH and marker Mdf2 at the RHO locus (3q21.3) showing 
retention of both alleles. In the present study, a deletion, starting between marker 
D3S1269 at 3q21.2 and FISH probe RP11-205A6 at 3q21.2 at the centromeric site, and 
ending between FISH probe RP11-88H10 (3q24) and FISH probe RP11-229G6 (3q24) at 
the telomeric site, was found. Combining present data with data from Tschentscher 
et al. (Tschentscher, et al. 2001) revealed a SRO, ranging from 3q21.3-3q24. Thus the 
SRO, previously defined by Tschentscher et al., who used a low-resolution marker 
set, could be reduced at the telomeric site. Furthermore, these data corroborate with 
a study by Dahlenfors et al. pointing to the 3q23 region as a possible TSG location, 
Fine mapping of chromosome 3 structural deletions in uveal melanoma cell lines
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based on a rearrangement found in one UM (Dahlenfors, et al. 1993). As far as we 
know, TSGs mapping to 3q21.3-3q24 have not been identified to date. In other tumour 
types loss of chromosome 3 has also been described. Loss of chromosome 3q seems 
to be an early event in pheochromocytomas as well (Dannenberg, et al. 2000).
Aberrations of the p-arm of chromosome 3 have also been described. In one uveal 
melanoma a translocation with a breakpoint at 3p13 was found (Blasi, et al. 1999).  
Tschentscher et al. suggested that in metastasised uveal melanoma two regions on 
chromosome 3 (a region on the q-arm and a region on the p-arm) harbour TSGs 
(Tschentscher, et al. 2001). This could explain the frequently observed loss of an 
entire chromosome 3 in those tumours. Although our CGH and FISH analysis did 
not reveal a chromosome 3p deletion in Mel270, microsatellite analysis pointed to a 
region of allelic loss, ranging from 3p24.1-3p24.3. This possible hemizygous region 
is flanked by marker D3S1293 (3p24.3) showing LOH and marker D3S1286 (3p25.1) 
showing retention of two alleles at the telomeric site. The border of the centromeric 
site is defined by marker D3S1211 (3p24.1) and D3S2432 (3p24.1), showing allelic 
loss and retention of two alleles, respectively. This region does not overlap with the 
SRO’s defined by Tschentscher et al. (3p25.3-3p26.1) and Parrella et al. (3p25.1-3p25.2) 
(Parrella, et al. 2003; Tschentscher, et al. 2001). However, in an earlier study by Sisley 
et al. allelic loss of the Thyroid Hormone Receptor B (THRB) locus was observed in 
60% of the uveal melanoma investigated (Sisley, et al. 1993). The human THRB locus, 
which maps to chromosome 3p24.2 (human genome draft, version May 2004), acts 
as a transcriptional activator and silencer. Aberrant expression and/or mutations 
in THR genes could be associated with carcinogenesis (Yang, et al. 2002). Another 
candidate TSG that is located in the hemizygous region is Retinoic Acid Receptor β2 
(RARβ2) (3p24.2). Decreased levels of this receptor are associated with malignancies, 
like breast tumours, lung cancer and squamous cell cancer of head and neck (Yang, 
et al. 2002). Other possible TSGs on 3p like the Von Hippel Lindau (VHL) gene (3p25.3), 
Ras association domain family 1 (RASSF1) (3p21.31) and the Fragile Histidine Triad (FHIT) 
(3p14.2) map to regions outside the hemizygous region, detected in the present study 
(Yang, et al. 2002). 
Although we have clearly reduced the SRO at chromosome 3q, the region is still 
large. It would be interesting to study metastasised uveal melanomas without 
apparent loss of 3q. For analysis, high-resolution techniques, like array-CGH should 
be used. Those kind of studies might finally pinpoint to candidate TSGs. 
96
Chapter 7
Acknowledgements
We would like to thank Anette Verhoeven for excellent technical assistance.
Part 3. Candidate genes and regions associated with 
uveal melanoma progression
Chapter 8
Differential expression of TP63 and TP73 in uveal melanoma reveals 
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Abstract
Loss of chromosome 1p and chromosome 3 are associated with metastatic disease and decreased 
survival of Uveal Melanoma (UM) patients. The p53 homologues, p73 and p63 are located 
on chromosomes 1p and 3q, respectively. Both are able to activate p53 target genes, resulting 
in growth arrest, apoptosis and differentiation. N-terminally truncated isoforms of these 
genes may act as dominant negative inhibitors of wild-type p53 and transactivating activity. 
Although, p53 is frequently involved in several malignancies it does not play a major role in 
UM. Altered expression has been reported for both p63 and p73 in various malignancies. In 
this study fluorescent in situ hybridisation was performed to identify gains or losses of p63 
and p73 loci in UM. The expression of the different p63 and p73 isoforms was evaluated by 
RT-PCR followed by Southern blotting analysis. Furthermore, the expression pattern of the 
various ∆TAp73-transcripts was analysed in 7 primary UM and eleven UM-derived cell lines 
using isoform-specific real-time PCR. Our results indicated that the isoform p73∆ex2/3 was 
abundantly expressed and a relative loss of the p73 locus was associated with upregulation 
of p73∆ex2 and TAp73 transcripts. TA-forms of both p73 and p63 were observed in primary 
and metastasis derived cell lines, as well as in primary melanomas, but in only one of the cell 
lines a ∆Np63 mRNA transcript was observed. Our data suggest a potential function of p73 
deletion transcripts in UM progression. Submitted for publication
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Introduction
Uveal Melanoma (UM) is the most common malignant intra-ocular tumour in the 
Western world. Over 80% of the tumours show non-random chromosomal aberrations, 
Loss of chromosome 3 is a typical change in UM and loss of chromosome 1p36 is 
commonly observed (Aalto, et al. 2001; Kilic, et al. 2005). Loss of chromosome 1p 
occurs frequently in solid tumours (Knuutila, et al. 1999), and in neuroblastoma loss 
of chromosome 1p is known to be a predictor of unfavourable outcome of the patient 
(Caron, et al. 1996; Casciano, et al. 2002). In UM loss of chromosome 1p was detected in 
metastasising UM (Aalto, et al. 2001), and concurrent loss of chromosome 1p and 3 was 
associated with decreased survival of UM patients (Kilic, et al. 2005). Interestingly, the 
candidate tumour suppressor genes p73 and p63, both encoding homologues of p53, 
are located on chromosome 1p36 and 3q27-28, respectively (Kaghad, et al. 1997; Yang, 
et al. 1998). Besides the structural resemblance to p53, p63 and p73 protein products 
are able to turn on a similar set of downstream genes, such as MDM2 and p21, and 
induce apoptosis (Kaghad, et al. 1997; Vossio, et al. 2002). Both, p63 as well as p73, can 
be transcribed as full length proteins with a N-terminal transactivation (TA) domain 
or as shorter truncated isoforms, lacking different parts or the complete N-terminal 
domain (Kaghad, et al. 1997; Yang, et al. 1998). Despite their functional similarity 
with p53, TA-transcripts of p63 and p73 compete with p53 and this leads to a lower 
transactivation of p53-target genes. The truncated transcripts, commonly denoted as 
∆, even have a stronger inhibiting effect. In this manner, apoptosis is inhibited and 
consequently cell proliferation is induced. 
P53 is frequently involved in human malignancies. Mutational inactivation of the 
p73 gene in human malignancies is rare (Stiewe and Putzer 2002), instead, increased 
expression of wild type p73 is correlated with tumour progression (Zaika, et al. 2002). 
This complicates the understanding of the role of p73 in tumour development. Next 
to the ∆N-p73 transcript, regulated by an independent promoter in intron 3, three 
different deletion variants (p73Δex2, p73∆ex2/3 and ∆N’-p73), regulated by the first 
promoter, are observed in tumour cells (Kaghad, et al. 1997; Stiewe, et al. 2002). The 
deletion-variants (∆) counteract p53 activity and suppress the transactivation activity 
of the full-length variant (TAp73) by oligomerisation and competition for DNA binding 
(Stiewe and Putzer 2000). Furthermore, the alternative intronic promoter has been 
shown to be p53/p73 responsive, resulting in an autoregulatory feedback loop (Grob, 
et al. 2001). Mutations of the p63 gene also appear to be rare in primary tumours and 
cell lines (Hagiwara, et al. 1999; Park, et al. 2000). Nevertheless, differential expression 
of various p63 isoforms may contribute to cancer development; high levels of ΔNp63 
were found in e.g. squamous cell carcinomas (Hibi, et al. 2000) .
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Aberrations in UM, such as loss of chromosome 1p and chromosome 3, can result in 
loss of one copy of the p73 and p63 genes. This may affect the expression of full-length 
or N-terminal deletion variants. Considering the potential relevance of both proteins 
in tumorigenesis, we investigated the expression of the deletion-variants in relation 
to copy number variation of p63 and p73 in several primary UM tissue specimens, 
primary UM-derived cell lines and metastases-derived cell lines.  
Material and methods
Patients and cell lines
Thirteen primary UM were randomly selected for this study (Table 1.). Informed 
consent was given prior to enucleation and the study was performed according to 
the tenets of the Declaration of Helsinki. In addition, eleven UM cell lines, isolated 
from primary and metastatic UMs were used. Mel 270, Mel 202, EOM 3, OCM-
1 and 92.1 are cell lines established from primary tumours (De Waard-Siebinga, et 
al. 1995; Kan-Mitchell, et al. 1989; Luyten, et al. 1996; Verbik, et al. 1997). OMM1, 
OMM 2, OMM 3 were established from metastases from three different UM patients 
(Luyten, et al. 1996). OMM 2-2, OMM 2-3 and OMM 2-6 are metastatic cell lines 
derived from separate tumour nodules in the liver of the same patient from whom 
Mel 270 was obtained (Verbik, et al. 1997). As a positive control for TA- and ΔN-p63/
p73 expression we used the breast cancer cell line MCF-7. Cell cultures derived form 
normal eye melanocytes, EMC1 and EMC4, were used as control for expression in 
normal melanocytic tissue.
Fluorescent in situ hybridisation
Dual colour FISH analysis using p73 (RPCI-11 62M23) or p63 (RPCI-11 53D15) BAC-
clones (CHORI-BACPAC Resources, Oakland, CA, USA) was performed according 
to protocols as described previously (Naus, et al. 2000). Per slide 75 ng of probe was 
used and the correct location of the probes was verified on normal peripheral blood 
lymphocyte metaphases. Signals were counted in 300 interphase nuclei. Cut-off limits 
for deletion (15% of the nuclei with one signal) or amplification (>15% of the nuclei 
with 3 or more signals) were adapted from the available literature (van Dekken, et al. 
1990). Relative loss and gain was specified. For those for which no cytogenetics was 
available, the relative loss or gain was estimated based on ploidy as determined by 
FISH. 
p63 and p73 expression in UM
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Expression analysis  
Total RNA was isolated with the RNeasy Mini Kit (Qiagen, Hilden, Germany) 
according to the manufacturer’s protocol. cDNA was synthesised from 1-3 mg 
of total RNA using 2 ml of a random primer (0.5 mg/ml) and 10 U super RT (HT 
Bio-technology LTD, Cambridge, England). cDNA synthesis was verified by 
performing a PCR reaction with primers for AF4 (Gu, et al. 1992). Primer TAp63s (5’-
ATGTCCCAGAGCACACAG-3’) or ΔNp63s2 (5’-GCCCAGACTCCATTTAGT GAG-
3’) with reverse primer TAp63αs (5’-AGCTCATGGTTGGGGCAC-3’) were used for 
detection of TAp63 or ΔNp63, respectively. Amplification products were separated 
on a 1% agarose gel and transferred to nylon membranes. The Southern blot was 
hybridised with α-32P labelled, sequence verified, RT-PCR product of p63.
Real-time quantitative PCR expression analysis
cDNA was synthesized from 1mg of total RNA. Real-time quantitative PCR 
reaction was performed in a total reaction volume of 50 ml containing 2.5 mM of 
each dNTP, 1x Taqman-buffer (Applied Biosystems), 0.25 U Amplitaq-Gold DNA-
polymerase, 15 pmol of each primer, 50 nM dual-labelled fluorogenic internal 
probe and 50 ng cDNA, and was carried out in a ABI prism 7700 sequence detection 
system (Applied biosystems). Sequences of the primers are as follows: TA-p73 
sense, 5’-GACGGACGCCGATG-3’ and antisense, 5’CTGGTCCATGGTG CTG-
3’; p73Δex2 sense, 5'-TGCAGGGAACCAGACA-3’’and antisense 5’-CTGGTC 
CATGGTGCTG-3’; p73Δex2/3 sense 5’-GCAGGCCCAGTTCAAT-3’ and antisense 
5’-CGGGGTAGTCGGTGTT-3’; ΔN’-p73 and ΔN- p73 sense 5’-CACGGCCCAGTT 
CAA-3’ and antisense 5’- CGGGGTAGTCGGTGTT-3’. The housekeeping gene 
Table 1. Clinical characteristics of patients from which primary UM were derived
Gender Age Localisation
Involvement 
ciliary body
Cell type
Epithelioid 
cells
LTD Prominence Metastases
P.1 M 59 Choroid No Spindle Yes 8 9 Yes
P.2 M 60 Choroid No Spindle No 11 9 No
P.3 M 57 Choroid Yes mixed Yes 15 12 No
P.4 M 54 Choroid No Epithelioid Yes 9 8 No
P.5 M 39 Ciliary body Yes Mixed Yes 20 7 No
P.6 F 76 Choroid No Mixed Yes 8 1.5 No
P.7 F 72 Choroid No Mixed Yes 14 9 Yes
P.8 F 74 Choroid No Mixed Yes 18 5 No
P.9 M 54 Choroid No Mixed Yes 11 7 No
P.10 M 82 Choroid No Epithelioid Yes 16 14 No
P.11 F 76 Choroid No Epithelioid Yes 15 15 Yes
P.12 F 70 Choroid No Mixed Yes 14 11 Yes
P.13 M 80 Choroid No Mixed Yes 14 14 Yes
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glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was quantified with the 
following primers: 5’-GTCGGAGTCAACGGATT-3’ and antisense 5’- AAGCTTCC 
CGTTCTCAG-3. A serial dilution of pooled human cDNAs was used to measure the 
amplification efficiency (96%) (Meijerink, et al. 2001; Stam, et al. 2003). Relative mRNA 
expression levels of each sample were normalized for input RNA using GAPDH 
expression of the sample. The relative mRNA expression level of each sample was 
calculated using comparative cycle time (Ct) method.  The target PCR Ct values, i.e. 
the cycle number at which emitted fluorescence exceeds 10x the standard deviation of 
base-line emissions as measured from cycles 1 to 20, is normalised by subtracting the 
GAPDH Ct value from the target PCR Ct value, which gives the ΔCt value. From this 
ΔCt value the relative expression level to GAPD, annotated in arbitrary units, can be 
calculated by using the following equation: relative mRNA expression = 2-ΔCtx 1000.
Results 
Detection of loss or gain of the p73 and p63 loci
FISH analysis, using locus specific probes was performed to detect numerical 
abnormalities for the p73 and p63 loci (Table 2). Classification was specified as a 
relative gain or loss based on cytogenetic data. Six cell lines and three primary UM 
showed variation in number of signals for the BAC-clone RPCI-11 62M23 at the p73 
locus. Loss of p73 was observed in two primary cell lines (Mel 202 and EOM 3), two 
metastatic cell lines (OMM 2-3 and OMM 1) and six primary melanomas (P.5, P.7, 
P.9, P.10, P12 and P.13), whereas gain was observed in one primary tumour cell line 
(OCM-1), one metastatic cell line (OMM 2-2) and one primary melanoma (P.4). The 
BAC-clone RPCI-11 53D15, p63, showed agreement between the number of signals 
and the reported cytogenetic findings in five cell lines. In six cell lines variation in the 
number of FISH signals was observed. Loss of the p63 locus on chromosome 3 was 
observed in two primary (Mel 202 and EOM 3) and one metastatic cell line (OMM 
1), whereas gain of p63 was observed in one primary (OCM-1) and one metastatic 
cell line (OMM 2-2). In one metastatic cell line we observed subclones with loss and 
subclones with gain of p63 (OMM 2-3). In the primary tumours we observed both loss 
(P.2, P.7 - P.13) and gain (P.4) (see Figure 1). 
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Table 2. Copy number of the TP73 and TP63 loci in primary UM and UM-cell lines
P73 P63
ploidy o† e‡ o e
P.1 diploid 2 2 2 2
P.2 diploid 2 2 1,2 2
P.3 diploid 2 2 2 2
P.4 diploid 2,4 2 2,4 2
P.5 diploid 1,2 2 2 2
P.6 diploid 2 2 2 2
P.7 diploid 1,2 1 1 1
P.8 diploid 2 2 1,2 2
P.9 diploid 1,2 2 1 2
P.10 diploid 1 2 1 1
P.11 diploid 2 2 1 1
P.12 diploid 1 2 1 2
P.13 diploid 1 1 1 1
OCM-1 tetraploid 4,5 4,5§ 5,6 4
92.1 diploid/tetraploid 2,4 2,4 2,4 2,4
Mel 202 diploid 1,2 2 1,2 2
EOM 3 diploid 1,2 2 1,2 2
Mel 270 diploid 2 2 2 2
OMM 2-2 tetraploid 4,5 4 4,5 4,5
OMM 2-3 diploid/triploid 1,2 2,3 3-5 4
OMM 2-6 diploid 2 2 2 2
OMM 1 triploid 2 2 2,3 3
OMM 2 diploid 2 2 2 2
OMM 3 diploid 2 2 2 2
Only significantly different cell populations (loss or gain >15% of the cells) are indicated. 
†Observed copy number by FISH analysis.
‡Expected copy number based on cytogenetic or FISH data.
§Tetraploid / triploid clone is indicated in bold.
Ploidy based on cytogenetic or FISH data.
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Analysis of TAp63 and ΔNp63 transcripts in UM cell lines and primary UM
Expression of the p63 genes was examined by performing a RT-PCR using primers for 
the N-terminal domain of the truncated and non-truncated isoforms in eight primary 
tumours and eleven cell lines (Figure 2). TAp63 was expressed in two of five primary 
cell lines (Mel 270 and EOM 3), four of six metastatic cell lines (OMM 2-2, OMM 
2-3, OMM 2-6 and OMM 1) and in six of eight primary melanomas (P.1-P.4, P.6 and 
P.8), as well as in one of the normal eye melanocyte cultures (EMC1), though very 
weak. The ΔNp63 transcript was expressed in only one of the metastatic melanoma 
cell lines (OMM 2-3), and neither in primary melanomas nor in normal melanocytes. 
Expression in the control cell line was clearly detectable.
Quantification of TA-p73 and ΔN-p73 transcripts in primary UM and UM cell lines 
compared to copy number alterations
To quantify the expression of the various TP73-transcripts we performed RT-PCRs 
using primers that discriminate between the N-terminal domain of the full length 
and deletion transcripts. Results were obtained for the cell lines and 7 primary uveal 
melanomas (P.3, P.5, P.9 - P.13) In general, the most abundantly expressed transcript 
was p73Δex2/3. Primary UM and cell lines were grouped on the basis of relative copy 
number of p73 obtained by Fluorescent in situ Hybridisation. In the group with a 
relative loss p73Δex2 and TAp73 were upregulated. P73Δex2/3 and ΔN’-/ΔN-p73 
transcripts were diminished independent of copy number of TP73 (Figure 3). 
Figure 1.
Interphase FISH with the BAC-clones RPCI-11 62M23 for p73 in green and RPCI-11 53D15, located on 3q24 
in red: A. P.7, B. P.13 and C. OCM-1. 
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Figure 2. 
The expression of TAp63, mNp63 mRNA was analysed in UM cell lines using RT-PCR. Lane 1 is the positive 
control MCF-7. Lanes 2-6 are cell lines derived from primary uveal melanoma. Lanes 7-12 are cell lines derived 
from metastases. Lanes 13 and 14 are cultured normal eye melanocytes. Lanes 15-22 are primary uveal mela-
noma. AF4 demonstrates a successful RT-reaction for all samples. 
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Figure 3.
Quantification of TP73 transcripts in primary UM and UM cell lines grouped according to copy number. Bars 
represent the arbitrary units, whiskers indicate the standard deviation: Relative loss of the p73 locus (n=9), 
Relative normal copy number (n=7), and normal copy number in eye melanocytes (n=2).
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Discussion
In UM the p53 pathway is not affected through alterations in p53 protein levels 
(Brantley and Harbour 2000). This indicates that different mechanism might be 
involved in functional inactivation of transcriptional target genes of p53, such as 
inactivation by interacting proteins encoded by p63 and p73. In this study we have 
investigated the expression of p63 and p73 and their deletion-variants in relation to 
copy number variation in uveal melanoma. Although no homozygous deletions were 
found in any of the cell lines and primary UM, some showed loss of one allele whereas 
others had extra copies of p63 or p73. Moreover, we observed an effect of copy number 
alteration on expression of TP73. Based on the knowledge that loss of chromosome 1p 
is associated with metastasis, we assumed that tumours with loss would progress and 
eventually metastasise (Aalto, et al. 2001). In this study we demonstrate that a relative 
loss of the p73 locus in UM is associated with an increased expression of p73Δex2. 
O’nions et al. showed that the TA-promoter derived p73Δex2 is the main expressed 
transcript in vulval cancers (O’Nions, et al. 2001). Considering the oncogenic potential 
of ΔTA-p73 (Stiewe, et al. 2002), a shift towards oncogenic ΔTA-form would be 
expected. Nevertheless, we observed that beside increased levels of p73Δex2 TAp73-
expression is also increased in comparison to normal eye melanocytes. This may 
be the result of an increased TA-promoter activity, which induces both transcripts 
(Fillippovich, et al. 2001; Ng, et al. 2000). Looking at all samples together increased 
expression of transcripts regulated by the first TA-promoter is observed (TAp73 and 
p73Δex2). In our analysis we were not able to differentiate between ΔN-p73 and ΔN’-
p73. The ΔN-p73 is expressed by an intronic promoter (Stiewe, et al. 2002), whereas 
ΔN’-p73 is transcribed by the TA-promoter, resulting in the other Δ-transcript 
variants (Fillippovich, et al. 2001; Ng, et al. 2000). We were not able to correlate both 
transcripts independently with loss of chromosome 1p, because on mRNA level ΔN-
p73 and ΔN’-p73 are not discernable (Stiewe, et al. 2002). However, analysed as a 
group we observed a slightly decreased level. In addition, the number of samples in 
our study was too small to perform reliable statistical analysis. 
Furthermore, we showed that differences in copy number did not have an obvious 
influence on the expression of TAp63 or ΔNp63. This was demonstrated in cell lines 
with a relative gain of p63 (OCM-1, OMM 2-2 and OMM 2-3) that showed different 
expression patterns. Likewise, in cell lines with loss of one copy (Mel 202 and EOM 
3) or with apparently normal copy numbers (92.1, Mel 270, OMM 2-6, OMM 2-3 and 
OMM 3) expression could not be associated with copy number. Also primary UM 
with either loss or gain of the TP63 locus showed no changes in expression. This is 
in contrast to findings in primary lung cancer and squamous cell cancers where the 
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predominantly expressed form is the ΔN-variant (Hibi, et al. 2000). In only one cell 
line (OMM2-3) that showed an extra copy of the TP63 locus, ΔN-p63 expression was 
demonstrated. Still, since amplification of chromosome 3 is generally not observed 
in UM a role for ΔN-p63 seems to be unlikely. Nevertheless, more studies need to be 
done. 
Our results indicate that oncogenic splice variants, such as p73Δex2, occur more often 
if there is a relative loss of the p73 locus. However, this hypothesis must be clarified 
within a larger series of uveal melanoma. Expression of Δ-variants of p73 may result 
in a dominant-negative feedback loop ending in diminished p53 and TAp73 activity 
(Vossio, et al. 2002). In uveal melanoma p53 target genes, such as p21, were upregulated 
whereas p53 expression was not affected (Mouriaux, et al. 2000). In our series 3 of 
the patients without loss had died due to metastases, whereas 3 of 6 patients with 
loss of a copy of TP73 died. Considering the metastatic potential of tumours with 
chromosome 1p loss these findings support the assumption that enhanced expression 
of dominant-negative splice variants is associated with cancer development (Stiewe 
and Putzer 2002; Zaika, et al. 2002). In this way, an oncogenic property is attributable 
to Δ-p73 and thus p73 is likely to play a role in tumorigenesis of UM.
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Abstract
An activating mutation has recently been observed in a downstream component of RAS, 
BRAF. The most common mutation in 80% of the cutaneous melanoma samples is a T-to-
A transition, resulting in a single amino acid substitution, V599E. Since cutaneous and 
uveal melanoma (UM) have a common origin, we aimed to establish whether activation of 
the BRAF proto-oncogene is also an important factor in the development of UM. Exons 11 
trough 18 of the BRAF gene were screened from 33 primary UM and eleven UM cell lines. 
Genomic polymerase chain reaction products were analysed using single-strand conformation 
polymorphism analysis, followed by sequencing aberrant products. The most common 
mutation, T1796A, in the kinase domain of BRAF was not observed in any of the primary 
UM samples. This mutation was also absent in ten of the eleven UM cell lines. In one of the 
UM cell lines, OCM1, this T1796A mutation was present. Mel. Res. 2004 Jun;14(3):203-5
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Introduction
The RAS-RAF kinase pathway plays a distinct role in melanogenesis. It mediates 
cellular responses to growth signals. In response to UVB-radiation cAMP is up 
regulated, leading to increased proliferation and melanogenesis. Two components of 
this pathway, RAS and RAF, are proto-oncogenes. RAS is a member of a family, which 
consists of three functional genes, H-RAS, K-RAS and N-RAS, encoding highly similar 
proteins with molecular weights of 21 kDa (Barbacid 1987). Activating mutations of 
RAS are found in 25% of all cancers (Bos 1989). Mutations of RAS, predominantly 
N-RAS mutations, have been identified in 9-15% of cutaneous melanomas (Carr and 
Mackie 1994; van Elsas, et al. 1995). However, uveal melanomas (UM) do not seem to 
harbour activating mutations of RAS (Mooy, et al. 1991). The RAS proteins differ in 
their ability to activate the downstream component of this pathway, RAF. The RAF 
family consists of three genes, ARAF, BRAF and CRAF, encoding for cytoplasmic 
serine/threonine kinases that are regulated by binding to RAS (Chong, et al. 2003; 
Peyssonnaux and Eychene 2001). Recently, Davies reported on mutations of BRAF 
in human cancer (Davies, et al. 2002). BRAF mutations were present in 60-66% of 
the malignant melanoma and at a lower frequency in a wide range of other human 
cancers (Brose, et al. 2002; Davies, et al. 2002). The most common mutation, T1796A, 
was located in the serine/threonine kinase domain of BRAF, resulting in a Valine to 
Glutamic Acid substitution at position 599. Thus, resulting in a constitutive active 
protein promoting proliferation (Zhang and Guan 2000). In cell lines harbouring the 
T1796A BRAF mutation, concurrent mutation of RAS was not required for oncogenic 
behaviour. Several less common mutations of BRAF that occurred together with 
RAS mutations were located in exon 11 (Brose, et al. 2002; Davies, et al. 2002). The 
discovery of BRAF mutations in cutaneous melanoma urged us to investigate the 
role of BRAF in UM, since both cutaneous and UM arise from neural crest derived 
melanocytes. We were particularly interested to see whether BRAF mutations were 
present within RAS mutation negative samples.
Material and methods
Genomic DNA
DNA was obtained from 33 fresh frozen primary UM tissue sections as described 
previously (Mooy, et al. 1991) and eleven UM cell lines, derived from primary and 
metastatic melanoma (Naus, et al. 2000). EOM 3, OCM1, 92.1, Mel 270 and Mel202 
were all established from primary tumours. OMM1, OMM2 and OMM3 were derived 
from metastases of three different UM patients. OMM2.2, OMM2.3 and OMM2.6 
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were derived from separate tumour nodules in the liver of the same patient from 
whom also Mel270 was obtained. Two malignant melanoma cell lines, SKMel28 and 
Bowes, and two colon carcinoma cell lines, HT29 and LS194, were used as controls 
(Davies, et al. 2002).
Single-strand conformation polymorphism analysis
Genomic DNA was screened for mutations using single strand conformation 
polymorphism analysis (SSCP). PCR reactions were performed using 8 pairs of 
primers for exon 11 through 18 resulting in PCR-fragments with lengths between 
196-370 bp (Davies, et al. 2002). The forward primer for exon 18 was modified 
resulting in primer 5’-TGTAGATTCTCGCCTCTATTGAG-3’. Genomic tumour DNA 
was amplified using 2.5U Pfu Turbo polymerase (Stratagene, California, USA), 20 
pmol of each primer, 2.5 mM dNTP’s per reaction. PCR products were purified using 
the Qiagen Quick Purification system (Qiagen Inc, Santa Clarita, USA). Fragments 
were end-labelled with 1 mCi [γ-32P] dATP and the labelled product was loaded on a 
MDE gel (J.T. Baker Inc., Philipsburg, USA) containing 0, 5 or 10% glycerol. The gels 
were run at 8W for 15-20 hours at RT. After electrophoresis, the gels were dried and 
exposed to a Kodak Biomax film for 24 hours. All aberrant bands were sequenced, 
using an automated sequencer (Base Clear, Leiden, The Netherlands).
Figure 1.
SSCP of exon 15 of eight uveal melanoma cell line samples and SKMel28, a cutaneous melanoma cell line. 
Difference in pattern is clearly visible, indicated by arrows, in OCM1 and SKMel28. Both have the T-to-A 
transversion 1796 in exon 15 of the BRAF gene that leads to the Valine-to-Glutamic acid substitution at codon 
599 (V599E).
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Results and discussion
Recent investigations show that 60-66% of the cutaneous malignant melanoma 
harbour mutations of the proto-oncogene BRAF (Davies, et al. 2002). This led us to 
investigate the occurrence of BRAF mutations in primary UM and UM cell lines. 
Mutation analysis was performed on the coding sequence and exon-intron borders of 
exons 11 through 18, encoding the complete serine/threonine kinase domain of BRAF. 
No BRAF mutations were observed in our 33 freshly frozen primary UM samples. 
These primary UM samples were previously screened for their N-RAS status; no N-
RAS mutations were observed (Mooy, et al. 1991). In ten out of eleven UM cell lines no 
BRAF mutations were found. However, SSCP analysis displayed an aberrant pattern 
in the case of OCM1 (Fig. 1). Sequencing analysis revealed the T1796A transversion. 
The same aberrant SSCP pattern was also seen in the control cutaneous melanoma 
cell line, SKMel28, and colon carcinoma cell line, HT29. While we were preparing 
this paper Edmunds et al. published their results on the absence of BRAF mutations 
in exons 11 and 15 (Edmunds, et al. 2003). Although we came to the same conclusion 
we have fully screened exons 11 through 18 and were able to detect a polymorphic 
nucleotide change (IVS12+35G>C) in four of the primary tumours (Fig. 2), the cell line 
Mel270 and its metastases (OMM2.2, OMM2.3, OMM2.6).
In view of the fact that we could not detect any BRAF, or earlier, RAS mutations in 
primary UM (Mooy, et al. 1991), suggest that RAS and its downstream components 
do not play a role in the aetiology of UM. This in contrast to primary cutaneous 
melanoma where mutations have been observed, indicating an involvement of BRAF 
(Brose, et al. 2002; Davies, et al. 2002). 
1 2 3 4 5 6 7
Figure 2.
SSCP of exon 12 of seven primary uveal melanoma samples. Sample 1, 3, 4, 6 and 7 represent the wild type 
pattern. Sample 2 and 5 show the pattern for the polymorphism (IVS12+35G>C), which is visible by an up-
ward shift of the bands indicated by the arrows.
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Despite the common embryonic origin, these tumours probably follow a different 
path towards tumorigenesis and have different biological behaviour. The fact that the 
activating BRAF mutation was present in OCM1 strongly suggests that OCM1 was not 
derived from a primary UM. Since the melanocytic origin of this cell line was shown 
we suppose that this cell line was in fact a metastasis of a cutaneous melanoma in the 
eye (Kan-Mitchell, et al. 1989; Luyten, et al. 1996). In addition, the characteristics in 
the karyotype of OCM1 are also not very specific for primary UM as we do not find a 
monosomy of chromosome 3, which is very specific for UM (Luyten, et al. 1996). 
 
In summary, our results indicate that BRAF is not involved in the pathogenesis of 
UM and that tumorigenesis of UM involves different sets of genes compared to these 
involved in cutaneous melanoma.
General discussion 
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General discussion and future prospects
Identification of prognostic parameters is an important goal of current cancer 
research. The prognostic factors may be subdivided into clinical, histopathological 
and genetic parameters. To be able to prevent or predict metastases we need more 
insight in the development and progression of the tumour. Therefore the aim this 
thesis is to identify reliable parameters involved in uveal melanoma development 
and progression.
Radiotherapy in uveal melanoma
The indication for enucleation or any other treatment modality is directed by the size 
of the tumour. Stereotactic radiotherapy (SRT) is a rather new treatment option with 
relatively limited side effects (Muller, et al. 2005; Muller, et al. 2004). The effectiveness 
of fractionated SRT on tumour control, visual acuity and chance on secondary 
enucleation seems to be comparable with the results for proton beam irradiation, but 
clinical trials are needed to evaluate these treatment options. Survival rates are also 
similar for enucleation and radiotherapy. Radiotherapy has become the first option 
to treat small and medium-sized tumours. In the study in chapter 2 we demonstrated 
that a fractionation schedule of 5x 10 Gy is sufficient to kill most radio-resistant 
cell lines. The radiosensitivity of uveal melanoma cell lines is mainly determined 
by the intrinsic radiosensitivity, the a-component, and less due to sublethal DNA 
damage (b-component). The intrinsic radiosensitivity, the a-component, indicates 
the regenerative capacity of the tissue, i.e. unrepairable damage. The b-component 
represents the self-renewal/repair capacity of the DNA. Cells displaying a low 
a/b ratio, which is indicative for a sparing effect after dose fractionation, require 
large doses per fraction for effective tumour treatment. The same low a/b ratio is 
also seen in late responding normal tissue, resulting in little benefit of the therapeutic 
ratio. The results of this study could be translated into a clinical setting to determine 
a therapeutic ratio for fractionated radiotherapy. Nevertheless clinical use of the 
individual radiosensitivity of the tumour is not possible at this moment, and further 
research focusing on this subject is necessary. On the other hand fractionated SRT 
is already in use for the small and medium sized uveal melanoma (Muller, et al. 
2005). The larger tumour, though, may not benefit from this treatment, mainly due 
to uncontrollable side effects, resulting in complications, s.a. neovascular glaucoma, 
total retinal detachment, and vitreous haemorrhage that will lead to secondary 
enucleation. Consequently, enucleation may be the first choice of treatment for the 
large tumours. Still enucleation is not without any risk, since it may induce micro 
metastases (Manschot and van Peperzeel 1980; Zimmerman, et al. 1978). The metastatic 
capacity of uveal melanoma is not clearly predicted by the size of the tumour, but late 
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occurring metastases might be avoided by pre-enucleation radiotherapy. The COMS 
studied the randomly assignment of patients to pre-enucleation radiotherapy or 
enucleation alone in a large study with medium and large sized tumours. The latest 
report confirmed earlier reports of no survival advantage attribute to pre-enucleation 
radiotherapy (Hawkins 2004). In chapter 3 we demonstrated that late occurring 
metastases, induced by enucleation, benefit from radiotherapy prior to enucleation. 
The survival advantage occurs after a period of 4 years, which is in concordance with 
the time required for a tumour to grow sufficiently to be detectable (Eskelin, et al. 
2000). We should therefore reconsider if we should re-introduce pre-enucleation 
radiotherapy in case of enucleation. 
Chromosomal aberrations in uveal melanoma
In the second part of this thesis, results of chromosomal and clinical analyses 
performed on primary uveal melanoma are described. Many studies have been 
performed concerning chromosomal aberrations and prognosis. The chromosomes 
that are consistently affected are chromosomes 1, 3, 6 and 8, with alterations reflected 
as gains and losses. We have analysed 120 uveal melanomas for chromosomal 
changes of chromosomes 1, 3, 6 and 8 using cytogenetic, FISH and CGH analyses. In 
previous studies monosomy 3 occurred in about 50% of the cases, in ciliary as well as 
choroidal melanoma (Prescher, et al. 1994; Sisley, et al. 2000; White, et al. 1996). The 
role of chromosome 1 is less apparent and some investigators have shown that loss 
of chromosome 1p is more common in large aggressive tumours (Sisley, et al. 2000) 
or metastasising tumours (Aalto, et al. 2001). In general a deletion or rearrangement 
of chromosome region 1p is observed (Horsman and White 1993; Parrella, et al. 1999; 
Prescher, et al. 1990; Sisley, et al. 2000). None of the previous studies, however, have 
evidently analysed concurrent loss of both, chromosome 1p and 3. We demonstrated 
that after correcting for confounding variables tumours with concurrent loss of 
chromosome 1p and 3 had a 7.8 time higher chance to metastasise than tumours 
without these losses or either 1p or 3 loss (Chapter 4). From a clinical view, it may 
enable clinicians to identify patients at high risk of developing metastases. In 
addition, some researchers have shown an increasing decreased disease free survival 
in the presence of amplification of chromosome 8q and uveal melanoma showed 
a clear tendency of progressive acquisition of additional copies of chromosome 8q 
(Sisley, et al. 1997). As amplification occurs subsequently to the loss of chromosome 
3 the change has been specifically related to the ability of some uveal melanoma to 
spread and metastasise (Prescher, et al. 1994; Sisley, et al. 1997). A large proportion 
of uveal melanomas with monosomy 3 show a multiplication of 8q (Horsman and 
White 1993; Prescher, et al. 1995; Sisley, et al. 1992). Though, in the study described in 
chapter 4 amplification of chromosome 8q did not appear to be of much prognostic 
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importance. Amplification of chromosome 6p and loss of chromosome 6q is present 
in approximately 40% of the uveal melanomas (Mudhar, et al. 2004; Sisley, et al. 2000; 
Speicher, et al. 1994; Tschentscher, et al. 2000; White, et al. 1998a). Up to now only one 
study showed a better survival with chromosome 6 alterations (White, et al. 1998a), 
whereas another study demonstrated that loss of chromosome 6q appeared more 
often in primary tumours and their metastases than in non-metastasising melanoma 
(Dahlenfors, et al. 1993). Therefore, chromosomal aberrations, such as of chromosome 
6 and 8, have been considered as a late event (Horsman and White 1993; Prescher, et 
al. 1995; Sisley, et al. 1992), with amplification of chromosome 8q as a promoter of 
tumour growth, resulting in a larger tumour diameter (Figure 1). 
Familial uveal melanoma account for only 0.6% of all uveal melanoma (Singh, et al. 
1996b). Studies on chromosomal changes in the tumour have not been performed 
as has been done for the sporadic tumours. Familial uveal melanomas have some 
aberrations in common with sporadic occurring melanoma, especially monosomy 
3, loss of chromosome 1p and gain of chromosome 8q. Considering the gains and 
losses observed in both, sporadic and familial UM, they might be etiologically related 
indicating common regions of interest (Chapter 6). Another interesting chromosome 
is 16; loss of chromosome 16q was observed in several studies (Hoglund, et al. 2004; 
Sisley, et al. 2000)(Chapter 5 and 6). Even though the occurrence of chromosome 
16q loss cannot be associated with survival it could still be involved in tumour 
progression or either tumour growth comparable to chromosome 8q gain, which 
was also considered to be a late prognostic factor. Therefore, delineation of a region 
on chromosome 16q may give us an opportunity to depict a region of interest with 
possible candidate genes involved in tumour progression.
NORMAL MELANOCYTE
CHROMOSOME 1P
CHROMOSOME 3
CHROMOSOME 8Q
CHROMOSOME 6P/6Q
UVEAL MELANOMA
Figure 1.
Simplistic model on accumulation of chromosomal abnormalities in uveal melanoma
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Candidate regions and genes associated with uveal melanoma progression
Loss of a complete chromosome 3 is considered an early event (Prescher, et al. 
1994; Sisley, et al. 2000; White, et al. 1996) and appears to be characteristic for uveal 
melanoma. In other solid tumours the region of loss is generally restricted to a certain 
area. Nonetheless, partial deletions of chromosome 3 have been reported (Horsman 
and White 1993; Kilic, et al. 2005; Prescher, et al. 1994; Sisley, et al. 1998; Tschentscher, 
et al. 2001) resulting in the hypothesis that two regions, one on the p-arm and one 
on the q-arm, might be involved in metastasis (Tschentscher, et al. 2001). In chapter 
4 several tumours with partial loss were described, but the precise region of loss was 
not defined for these tumours. To study the biological and molecular characteristics 
of factors involved in melanoma progression and metastases fresh tumour tissue and 
cell lines are available. Although cell lines are not often identical to the original tumour 
cells due to culture environment, they are of high value to study these characteristics. 
We have delineated a region on the q arm of chromosome 3, 3q21.2-3q24, in uveal 
melanoma cell lines (Chapter 7). Combined with the results of previous studies, 
which showed a smallest region of overlap (SRO) spanning 3q24-3q26, the size of 
region of interest could be reduced. Candidate genes within this second region 
might be the putative osteosarcoma tumour suppressor gene at 3q26. Another gene 
p63, mapped to 3q27 is located distal to the SRO. P63 is a p53 homologue encoding 
different transcripts, some with dominant negative function, resulting in a negative 
feedback of p53 expression. In chapter 8 expression of different transcription variants 
encoded by p63 could not be correlated with loss of the chromosome locus of p63, 
indicating that p63 does not play key role in uveal melanoma. In addition, ATR (Ataxia 
Telangiectasia and Rad3 related), THRB (Thyroid Hormone Receptor B) (Sisley, et 
al. 1993) and  RARβ2 (Retinoic Acid Receptor β2) at the hemizygous region at 3q24 
(Chapter 7) might be possible candidates. Chromosome region 1p may also harbour 
some candidate genes, since tumours with concurrent loss of chromosome 1p36 
and monosomy 3, were associated with a decreased survival. As mentioned before 
Aalto et al. described that chromosomal region 1p is associated with metastasising 
UM (Aalto, et al. 2001). These findings are suggestive for an interaction of proteins 
encoded by genes located on these chromosomes that might promote tumorigenesis, 
metastatic disease and consequently reduce survival. Ample research is done in 
neuroblastoma demonstrating a strong correlation of chromosomal region 1p36 with 
worse prognosis. Interesting genes, that are selectively downregulated in this tumour 
are UBE4B, KIF1B, PGD, APITD1, DFFA and PEX14 (Caren, et al. 2005). P73, a gene 
associated with worse prognosis in neuroblastoma, is located on chromosome 1p36. 
Increased expression of the p73Δex2 transcript, which is one of the transcription 
variants encoded by p73, was observed in primary tumours and cell lines with loss 
of chromosome 1p (Chapter 8). Supported by studies in various cancers we assume 
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that a role is attribute for this gene in UM progression. The p73Δex2-transcription 
variant may act as a dominant negative regulator op p53 induced apoptosis (Kaghad, 
et al. 1997; Yang and McKeon 2000) and consequently promote cell division. Another 
gene associated with prognosis in neuroblastoma is the APITD1 gene, particularly 
involved in cell division and cellular growth. Due to expression variants this gene 
may act as a dominant negative regulator of cell growth and induce apoptosis. It was 
suggested that low expression of APITD1 might interfere with ability of apoptosis 
through the p53 pathway (Krona, et al. 2004). In UM APITD1 has not been studied 
yet and might be a candidate for future research, considering the role chromosome 1p 
deletion plays in uveal melanoma survival.
As depicted earlier monosomy 3 is considered as an early event in UM. In previous 
studies monosomy 3 was consistently present in several subclones of a primary 
uveal melanoma, whereas isochromosome 8q and other aberrations appeared not 
everywhere (Aalto, et al. 2001; Prescher, et al. 1995). This tumour heterogeneity 
complicates the study of uveal melanoma. In general the initial changes will be 
observed in all subclones, whereas late changes may appear in only a subset of the 
tumour. Onken et al. described a novel molecular classification of uveal melanoma, 
based on gene expression profile, which distinguished low-grade from high-grade 
tumours (Onken, et al. 2004). This profile demonstrated overexpression of a cluster 
of genes on chromosome 8q in high-grade tumours, implying a role for chromosome 
8q amplification in uveal melanoma progression (Ehlers, et al. 2005). DDEF1 
(development and differentiation enhancing factor 1) is one of the genes in this cluster 
and had a much stronger correlation with metastatic death than MYC (Chana, et al. 
1999; Ehlers, et al. 2005). DDEF1 mRNA as well as protein level overexpression are 
correlated with gain of chromosome 8q. The gene itself is an ADP ribosylation factor-
GTPase activating protein involved in growth and differentiation. Therefore it might 
be a good candidate that may be involved in tumour progression and ability of the 
tumour to metastasise (Ehlers, et al. 2005).
Genes involved in malignant melanoma development and progression are regularly 
investigated in uveal melanoma, as both tumours are frequently compared. However, 
both may have a different etiology. For instance a specific mutation of the BRAF gene, 
V599E mutation, was observed in 60%-66% of the malignant melanoma of the skin 
(Davies, et al. 2002). Once having the V599E mutation it results in a constitutively 
active protein in the RAS-BRAF pathway promoting proliferation (Zhang and 
Guan 2000). Several studies could not demonstrate this BRAF mutation in primary 
uveal melanoma (Chapter 9) (Zuidervaart, et al. 2005). However, one of the primary 
uveal melanoma cell lines we investigated did have the V599E mutation. The first 
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publications on this cell line, OCM1, demonstrated an uveal melanoma origin. In 
OCM-1 a 28 bp deletion in exon two of the CDKN2 locus was detected (Naus et al. 
unpublished results). Inactivation of p16ink4a  in uveal melanoma generally occurs 
through methylation and not through mutation or deletion as in cutaneous melanoma 
(Singh, et al. 1996b). That’s why OCM1 may resemble cutaneous melanoma, and since 
the melanocytic origin of the OCM1 cell line was shown (Foulkes, et al. 1997; Kan-
Mitchell, et al. 1989; Luyten, et al. 1996; Walker, et al. 1998) this cell line may have 
been contaminated during cell culture. 
 
Conclusions and future prospects
As all analyses are focused on identification of highly malignant tumour profiles, 
it is important to find a simple method that identifies these patients in a relative 
easy manner. FISH or CGH analyses are clear methods to identify tumours with 
monosomy 3. For the samples that do not show evident chromosomal abnormalities 
a technique that characterises small gains and losses may be useful (CGH-arrays). 
DNA copy number alterations have already been successfully analysed with 
CGH-arrays (Hughes, et al. 2005) Compared to metaphase chromosomes, which 
are conventionally used for CGH, a much more sensitive and higher resolution 
can be achieved. Arrays with mapped clones are useful to obtain information on 
known chromosomal regions, resulting in a simplified search for candidate regions. 
Furthermore, subtle structural aberrations may be resolved with techniques with 
higher resolution, s.a. LOH studies or SNP-arrays. However, changes such as base 
substitutions, very small deletions or insertions will still be missed. Oligonucleotide-
arrays have become available for identification of candidate genes in a more rapid 
way. This technique will be a valuable tool for identification of interesting genes in 
uveal melanoma. Especially when combined with the results obtained by CGH-array 
analysis regions and genes of interest may be detected elucidating pathways involved 
in uveal melanoma progression. Moreover, defining chromosomal regions predictive 
of metastasis gives the opportunity to produce diagnostic arrays, and in a later stage 
these methods may be helpful to determine a chemo- or radioresistance profile useful 
in the therapeutic strategies against UM. Since the current treatment modalities have 
similar results, selection of patients at high risk for developing distant metastases 
is clinically the most important aspect. The present information on chromosomal 
abnormalities already enables us to select patients at high risk. Data from our study 
suggests the feasibility of studying patients with uveal melanoma in prospective trials 
using samples retrieved by FNABs (Naus, et al. 2002; Sisley, et al. 1998). 
Micrometastatic spread of tumour cells during enucleation may be prevented by pre-
enucleation radiotherapy. Contrary to the COMS who could not observe a survival 
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benefit of this treatment, we demonstrated a significant benefit in survival. The pre-
enucleation radiation is a relatively innocent treatment with low dose irradiation and 
consequently limited side effects. 
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Summary
Uveal melanoma is the most common primary malignant intra-ocular tumour in the 
Western world with an annual incidence of seven per million. Approximately 50% of 
the patients die eventually due to metastatic disease, most commonly located in the 
liver. Besides enucleation there are nowadays more conservative treatment methods 
aimed at sparing the affected eye and retaining vision, s.a. plaque radiotherapy, 
proton beam or stereotactic radiotherapy, with or without additional transpupillary 
thermotherapy (TTT). The effect of radiotherapy in uveal melanoma cell lines and 
primary uveal melanoma was described in the first part of this thesis. In chapter 2 
an experimental study that investigated the amount of radiation needed to eradicate 
tumour cells is described. Every tissue has an intrinsic regenerative capacity (a) 
besides the repair capacity to overcome DNA damage (b). With survival assays the 
sufficient amount of radiation to kill most of the radioresistent cells was determined. 
Data from single and fractionated doses indicate large variations in radiosensitivity, 
which are mainly dominated by the intrinsic radiosensitivities. Therefore doses of 
5 fractions of 8 Gy would be more than enough to kill most of the radiosensitive 
tumour cells. These results may be extrapolated to a clinical setting where they may 
be used to plan the individual amount of radiation for treatment with stereotactic 
radiotherapy. In spite of the new treatment modalities enucleation is still performed 
on larger tumours. Manipulation of the tumour-containing eye during enucleation 
could induce metastatic spreading of tumour cells. Furthermore, tumour cells may 
have spread prior any treatment, explaining the peak incidence of metastatic disease 
at 2 years after enucleation. By means of pre-enucleation radiotherapy the spreading 
of tumour cells during enucleation may be diminished. In chapter 3 is demonstrated 
that pre-enucleation radiotherapy has a beneficial effect on survival compared to 
enucleation alone.
 
The second part of this thesis focuses on identification of clinical and genetic prognostic 
parameters. It concentrates on parameters that identify patients at high risk of 
metastatic disease, in particular. Several prognostic markers have been associated with 
disease free survival. In chapter 4 we describe the analysis of 120 uveal melanomas 
of patients treated with enucleation for chromosomal changes using conventional 
cytogenetics, FISH and CGH techniques. Concurrent loss of chromosome region 
1p36 and monosomy of chromosome 3 was the strongest predictor for disease free 
survival of uveal melanoma patients. Gain of chromosome 8q did not appear to be of 
much prognostic importance.  In chapter 5 once more the significance of monosomy 
3, compared to classical clinical and histopathological parameters, is emphasised. In 
contrast to sporadic primary uveal melanoma, familial uveal melanomas are rare. 
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However, these tumours have similar aberrations, such as loss of chromosome 1p, 
3 and 8p, and gain of chromosome 8q (Chapter 6). Furthermore in both, familial as 
sporadic uveal melanoma, abnormalities of chromosome 16q are relatively common, 
but are not associated with survival or other cytogenetic or histopathological 
parameters (Chapter 5 and 6). Besides monosomy 3 some tumours may show partial 
loss of chromosome 3. The last part focuses on delineation of critical regions and 
genes of interest. Two regions, one on the p-arm and one on the q-arm of chromosome 
3, might be involved in metastases. In chapter 7 we studied the partial aberrations 
observed in uveal melanoma cell lines. The cell lines used were a primary tumour 
derived cell line and three metastases-derived cell lines, which originated from the 
same primary tumour. A region on chromosome 3q was delineated and reduced the 
size of the smallest region of overlap compared with literature. The strong correlation 
between concurrent loss of chromosome region 1p36 and monosomy 3 (Chapter 4) 
was suggestive for genes encoded on these chromosomes that might play a role in 
tumour progression. Two genes, p73 and p63, located on chromosome 3q24 and 1p36 
respectively were investigated in chapter 8. These genes are transcribed with several 
dominant negative isoforms, implying that they may induce cell growth. P73 showed 
an upregulation of a dominant negative isoform, in tumours with loss of chromosome 
1p36 region. On the other hand p63 showed no aberrant expression, meaning it does 
not play a role in UM progression. Both, uveal melanoma and cutaneous melanoma 
are derived from melanocytes. In cutaneous melanoma mutations in exon 15 of the 
BRAF gene appeared to promote malignant transformation of melanocytes. In chapter 
9 mutation analysis of BRAF in thirty-three primary uveal melanoma and commonly 
used uveal melanoma cell lines is described. Contrary to cutaneous melanoma, where 
66% of the tumours have this mutation, no mutations were found in this gene in 
primary uveal melanoma. This suggests that both uveal and cutaneous melanoma 
follow a different pathway in tumorigenesis.
Finally, in chapter 10 the results of this thesis are discussed and considerations for 
further research are given. The content of this thesis has given us more insight into 
identification of patients at high risk and may be useful in the therapeutic approach 
towards uveal melanoma patients.
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Samenvatting
Het oogmelanoom is de meest voorkomende primair maligne intra-oculaire tumor 
in het westen met een jaarlijkse incidentie van 7 op de miljoen. Ongeveer 50% van de 
patiënten overlijdt ten gevolge van metastasen, voornamelijk gelokaliseerd in de lever. 
Naast enucleatie zijn er tegenwoordig ook andere behandelingsmogelijkheden die erop 
gericht zijn het oog en het zicht te sparen, zoals plaque radiotherapie, proton beam of 
stereotactische radiotherapie, met of zonder transpupilaire thermotherapie (TTT). Het 
effect van radiotherapie op oogmelanoom cellijnen en primaire tumoren is beschreven 
in het eerste deel van dit proefschrift. In hoofdstuk 2 wordt een experimentele studie 
beschreven, waarin is onderzocht hoeveel bestraling  noodzakelijk is om tumorcellen 
te elimineren. Elk weefsel heeft een intrinsieke regeneratieve capaciteit (a) naast 
het normale herstelmechanisme (b) om DNA schade te repareren. Door middel van 
overlevings-assays werd de mate van bestraling, die voldoende is om het overgrote 
deel van de bestralingsresistente tumorcellen uit te schakelen, bepaald. Data van 
enkele en gefractioneerde doses tonen een grote variatie in bestralingsgevoeligheid, 
welke voornamelijk gedomineerd word door de intrinsieke bestralingsgevoeligheid. 
Zodoende zijn vijf doses van acht Gy meer dan voldoende om het merendeel van 
de bestralingsgevoelige cellen te elimineren. Deze resultaten kunnen vertaald 
worden naar een klinische setting, alwaar er gebruik van kan worden gemaakt om 
de individuele hoeveelheid bestraling voor de stereotactische bestraling te bepalen. 
Ondanks de nieuwe behandelingsmogelijkheden worden grote tumoren nog steeds 
geënucleëerd. Manipulatie van het oog met de tumor gedurende de enucleatie kan 
verspreiding van tumorcellen veroorzaken. Daarnaast kan de tumor ook metastaseren 
voor de behandeling, welke de piek incidentie van metastasen twee jaar na enucleatie 
verklaart. Door middel van voorbestraling zou de verspreiding van tumorcellen 
tijdens de enucleatie verminderd kunnen worden. In hoofdstuk 3 is beschreven dat 
voorbestraling van uvea melanomen een gunstig effect heeft op de lange termijn 
overleving van patiënten.
Het tweede deel van dit proefschrift richt zich op identificatie en klinische en 
genetische prognostische parameters. Het besteedt vooral aandacht aan parameters 
die patiënten met hoog risico op metastasen identificeren. Verscheidene prognostische 
markers zijn geassocieerd met ziektevrije overleving. In hoofdstuk 4 wordt een studie 
beschreven van 120 oogmelanomen van geënucleëerde patiënten die geanalyseerd 
zijn voor chromosomale veranderingen met behulp van conventionele cytogenetica, 
FISH en CGH. Gelijktijdig verlies van chromosoom regio 1p en monosomie van 
chromosoom 3 was de sterkste voorspeller van ziektevrije interval van oogmelanoom 
patiënten. Winst van chromosoom 8q was niet van prognostisch belang. In hoofdstuk 
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5 wordt nogmaals de significantie van monosomie 3, in vergelijking met klassieke 
klinische en histopathologische parameters, benadrukt. In tegenstelling tot de 
sporadische primaire oogmelanomen zijn familiaire oogmelanomen zeldzaam. 
Echter deze tumoren hebben soortgelijke afwijkingen, zoals verlies van chromosoom 
1p, 3 en 8p en winst van chromosoom 8q (Hoofdstuk 6). Verder zijn afwijkingen 
van chromosoom 16q, zowel in familiaire als sporadische oogmelanomen, vaak 
voorkomend, maar zijn niet geassocieerd met overleving of andere cytogenetische 
of histopathologische parameters (Hoofdstuk 5 en 6). Behalve het verlies van heel 
chromosoom 3 laten sommige tumoren partiële verliezen van chromosoom 3 zien. 
Het laatste deel richt zich op de afbakening van kritische regio’s en interessante 
genen. Twee regio’s, één op de p-arm en één op de q-arm van chromosoom 3, zouden 
mogelijk betrokken kunnen zijn bij metastasering. In hoofdstuk 7 werden partiële 
afwijkingen in oogmelanoom cellijnen geanalyseerd. De gebruikte cellijnen waren 
afkomstig van één primaire tumor en drie metastasen, welke van dezelfde primaire 
tumor waren. Op chromosoom 3q is er een gebied afgebakend, welke de grootte van 
de kleinste regio van overlap verminderde in vergelijking met de literatuur. De sterke 
correlatie tussen verlies van chromosoom regio 1p36 en monosomy 3 (Hoofdstuk 4) 
was suggestief voor genen op deze chromosomen welke een mogelijke rol zouden 
kunnen spelen in tumor progressie. Twee genen, p73 en p63, gelegen op chromosoom 
3q24 en 1p36, zijn onderzocht in hoofdstuk 8. Deze genen worden overgeschreven 
met verscheidene dominant negatieve iso-vormen, betekenend dat zij mogelijk 
celgroei zouden kunnen induceren. P73 liet een opregulatie van een dominant 
negatieve iso-vorm in tumoren met verlies van chromosoom 1p36. Aan de andere 
kant liet p63 geen afwijkende expressie zien, beduidend dat het geen rol speelt in 
oogmelanoom progressie. Zowel oogmelanomen als huidmelanomen zijn afkomstig 
van melanocyten. In huidmelanomen lijken mutaties in exon 15 van het BRAF gen 
maligne transformatie van melanocyten te bewerkstelligen. In hoofdstuk 9 wordt de 
mutatie analyse van BRAF in 33 primaire oogmelanomen en oogmelanoom cellijnen 
beschreven. In tegenstelling tot huidmelanomen, waar 66% van de tumoren de 
mutatie hebben, zijn er geen mutaties waargenomen in primaire oogmelanomen. Dit 
was suggestief voor een verschil in etiologie van huid en oogmelanomen.
Uiteindelijk wordt in hoofdstuk 10 de resultaten van dit proefschrift bediscussieerd 
en overwegingen voor toekomstig onderzoek gegeven. De inhoud van dit proefschrift 
heeft ons meer inzicht gegeven tot identificatie van patiënten met hoog risico en is 
mogelijk bruikbaar in de therapeutische benadering van oogmelanoom patiënten.
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EOM gender age localisation cell type Largest 
tumour 
diameter
vascular 
pattern
metastasis Karyotype
3 m 62 choroid mixed 12 ND no* 46,X,-Y,+5,-6,+18 
9 m 62 choroid epithelioid 15 ND yes 46,XY (6/11)/ 46,X,-Y,i(6)(p10),i(8)(q10),+i(8)(q10),+i(8)(q
10),der(13)t(13;16?)(p12;p11?),-16 (4/11)
27 m 86 ciliary body epithelioid 8 ND no* 46,XY normal
31 m 65 choroid epithelioid 7 yes yes 44,X,-Y,der(1)t(1;6)(p11;p11),add(2)(q22),-3,-6,+8
36 m 27 ciliary body epithelioid 10.5 yes yes 45,XY,-3 (37,5%)/45,XY,-3,i(8q) (62,5%) 1/16 46,XY,-
3,i(8q),+8
37 m 71 choroid mixed 7 ND yes 46, XY,del(11)(q22q25),add(15)
38 m 49 choroid mixed 5.5 ND no 45,X,-Y (79%)/46,XY (21%)
40 m 33 choroid mixed 13 ND no 47,XY,del(1)(p22),add(7)(q36),+i(8q)? (18%)/47,XY,del(1)
(p22),del(6)(q13q24),add(7)(q36),+i(8q) (82%). 
42 f 47 choroid mixed 14 yes yes 46,XX normal
43 m 80 choroid mixed 13 yes no* 45,X,-Y,del(1)(p22p32),+der(2;8)(q10;q10),+i(2)(q10),-3,+
4,der(6)t(6;15)(p22;q21),7?,-8,-8,del(9)(p13),add(21)(p11)
45 m 61 choroid epithelioid 11 ND yes 46,XY (56%)/ 45,X,-Y (44%)
48 f 55 ciliary body spindle 10 no yes 43,XX,i(1)(q10),-3,-4,der(6)del(6)(q1?5q2?5)ins(6;?3)(q1?
5;?p12p22),der(13;22)(q10;q10),t(14;19)(q22;?p13),der(16
)t(3;16)(q21;p12),-18,+20
50 m 57 choroid epithelioid 6 no yes 45,X,-Y (18%)/ 45,X,-Y,add(13)(q14)(70%)/ 45,X,-Y,der(10
;15)(q10;q10),add(13)(q14)(12%)
53 m 68 choroid mixed 13 ND yes 46,X,-Y,dic(1;16)(p11;q11),inv(2)(p11p13),-3,+8[16]
55 f 38 choroid spindle 11 ND yes 46,XX(20%)/ 45,X,-X(20%)/ 88,XXXX,der(1)t(1;6)(p12;p
11)x2,+der(1)t(1;6)[1],add(2)(q36 of q37)x2,-6,-6,+8,+8,-
14,-15,-16,-21
62 f 21 choroid spindle 7 no no 46,XX,t(11;15)(q13.2;q13)(87.5%)/46,XX (12.5%)
63 f 73 choroid epithelioid 12 ND no* 46-48,XX,-3,i(6)(p10)[5],i(8)(q10),+i(8)(q10),+i(8)(q10)x2
[4],del(16)(q21)[5]
71 m 66 choroid mixed 10 no yes 45,X,-Y 
97 m 73 choroid spindle 8 no no* 45,X,-Y(57%).46,XY(43%)
102 m 76 choroid spindle 12 no no* 46,XY,add(9)(q34),add(22)(p11)[3]/
46,XY,add(9)(q34),add(9)(p24),add(22)(p11)[15]
107 m 76 choroid mixed 19 yes no* 43,X,-Y,dic(3;19)(q11;q13.2),-13,der(17)t(13;17)(q13;p
12),-21,add(22)(p11) [4]/43,X,-Y,dic(3;19)(q11;q13.2),-
13,der(17)t(13;17)(q13;p12),add(22)(p11) [6]
121 m 49 choroid mixed 14 yes yes 46-47,XY,del(1)(p31p36),-
3,der(4)t(1;4)(q12;q21),+8,+21[cp3]/45,X,-Y[3]/46,XY[8]
123 m 58 choroid epithelioid 11 yes no 46,XY[22]
125 f 74 choroid mixed 18 yes no 72-76,XXX,dic(1;7)(p10;p14),+dic(1;7)(p10;p14),-3,+4,+6,-
7,+i(8)(q10),+9,-11,-15,+16,+18,+20,+?21,+22[cp12]/49-
54,idem[cp2]
130 f 57 ciliary body mixed 16 yes no 41-48,XX,der(1)t(1;6)(p11;p1?2),add(4)(q1?2),-5,-
6,+7,+8,+8,-9,add(11)(q13~14),+add(11)(q13~14),-13,-
16,+22,+mar.ish der(6)(wcp6+),+mar.ish der(16)t(6;16)(w
cp6+,wcp16+)[cp6]
131 f 60 choroid mixed 8 yes no 46,XX[11]
136 f 85 choroid mixed 15 no yes 41-44,XX,der(1;8)(q10;q10).ish der(1;8)(wcp8+,2053
b3+,p1.164+,D8Z2+,puc1.77+,wcp1+),-3,+der(8).ish 
der(8)ins(8)(p?21q?23q?24.1)del(8)(q22q22)(wcp8+,114
C11+,105H8+,p1.164-,
2053b3+),-15,del(16)(q11q1?3).ish 
del(16)(wcp16+,pHUR195-)[cp15]
141 m 54 choroid mixed 11 no no 46,XY,+2,dic(6;13)(q12;p10),dic(6;14)(q12;p10)[16]
147 m 56 choroid spindle 13 no no 44~47,XY,del(1)(p2?)[5],add(7)(p?2)[4],+9[2],-
15[4],add(19)(q1?3[3],+mar[2][cp6]/46,XY[3]
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148 m 59 choroid mixed 13 yes yes 45,X,-Y[3]/46,XY[10]/47,XY,+?der(2)[2]/
46,XY,add(8)(p),der(15)t(1;15)(q11;p11)[1]
150 m 42 choroid spindle 12 no no 46,XY[4]/47,XY,+9[3]/47,XY,+9,der(10)t(6;10)(p12;q26)[4]
151 f 48 choroid spindle 12 no no 46,XX[3]/46,XX,der(20)t(6;20)(p12;p12)[5]/
47,XX,idem,+8[4]/
47,XX,idem,+8,psudic(17;15)(p13;p11)[3]
152 f 76 choroid epithelioid 15 yes yes 45~48,XX,-3,i(8)(q10),+i(8)(q10),+i(8)(q10)[cp5]/46,XX[4]/
47~49,XX,+3[3],+5[2],+6[2][cp4]
157 f 72 choroid mixed 13 yes no* 46,XX[10]/47,XX,+8[7]
158 m 61 choroid spindle 11 no yes 45,X,-Y[10]/46,XY[4]
159 f 37 choroid spindle 12 no no 40~46,XX,add(2)(q3?4).ish der(2)t(2;6)[6],der(5)t(5;6)(q
34;?)[9],del(6)(q?)[3],der(7)t(7;8)(p21;q?),add(10)(p1?4).
ish der(10)t(8;10)[2],add(11)(q1?4).ish der(11)t(8;11)[9],
der(16)t(8;16)(q?;q24)[7],
add(18)(q23)[1] [cp19][19]/46,XX[1]
160 f 72 choroid mixed 14 yes yes 46,XX[10]/40~42,XX,del(1)(p21),-3,-6,i(8)(q10)[1],-
12,-18[cp5]/47,XX,del(1q),der(1)t(1;8)(p;q),+7,-
8,+9,del(11p)[1]
165 m 42 choroid spindle 12 no no 47,XY,add(6)(q21),der(7)t(1;7)(q12;q36),+8[20]
166 f 49 choroid mixed 18 no no 47,X,-X,-3,+7,i(8)(q10),+i(8)(q10)[1]/46,XX[4]
174 f 59 choroid spindle 19 no yes 75,XXY,1p+,-3,+i(6)(p),i(8)(q),9p+
177 m 59 choroid spindle 8 yes yes 45~47,XY,-5[2],+8[2],add(8)(p22),+add(8)(p22)[4],-9[2],d
el(13)(?q14q21),der(17)ins(17;13)(q12;?q14q21)del(17)(q
22q23),-19[2],-22,+mar[cp7]
178 f 73 choroid mixed 17 yes no 45~47,XX,del(1)(p21),add(7)(q36),+
8[2],-15,add(17)(p12),+ring[1][cp5]/
46,XX,del(1)(p21),der(5)t(5;14),add(7)(q36),+8,-14,-
15,add(17)(p12),+ring[5]
179 m 60 choroid spindle 11 no no 46,XY[15]
180 f 79 choroid epithelioid 16 no yes 43~45,X,-X,-3,i(8)(q10),+i(8)(q10),+i(8)(q10)[2],der(16;21)
(q10;q10),der(22)[1][cp5][5]
182 f 52 choroid spindle 14 no no 46,XX,der(6)t(6;6)(q16;p12),add(22)(p11),add(22)(q1
3)[16]
187 m 65 choroid epithelioid 15 yes yes 45,X,-Y,-3,-4,i(8)(q10),+i(8)(q10),+mar
189 m 80 choroid mixed 14 yes yes 44,XY,-1,-2,-3,dic(1;6)(q10;q10),+ring[5]/45,XY,-1,-2,-
3,dic(1;6)(q10;q10),+8,+ring[12]/90,XXYY,idem,+8,+8[1]
191 f 46 choroid spindle 14 no yes 46,XX,add(1)(q42),add(4)(q3?2),del(6)(q1?4q2?5),der(8)t
(6;8)(p12;q24),-16,add(16)(q?2),add(17)(p13),add(21)(p1
1),+mar1,+mar2 [19]
193 m 44 choroid epithelioid 16 yes yes 46, XY[16]
195 m 68 choroid epithelioid 16 no no 46, X,-Y,-3,+i(8)(q10),+i(8)(q10)[4]/47,idem,+add8(p?)[12]
199 f 64 choroid spindle 17 yes yes 44~45,XX,der(1)t(1;6)(p12;p11),-3,+i(8)(q10),+i(8)(q10)[1]
,der(14)t(14;22)(q13;q11),-16,-22[cp19]
205 m 46 choroid spindle 7 yes no 44,X,-X,der(22)t(12;22)(q12;p12) [3]/45,X,-X,I(12)(q10),id
ic(22)(p12) [2]/46 XX [26]
207 m 76 choroid spindle 15 yes no 45,X,-Y,-3,i(6)(p10),+8[8]/46,XY[7]
211 f 66 choroid spindle 14 no yes 73,X,-X,-X,add(1)(q43),+2,-3,+7,+8,+i(8)(q10),+i(8)(q
10),-9,add(9)(q?13),-10,+11,+12,+13,+14,+15,-17,+19,-
21[1]/149,idemx2[1]
218 m 60 choroid spindle 17 no no 41,XY,-1,der(11)t(1;11)(q12;p15),add(12)(p13),-15,-16,-
21,-22[16]
219 m 69 choroid mixed 18 yes yes 45,XY,-3,i(8)(q10)[14]
226 m 27 choroid mixed 13 yes no 46,XY,-3,i(8)(q10),+i(8)(q10)[6]/47,XY,-
3,i(8)(q10),+i(8)(q10)[3]/46,XY[2]
237 m 77 choroid spindle 14 no yes 45,X,-Y,add(1)(p2),-3,+i(8)(q10)[4]
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240 m 52 choroid spindle 15 no yes 46,XY,-3,+i(8)(q10)[17]
241 f 84 choroid spindle 14 no no 46,XX[22]
242 f 47 choroid spindle 16 no no 46,XX,der(3)t(3;8)(q2?9;q11),der(6)add(6)(p?22)t(6
;8)(q16;q?21),+der(6)add(6)(p?22)t(6;13)(q11;q11),
-13,add(17)(p13)[10]
246 m 57 choroid epithelioid 15 no no 40-47,X,-Y,-3.?add(6)(q13),i(8)(q10),+i(8)(q10),+i(8)(q10)[
2],+i(8)(q10)[1][cp3][3]
253 m 74 choroid epithelioid 19 yes yes 77-86,XXYY,i(1)(q10),+der(1)i(1)(q10)t(1;17)(q21;p12)or 
der(1)i(1)(q10)t(1;17)(q21;24)x3,-3[3],i(4)(p10),+i(4)(p10
)[3],-6[3],i(6)(p10),i(8)(q10)x2,-9,-9,-10,add(11)(p14)x2,-
13,-14[3],-15,-15,-16[3],
add(20)(q13)x2[cp4][4]/79-86,XXYY,i(1)(q10),+i(1)(q
10),+i(1)(q10)[6],+2[5],-3[5],-3[4],-4[4]i(4)(p10),+i(4)(
p10)[7],-5[8],-6,i(6)(p10)[8],-7[3],+7[3],i(8)(q10)x2,-9,-
10[8],-11[7],-12[6],-13[6],-14[5],-15[6],-15[3],-16[7],-
17[3],+18[3],-19[3],add(20)(q13)x2,+mar[2][cp9][9]
254 f 74 choroid mixed 18 yes yes 45,XX,der(1)t(1;16)(p22;p11),-3,+i(8)(q10),-16[16]
256 m 40 choroid spindle 12 no no 46,XY,der(19)t(6;19)(p23;p13.3)[18]
257 m 87 choroid spindle 12 no no* 46,XY,der(8)t(8;18)(p12;q12),der(21)t(6;21)(p11;p11)[12]/
46,XY,del(6)(q15q26),der(8)t(8;8)(p12;q12),der(21)t(6;2
1)(p11;p11)[3]
261 m 40 choroid spindle 9 no no 55,XY,+2,+add(5)(q12),+der(5;17)(q10;q10),del(6)(q12q2
7),+8,+8,+der(9)t(8;9)(q11;p12),+11,+20[16]
262 f 64 choroid epithelioid 13 yes yes 45-91,X,-X,-3,+i(8)(q10),inc.[6]/46,XX[8]
265 m 40 choroid spindle 13 no yes 46,XY,del(6)(q15q22)[2]/
46,XY,del(6)(q15q22),add(14)(q32)[1]/ 46,XY,del(6)q15q
22),der(17)t(7;17)(q11.2;p13)[5]/ 46,XY,del(6)(q15q22),ad
d(14)(q32),der(17)t(7;17)(q11.2;p13)[8]
270 m 65 choroid spindle 14.5 yes yes 46,XY,add(6)(q21),add(7)(q21),?del(9)(p13p23),dup
(10)(q26q23),del(11)(q22),add(14)(p11),add(19)(13.4
)[1]/46,XY,add(6)(q21),add(7)(q21),?del(9)(p13p23),dup
(10)(q26q23),del(11)(q22),
add(14)(p11),add(19)(13.4),der922)t(8;22)9q21;p10)[13]/
43,XY,add(6)(q21),add(7)(q21),add(8)(p11),?de
l(9)(p13p23),-10,dup(10)(q26q23),del(11)(q22),add(14)(p
11),der(15;15)(q10;q10),add(19)(q13.4)[2]
271 f 55 choroid spindle 13 yes no 45,XX,-3,der(8)t(8;8)(p23;q13)[14]
272 f 52 choroid spindle 15 yes no* 46,XX,der(1)t(1;16)(p2?1;p11),-3,+(8)(q10),-16[16]
274 m 42 choroid spindle 17 no no 46,XY,del(11)(q2?2),der(18)t(6;18)(p21;q23),add(19)(p13.
3)[4]/ 46,XY,add(9)(q34),del(11)(q2?2),der(18)t(6;18)(p21
;q23),add(19)(p13.3)[19]
281 m 69 choroid spindle 16 no no 46,XY,der(7)t(6;7)(p22;p22)[20]
*Patients without metastases, death due to other causes
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Chapter 1
Figure 1.
Schematic illustration of the eye on the left. Histological sections of uveal melanoma on the right; melanoma 
located in the iris (A), ciliary body (B) and choroid (C).
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Chapter 6
Figure 1B.
Summary of the most frequent DNA copy number changes detected by CGH in six familial uveal melanoma, 
upper panel, and 15 sporadic uveal melanomas, lower panel. Vertical lines on the right side of the chromosome 
represent gains and vertical lines on the left side of the chromosome indicate losses. Bold lines indicate high-
level amplifications.
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Chapter 6
Figure 1.
CGH analysis of Mel270 
The green and red line represent, respectively, the upper and lower thresholds of the normal range. The 
red line on the left of the ideogram represents the copy number decrease. Average expression profile of 9 
metaphases.
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Chapter 7
Figure 4.
FISH analysis of Mel270
A: representative results of dual color FISH on Mel270 cells, hybridised with a combination of a chromosome 
3q probe (red) and a centromere 3 probe (Pa3.5) (#3) (green), except for probe RP11-95H16 (green) that was 
combined with a 3pter probe (B47A2) (red). Panel A: 3pter probe and RP11-95H16; #3 and RP11-88H10; and 
#3 and RP11-229G6.
B: representative results of dual color FISH on Mel270 cells, hybridised with a combination of a chromosome 
3p probe (red) and a centromere 3 probe (Pa3.5) (#3) (green). Panel B: #3 and RP11-208G16, #3 and RP11-
255O19, and #3 and RP11-41F5.
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Chapter 8
Figure 1.
Interphase FISH with the BAC-clones RPCI-11 62M23 for p73 in green and RPCI-11 53D15, located on 3q24 
in red: A. P.7, B. P.13 and C. OCM-1. 

